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Men with localized prostate cancer (PCa) have a 100% five-year survival rate, 
but this rate drops to 33% for men with metastatic disease.  A better understanding of 
the metastatic process is needed to develop better therapies for PCa. Aberrant activation 
of protein tyrosine kinases, including Src Family Kinases (SFKs) contribute to 
metastasis through numerous functions, one of which leads to increased expression of 
cytokines, such as IL-8. However, the relationship between Src activity and IL-8 
regulation is not completely understood.  In cell line models, I determined that IL-8 
activates Src and in turn Src activates IL-8 demonstrating a feed forward loop 
contributing to the migration and invasion of PCa cells.   
However, IL-8 is also produced by tumor-associated stromal cells.   In bone 
marrow derived stromal cells (HS5), I demonstrated a feed forward loop occurs as was 
observed in tumor cells. HS5 conditioned media increased Src activity in PCa cells. By 
silencing IL-8 in HS5 cells, Src activity was decreased to control levels in PCa cells as 
was migration and invasion. Thus, stromal cells producing IL-8 contribute to metastatic 
properties of PCa by a paracrine mechanism.  
To examine the effect of stromal cells on tumor growth and metastatic potential 
of PCa in vivo, I mixed HS5 and PCa cells and co-injected them intraprostatically.  I 
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determined that tumor growth and metastases were increased. By silencing IL-8 in HS5 
cells and co-injecting them with PCa cells intraprostatically, tumor growth and 
metastases were still increased relative to injection of PCa cells alone, but decreased 
relative to co-injections with PCa cells and HS5 cells.   
These studies demonstrated: (1) a feed forward loop in both tumor and stromal 
cells, whereby IL-8 activates Src, derepressing IL-8 expression in PCa cells in vitro; (2) 
stromal produced IL-8 activates Src and contributes to the migration and invasion of 
PCa cells in vitro; and (3) stromal produced IL-8 is responsible, in part, for increases in 
PCa tumor growth and metastatic potential.   
Together, these studies demonstrated that IL-8-mediated Src activity increases 
the metastatic potential of PCa and therapeutic agents interfering with the IL-8/SFK 
signaling axis may be useful for prevention and treatment of metastases. 
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CHAPTER 1 
INTRODUCTION 
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OVERVIEW OF PROSTATE CANCER 
Prostate cancer (PCa) is the most common cancer in men in the United States   
and is the second leading cause of cancer mortality in western civilization.  It is 
estimated that that there will be 241,740 new cases and 28,170 deaths in 2012 (1).
 
 The 
incidence of disease increases with age and as many as 35% of men ages 60-69 years 
old and 46% of men ages 70-81 years old will develop PCa (2,3).  When diagnosed 
early, the 5-year relative survival rate for men with localized disease is nearly 100%, 
but when disease is no longer organ confined, the 5-year survival rate for men 
dramatically drops from nearly 100% to 29% (4).  For localized disease, patients 
initially respond to the front-line androgen ablation or surgical castration therapies, but 
many patients progress to castration resistant prostate cancer (CRPC) where mortality 
increases. The increased mortality is due, in part, to sustained androgen receptor 
signaling.  
Although recent therapies, discussed in detail in the current therapies section, 
have been developed that more effectively block androgen synthesis or inhibit androgen 
binding to AR, there are patients that still progress and eventually die (5-7).  This 
suggests that other mechanisms, in conjunction with AR signaling, must be explored in 
CRPC.  This also suggests that there are differences, either morphologically, 
mechanistically or biologically, associated with stages of PCa development.   In light of 
this, we must first understand the current theories of how PCa develops and progresses 
to CRPC which will be discussed in the next sections.   
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DEVELOPMENT OF THE PROSTATE 
To better understand the development of PCa, we must understand the 
morphology and organization of the prostate.  The prostate is a small walnut size organ 
sitting below the bladder, posterior to the pubic bone and anterior to the rectum.  
Comprised of ~70% glandular tissue and 30% muscular tissue, the prostate houses an 
epithelial and stromal compartment separated by a basement membrane (8).  The 
normal prostate gland comprises three cell types: luminal, basal and neuroendocrine 
cells. (Figure 1) The origin of each cell type is thought to develop from presumed 
prostate stem cells, located in the basal layer and proximal ducts of the prostate gland, 
which become differentiated and can be identified by their position, cell-type specific 
markers and function (9). 
The luminal cell layer, composed of columnar epithelial cells and located in 
the lumen of the prostate, expresses the AR and prostate specific antigen (PSA), while, 
functionally, it secretes seminal fluids.  The basal cells, located in the basal layer of the 
prostate gland, express low levels of AR, cytokeratins and cell adhesion molecules 
(CAMs), while, functionally, separating the stromal compartment from the luminal cells 
(10).  The neuroendocrine cells, which express various basal cell markers, are unevenly 
distributed within the basal layer representing a post-mitotic population of cells. In 
addition, there is a stromal compartment that represents a cellular niche containing 
mesenchymal and fibroblastic cells as well as lymphocytes, endothelial cells, 
myofibroblasts and pericytes required to support the prostate for survival.  
Androgen expression is a critical characteristic of prostate development. 
Androgen signaling occurs through the AR supporting survival of the prostate.  AR  
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Figure 1 
Histological Architecture of the Prostate   
The normal epithelium consists of a luminal cells enveloped by a basal cell layer. The 
stromal cell compartment is the outermost portion of the prostate epithelium.  
Neuroendocrine cells are a post-mitotic cell type that can result transform into prostate 
cancer. 
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serves as a ligand-dependent transcription factor that, in the absence of ligand binding, 
is distributed diffusely throughout the cytoplasm bound to heat shock proteins in an 
inactive state. Ligand binding to the AR facilitates dimerization and nuclear 
translocation where AR dimers bind to androgen response elements (AREs) stimulating 
transcription of androgen regulated genes, such as KLK3, the gene encoding PSA 
protein (11-12).  As a result, PSA, serine protease protein secreted by prostate, as a 
marker of AR function is widely used to assess prostate-specific AR activity (13-14).   
Although controversial, PSA screening methods are utilized to monitor disease 
progression and response to therapeutic intervention.  
Thus far, we have described prostate development in terms of organization, 
anatomy and androgen regulation.  McNeal provides a well-accepted theory assessing 
the anatomy of the prostate as a means to understand the regions of PCa development.  
McNeal describes two zones of the prostate: the peripheral and the transition zone.   The 
peripheral zone, localized in the posterior portion of the gland, is considered the 
primary site where PCa develops and accounts for ~75%  of the region where PCa 
originates.  The transition zone, localized near the urethra, accounts for origination of 
~20% of cancers, a less frequent site of cancer development (8,15). 
Benign Prostate Hyperplasia 
Benign prostate hyperplasia (BPH) represents a clinically significant 
pathologic process that the prostate undergoes, but is not considered a precursor of PCa.  
BPH is characterized by cellular proliferation and gland enlargement mainly in the 
periurethral and transition zones of the prostate. Considered to be a normal process for 
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aging men, only 10% of men with BPH require medicinal treatment making this 
condition treatable and curable (16). 
DEVELOPMENT OF PROSTATE CANCER 
Prostate Stem Cells 
PCa arises from cancer stem cells (CSCs), but there is controversy as to 
whether the stem cell of origin is basal or luminal (17,18).  
 
The evidence that PCa 
arises from luminal cells is due to the presence of non-terminally differentiated 
secretory luminal cells along with minimal presence of basal cells and basal cell-
markers (19).  This theory is also supported by the expression of luminal cell markers, 
such as cytokeratins 8 and 18 (CK8 and 18), PSA, stem cell antigen-1 (Sca1) and 
prostate stem cell antigen (PSCA) in cancer cells (9,18,20-23).
 
 In addition, Liao et al. 
report that cancer stem cell differentiation to a luminal cell lineage also requires the 
presence of the microenvironment suggesting that determining the stem cell origin is 
further confounded by interactions with the microenvironment (24).
 
There is also evidence supporting the theory that PCa arises from a basal cell 
origin (25).  Studies report that a small population of cells in the prostate tumor express 
basal markers, such as p63, hTERT and Bcl-2 (21,26).  However, it is not clear whether 
there is a conversion between basal and luminal stem cells leading to the development 
of PCa.   Wang et al. discuss two newer theories where, 1) there may be overlap in stem 
cell activities such that the basal and luminal cells have autonomous progenitors or 2) 
PCa arises from a basal cell progenitor that differentiates into luminal progenitor cells 
(27). These studies highlight that there are still confounding questions about the true 
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stem cell origin of PCa and what role the microenvironment plays, but it does shed light 
on possible mechanisms of tumor initiation (19). 
Prostatic Intraepithelial Neoplasia
 
Prostatic intraepithelial neoplasia (PIN) is suggested to occur under two 
models- the stem cell hypothesis where transforming events in stem cells occur or by 
the stochastic model where PIN develops from any cell harboring specific gene 
mutations (28).  The stem cell model is considered to be the most accepted model of 
PIN initiation. PIN, first identified by Bostwick and Brawer,  is defined as highly 
proliferative epithelial cells, usually non-invasive, located within the normal prostatic 
acinar ducts exhibiting large acini (29).
 
 There are two types of PIN- low grade 
(LGPIN) and high grade (HGPIN) with different clinical outcomes. While LGPIN, 
usually, does not progress to PCa and is less reported, HGPIN represents the earliest 
recognized stage of carcinogenesis (30,31).  Multiple studies report an increased 
frequency of HGPIN in prostates with PCa and, amongst other highly significant 
predictors of cancer, HGPIN ranks as having the highest risk ratio making it a marker 
with high predictive value for PCa development (31-33). 
 
There are multiple progressive morphological, genetic and phenotypic changes 
associated with HGPIN in the progression to PCa, but some are also observed in PCa.  
Some morphological changes involve the presence of dysplastic epithelial cells with an 
enlarged nucleus and the disappearance of a defined basal cell membrane, although the 
presence of basal cells still exist (31).  Some progressive genetic and phenotypic 
alterations associated with HGPIN, also observed in PCa, are decreased expression of 
genes, such as the NKX3.1 and p27 genes, while there are also decreases associated 
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with some genes involved in secretory differentiation, such as PSA and prostatic acid 
phosphatase.  There is also an increase in other genes, such as b-cell lymphoma 2 (bcl-
2), p53 and c-met (34-35).  Along with morphological, phenotypic and genotypic 
changes, multiple studies demonstrate that there is an observance of PIN lesions within 
close proximity of malignant disease suggesting, at least morphologically, that PIN is a 
pre-neoplastic condition to PCa (36).  PIN is best distinguished from PCa by its organ-
confined phenotype and the inability of cells to become invasive. 
Progression to Prostate Cancer 
The transition from PIN to PCa involves progressive phenotypic and genotypic 
changes, mentioned above, but there is also evidence suggesting that androgen signaling 
is involved in the initiation of PIN and development of PCa (37). The initial survival 
and dependence of PCa is due in large part to the presence of androgens. One of the 
most predominant androgens found in the sera of males, testosterone, is converted by 
the steroid 5α-reductase type 2 (SRD5A2) into a higher affinity androgen, 5α-
dihydrotestosterone (5α-DHT) in men with PCa (38).  The subsequent binding of 
androgen to AR, as described earlier, results in the transcription of androgen-regulated 
genes that facilitate survival and proliferation. Huggins and Hodges provided some of 
the earliest studies demonstrating that androgens increase PCa cell growth leading to the 
development of multiple endocrine therapies (39).  Androgen ablation therapies, such as 
biclutamide, flutamide and leuprolide, were introduced to control disease (40).  Patients 
respond to these therapies and a small subset of patients are cured, but many progress 
suggesting that AR is sustained and signaling still occurs (40-42).  When patients 
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become resistant to this treatment, this disease is termed castration resistant prostate 
cancer (CRPC) and life expectancy drops.   
Sustained signaling through AR, despite androgen ablation, is a major 
consequence of CRPC.  In an effort to understand the mechanisms underlying androgen 
activity and the AR in CRPC, multiple in vitro and in vivo models have shown that, 
even in the absence of androgen regulation, cells still express androgen-responsive 
genes as well as AR (43-47).  In fact, many cases of CRPC display aberrant AR activity 
due to changes, such as amplifications, splice variants and/or altered AR target genes 
(45,48,49).  This suggests that CRPC utilizes a mechanism that bypasses the need for 
androgen without deregulation of AR.  There are additional mechanisms, outlined 
below, that have been postulated describing reasons for aberrant activity of AR in 
CRPC. 
  One mechanism suggests that AR is active due to alternate sources of 
androgen, such as circulating dehydroepiandrosterone (DHEA) by the adrenal glands 
(50-52).  Other mechanisms suggest that increased AR sensitivity to low androgen 
levels creates a hypersensitive mechanism, while increased levels of coactivators can 
also enhance AR sensitivity, but to androgen and non-androgen ligands (53,54).  Non-
androgen factors and non-androgen steroid hormones, such as estrogens and cortisol, 
are also thought to be responsible for sustained AR activity through promiscuous ligand 
binding (55).  In conjunction with promiscuous ligand binding, studies demonstrate that 
AR activation is also achieved through growth factor and/or receptor tyrosine kinase 
pathways, such as IGF, HER-2/neu and Src, creating, what is commonly termed as an 
outlaw mechanism (56-57).  Studies suggest that steroid-induced Src, a non-receptor 
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tyrosine kinase, activation results in association with AR stimulating signaling cascades 
that regulate metastatic events, such as proliferation and migration (53,59).  This further 
suggests that, in CRPC where there is aberrant AR activity, Src activation may be a 
contributing factor, which will be discussed in detail later (59).  Although all the 
mechanisms, albeit important in understanding the role of the AR in CRPC, are not 
mutually exclusive and may work together to sustain CRPC, more studies are needed 
addressing pathways that may lead to metastatic disease. 
Metastatic Disease 
While PCa, when detected at an early stage in patients, results in curable 
disease, its progression to CRPC can lead to aggressive and metastatic disease. 
Metastatic disease comprises distant metastases confined to the spleen, liver and, most 
frequently, the bone and lymph nodes.  Bubendorf et al. report that 80% of men dying 
from PCa incurred bone metastases suggesting that metastatic sites offer a host of 
factors that support the growth and survival of PCa (60).  Paget’s ‘seed and soil’ 
hypothesis, explaining the cross-talk between cancer cells and organ-specific 
microenvironments, is widely accepted as a model for understanding the 
interdependency of tumor cells and cells in their metastatic microenvironment
 
and 
strongly suggests that organ-specific metastases require the metastatic ‘soil’ for 
continued tumor growth (61,62).  Thus, understanding the metastatic process involved 
in cancer progression is important and we now understand that the biological 
aggressiveness of metastatic disease is vastly a result of interactions between PCa cells 
and their microenvironmental changes, increasing interest in studies that interrogate 
organ-specific metastases. 
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In an effort to understand the nature of how the microenvironment affects PCa, 
Kaplan et al. describe site-specific niches that exist to support tumor cells in their 
passage to distant sites and upon their arrival at the distant site, such as the primary 
tumor, vascular, osteoblastic and pre-metastatic niches (63).  It has been further 
suggested that the preferential metastasis of PCa to specific organs is due, in part, to 
heterotypic cell interactions, but there may be modifications to distant tissue sites which 
prime the “soil” for cancer cells yielding a “pre-metastatic” niche (64).  The pre-
metastatic niche consists of immigrant and resident cells that “prime” the soil through 
signaling mechanisms conducive to tumor seeding (63,65,66).  An example of a 
resident cell that may prime the “soil” are stromal cells. The bidirectional activities 
between stromal cells and PCa cells provides a host of factors which contribute to 
progression of metastatic disease (67,68).  
Although there is ample evidence suggesting that bidirectional activities at the 
primary site contribute to PCa growth and survival, there has been increased interest in 
understanding the stromal-epithelial crosstalk at the metastatic site (69-71).
 
 Part of the 
reasoning is that, even though the genetic and molecular changes in tumor cells are 
required during tumor progression, they are not sufficient to fully drive tumors to be 
metastatic.   As a result, studies suggest that the metastatic potential of PCa is a stroma-
dependent event and the balance of stromal factors within the metastatic tissue 
determines metastatic behavior (43,72,73).  This aspect is integral to the studies of my 
thesis. 
The role of the stroma in metastatic disease involves factors, such as 
interleukin-6 (IL-6), CXCL-12, transforming growth factor beta (TGF-β), vascular 
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endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs),  that initiate 
signaling cascades increasing metastatic properties of PCa (74,75).  This reciprocal 
signaling mechanism is thought to permit the promotion of metastasis to the host 
environment.   More recent, in vivo and in vitro, studies support the hypothesis that 
organ-specific PCa cell and stromal interactions contribute to a “vicious cycle” whereby 
the stroma modifies the PCa cells and the PCa cells modify the stroma (76-78).  
Increasing evidence suggests that there are many vicious cycles, not only, cultivating 
and maintaining an environment for cancer progression, but also transforming the 
stroma as PCa progresses to aggressive disease (59).  By interrogating pathways 
integral to the tumor-stromal interactions at the metastatic sites, we may be able to 
develop strategies that effectively disrupt the stroma-dependent tumor interaction.   An 
integral part of this thesis is to delineate factors expressed and secreted by the tumor 
and stroma contributing to metastatic disease.  As a result, we must first understand the 
current molecular biology of PCa and factors that contribute to the initiation and 
progression of PCa.  
MOLECULAR BIOLOGY OF PROSTATE CANCER  
Both genetic and epigenetic events have been shown to play a role in the 
development and progression of PCa.  Epigenetic changes, including methylation and 
acetylation, represent some of the most common changes seen in early stage PCa. In 
particular, DNA hypermethylation is a common event involving increased methylation 
of DNA in multiple genes. The most hypermethylated genes contributing to PCa 
initiation are glutathione S-transferase (GST) P1 gene, RASSF1A, RABB2, MDR1 and 
APC.  Of these hypermethylated genes, GSTP1 is cited heavily as being a major 
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contributor to PCa initiation. GSTP1 is an enzyme catalyzing the addition of glutathione 
to toxic compounds which in turn decreases cellular oxidative damage. Silencing and 
promoter hypermethylation of GSTP1 is observed in 90% of PCa and these changes 
may contribute to increases in cellular oxidative damage. Since GSTP1 expression is 
decreased during the differentiation of basal cells to luminal cells, there may be a 
predisposition to increased oxidative damage.  Although important, these epigenetic 
changes are only one event contributing to PCa initiation and progression.  There are 
also genetic changes, such as chromosomal losses, gains and rearrangements, 
contributing to PCa progression. The loss and gain of chromosomal regions, specifically 
regions of chromosomes 8, 10 and 21, represent some of the most frequently observed 
changes in PCa progression and will be discussed in detail below. 
One of the most frequently altered chromosomes is chromosome 8 with 
frequent loss of 8p21 (79).  Loss of the 8p21 region is an early and frequent event in 
PCa, seen in 85% of carcinoma. One gene located in this region is the prostate-specific 
homeobox transcription factor, Nkx3.1. Studies demonstrate that Nkx3.1 expression is 
decreased in PCa, while deletion of Nkx3.1 results in PIN.  This is supported by mouse 
model studies demonstrating that Nkx3.1 -/- results in PIN lesions that do not progress 
to PCa, but that cooperation of Nkx3.1oss and PTEN loss results in progression to PCa 
and metastatic disease (80,81).  As a result, loss of Nkx3.1 expression is alone 
insufficient for progression to advanced PCa and involves other genetic events (82).  
Another altered chromosome is chromosome 10 with frequent loss of 10q23. 
One gene located in this region is the phosphatase and tensin tumor suppressor, PTEN, 
which is also frequently lost in PCa (83).  The loss of PTEN expression is mostly 
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observed in advanced stage disease and accounts for >50% of PTEN gene alterations in 
metastatic disease, while only a small fraction of primary tumors exhibit PTEN deletion 
or mutation (84,85).  This evidence is supported by genetically engineered mouse model 
studies where PTEN inactivation in normal prostate epithelium drives the development 
of advanced PCa (84). 
Pten deletion studies demonstrate that PCa progression to metastatic disease is 
a result of cooperation with multiple genes, such as simultaneous loss of Nkx3.1 and 
Pten or inactivation of Pten and up-regulation of the proto-oncogene c-Myc (84,86-88).  
These studies provide strong evidence that PTEN loss plays an important role in early 
stage PCa and metastatic disease. There are also gains of chromosomal regions resulting 
in changes that contribute to PCa progression. 
One of the most frequently gained chromosomal regions is 8q24. One gene 
frequently amplified in this region is c-Myc, a proto-oncogene known to regulate genes 
involved in cell proliferation. It is overexpressed in ~40% of primary tumors and ~90% 
of metastatic PCa (89,90).  Mouse model studies report that prostate epithelium 
overexpressing c-MYC develop PCa, but there is no observance of metastatic lesions 
(91).  More recent evidence suggests that progression to metastatic disease is thought to 
require additional genetic alterations (92,93). These results demonstrate that changes to 
chromosome 8, encompassing the Myc gene, play an important role in PCa, but Myc is 
not a major contributor in the progression to metastatic disease.  While chromosomal 
losses and gains represent changes integral to PCa progression, chromosomal 
rearrangements are a more recent area of interest in PCa progression.
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Chromosomal rearrangements were considered a rare event in PCa, but recent 
evidence suggests that a specific chromosomal rearrangement at 21q plays an important 
role in the progression of PCa. Studies demonstrate that the chromosomal 
rearrangement of 21q, results in the fusion of the transmembrane protease serine 2 gene 
(TMPRSS2) and the ETS gene, ERG, yielding a fusion protein found in the majority of 
PCa (94,95).
 
 Specifically, the androgen-responsive TMPRSS2 promoter fuses with 
select coding regions of the ERG family transcription factors, but other ETS-family 
genes are also involved in recurrent fusions (96).  The overexpression of the ETS family 
of transcription factors accounts for ~60% of gene rearrangements in PCa and is 
considered the most frequent event in human PCa (97).  The rearrangement between 
TMPRSS2 and ERG is the most frequent of all ETS-family genes. Although the 
functional significance is not fully understood, in vitro and in vivo studies suggest that 
activation of ETS genes enhances tumor-invasive properties (98,99).  In addition, 
mouse model studies demonstrate that ERG expression along with PTEN loss results in 
HGPIN transition to PCa (99,100).  These studies demonstrate that, although important 
to PCa progression, these gene rearrangements are alone insufficient in driving 
malignant disease.   
The previous sections have discussed that epigenetic alterations and genetic 
changes play a role in PCa progression.  Signal transduction changes which may or may 
not result from mutations comprise other changes that contribute to PCa progression.  In 
particular, the overexpression of kinases has been an area extensively studied and there 
is more recent evidence implicating their role in PCa progression to metastatic disease.  
Many kinases have been implicated in PCa progression, such as Her2/Neu, EGFR, 
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PDGFR, FAK, Raf, VEGFR, PI3K/Akt, MAPK, Axl, MET and Src (101-106).  In 
particular, our laboratory has provided evidence that the oncogenic activity of Src plays 
an integral role in PCa progression, especially, metastatic CRPC (107).  The next 
section will discuss the role of SFK activity in PCa  and will provide information on 
factors that may be associated with increased SFK activity in metastatic PCa.   
THE ROLE OF SRC FAMILY KINASES IN PROSTATE CANCER 
Of the nine family members, Src, Yes, Fyn, Lck, Lyn, Blk, Fgr, Yrk and Hck. 
Of these nine members, Src, Yes and Fyn are the most ubiquitously expressed.  In 
normal tissues, SFKs act as key signal transduction molecules facilitating cellular 
signals elicited by receptor protein tyrosine kinases, cytokine receptors, integrins, ion 
channels and G-protein coupled receptors. Upon activation, SFKs regulate biological 
processes, such as adhesion, migration, invasion, cell cycle and cytoskeletal changes. 
These processes are regulated by mechanisms of SFK activity and involve changes in 
the structural features of SFKs, which are outlined below. 
Src Family Kinase: General Structure and Mechanism of Activation  
Peyton Rous was the first to isolate the virus named Rous Sarcoma virus from 
chickens.  Years later, the identification of Rous Sarcoma virus as a type of retrovirus 
that harbored transforming protein, v-Src, was recognized (108).  These findings 
contributed to the discovery, by Bishop and Varmus, of Src as the cellular form of v-Src 
which was determined to be the product of the transforming gene harbored by avian 
Rous Sarcoma Virus (109).  A  major finding regarding Src function demonstrated that 
the Src protein possessed intrinsic protein tyrosine kinase activity making it the first 
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identified gene product of this kind (110).  Peyton Rous was awarded the Nobel Prize in 
Medicine for his efforts in the discovery of the virus (111,112). 
 
 
The structure of SFKs is composed of the following domains important to the 
complete activation of the protein shown in Figure 2a and b.
 
 The Src homology 
domain-4 (SH-4) is important for membrane localization by either palmitoylation or 
myristoylation of which Src is the only member that does not undergo palmitoylation. 
The SH-3 domain is a domain that recognizes prolines in the Pro-xx-Pro motif of other 
substrates important for protein-protein interactions.  The SH-2 domain recognizes 
phosphorylated tyrosine residue-containing substrates and also serves to stimulate 
protein-protein interactions.  The SH1 domain serves as the catalytic kinase domain 
comprising Y
419 
which is autophosphorylated upon Src activation.  The C-terminal also 
contains a negative regulatory phosphorylation residue at Y
530
.  In the inactive state, 
Y
530
 is phosphorylated forming an intramolecular interaction with the SH2 domain that 
also associates with the SH3 domain and the linking region between the SH2 and kinase 
domain. In particular, C-terminal kinase (Csk) and Csk homologous kinase are two 
kinases that inactivate SFKs and the intramolecular interactions limit the accessibility of 
substrates to be phosphorylated further maintaining an inactive Src state. In terms of 
regulation of Src activation, there are several mechanisms outlined below.   
One mechanism involves dephosphorylation of Y
530
 which increases the 
dissociation of the C-terminal region from the SH2 domain resulting in an open 
confirmation. Multiple phosphatases dephosphorylate the Y
530
, such as SH2-containing 
phosphatase 1, protein tyrosine phosphatase (PTP)1B and PTP1α (112,113-115).  
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Figure 2 
Structure and Activation of Src Family Kinases 
A. Structure of Src Family Kinase 
Src family kinases consist of four domains and two regulatory regions that facilitate 
intra and intermolecular interactions.  These domains represent Src homology domains .  
The regulatory regions are the negative regulatory (NR) domain and the unique region.  
B.   Regulation of Src activation 
Src contains multiple domains serving different functions.  SH4 domain contains  a 15 
amino acid sequence required for lipid modification along with a glycine  needed for 
myristoylation of Src.  This site is critical for membrane localization.  The unique 
domain consists of multiple serine and threonine residues needed to facilitate 
interactions with proteins, such as PKA, PKC and cdk2/cyclin.  The SH3 domain 
consists of the proline-rich (PXXP) motif needed for intra and intermolecular 
interactions.  The SH2 domain binds proteins containing phospho-tyrosine sites.  The 
SH1 domain is a highly conserved protein kinase domain containing Y419.  This 
domain facilitates autophosphorylation of Y419 upon Src phosphorylation. Lastly, the 
negative regulator (NR) domain consists of Y530 which interacts with the SH2 domain 
upon Csk (C-terminal Src kinase)-mediated phosphorylation. 
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Other mechanisms involve deregulation of regulatory proteins, such as Csk, or 
increased activity of cytoplasmic proteins.  However, for full SFK activation, 
autophosphorylation of Y
419
 must occur within the catalytic kinase domain. SFK 
activation is also activated by cellular signals, such as RTKs, integrins and cytokine 
receptors which modulate normal cellular functions, such as, survival, migration, 
proliferation and invasion.  SFK activation has been demonstrated to be aberrantly 
active in multiple cancers, including PCa.  However, studies have failed to provide 
evidence of mutations as a mechanism for this aberrant SFK activation along with 
previous studies suggesting that SFKs are not capable of cellular transformation.  These 
findings raised questions about how SFKs contribute to cancer progression. This has 
prompted an increase in research investigating how SFK activity plays a role in cancer 
progression.  
Significance of SFK activity in cancer and PCa progression 
Clinical studies report that SFK activity is increased in patients with advanced 
disease correlating with shorter overall survival and increased metastatic incidence 
(116-118).   In vitro and in vivo studies supporting these reports come from our 
laboratory and others demonstrating that SFK inhibition decreases tumor growth and 
metastatic potential in multiple cancers, including PCa (107,119-123).  A pinnacle 
study, providing strong evidence that Src promotes tumor progression, by Agarwal et al. 
demonstrated that increased Src activity is an independent prognostic indicator at 
multiple stages of colon carcinoma (124).  This provided foundational evidence 
suggesting that Src, of the many SFKs, may play a role in many stages of mulitple 
cancers, including PCa.   
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Earlier reports demonstrate that Src is important in the development of PCa 
and progression (125-129).  In contrast to earlier reports, recent evidence suggests that 
Src, along with Fyn and Lyn, result in transformation of prostate epithelium suggesting 
a more functional role in the early events of PCa progression (37).  This study further 
reports that among Src, Lyn and Fyn, Src demonstrates the strongest transforming 
capacity and oncogenic phenotype.  As a result, increased Src activity has been 
implicated as a central signaling component of PCa progression that contributes to 
changes in multiple stages of PCa progression.  One thought regarding Src’s increased 
activity is that Src’s activity has also been demonstrated to be regulated by upstream 
signaling mechanisms which may contribute to changes in PCa progression.  Upstream 
signaling is thought to be one mechanism by which Src activity is increased in cancer 
and, as such, the investigation of signaling mechanisms mediating Src activity in PCa 
has been of interest. Rather than provide all of the signaling mechanisms involved, this 
thesis aims to focus on signaling families that mediate Src activity in PCa progression, 
which will be discussed in the next section.    
Significance of Src signaling mechanisms in PCa 
Multiple studies demonstrate that Src activation can occur through activation 
of integrins, RTKs and cytokine receptors in many cancers show in Figure 3 (130-132).  
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Figure 3 
Src-Mediated Pathways in Cancer 
This figure displays pathways that Src regulates in multiple cancers.  Src regulates 
pathways that modulate survival, angiogenesis, proliferation and motility/migration 
events.    
Summy JM and Gallick GE. Clin Cancer Res 2006 Mar 1; 12(5): 1398-401  
Reproduced with permission 
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In PCa, our laboratory reports that integrin clustering regulates the recruitment of Src to 
activated FAK stimulating the activation of related signaling pathways, such as PI3K, 
Rho, Ras, paxillin, p130Cas, ERK and MAPK  leading to changes in motility/migration, 
invasion and cell spreading (131).  In addition, there are multiple RTKs with intrinsic 
protein kinase activity that have been demonstrated to modulate Src activation in PCa, 
outlined in multiple reports (103,133-136).  Our laboratory offers additional reports 
demonstrating that tyrosine kinases, receptor and  non-receptor, contribute to metastatic 
properties of PCa cells (107, 137,138).  This work has provided a great deal of evidence 
showing that signaling through integrins, RTKs and other tyrosine kinases, not only 
regulates Src activation, but facilitates changes in metastatic properties of PCa.  More 
recently, another upstream signaling mechanism has received more attention for its role 
in tumor progression, GPCRs, but whether it modulates Src activation and facilitates 
changes to metastatic properties of PCa progression is unclear and is the focus of this 
thesis. 
 
GPCRs are considered to be the largest family of cell surface molecules 
facilitating signal transduction pathways regulating biological functions through stimuli, 
including peptide growth factors, hormones and cytokines.  Studies demonstrate that the 
expression of GPCRs and GPCR ligands are increased in multiple cancer cell lines and 
tumors, including PCa (138-141).  This has been outlined in a comprehensive review of 
the role of GPCRs in cancer by Dorsam and Gutkind (142).   There is emerging 
evidence demonstrating that GPCRs and GPCR ligands, such as interleukins, initiate 
intracellular signaling cascades involving many factors, including protein kinases and 
cytokines, regulating many metastatic properties of PCa (143-145).  This information, 
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provided in the next section, is minimal and limited in scope, but provides foundational 
support for the role of GPCR ligands and GPCRs in PCa progression. 
There is evidence demonstrating that Src-mediated changes may be influenced 
by GPCR ligands, such as IL-8, in PCa, the focus of this thesis (146,147).  
 
One study, 
from our laboratory, demonstrates that Src inhibition decreases interleukin 8 (IL-8) 
cytokine production in PCa cells suggesting that Src-mediation of PCa progression may 
be regulated by, not only integrins and RTKs, but also by GPCRs and/or GPCR ligand 
upstream signaling (148-149).  However, there is limited information about what 
GPCR-initiated signaling cascades are involved in regulating Src activation and what 
metastatic properties it modulates in PCa. As a result, it is of interest to this thesis to 
identify GPCR-regulated mechanisms that facilitate Src-mediated changes in metastatic 
properties of PCa.   However, signaling mechanisms facilitating Src activation in PCa 
provide only one possibility of how Src regulates PCa progression.  There may also be 
Src signaling mechanisms present in the tumor microenvironment which contribute to 
PCa progression, an emerging field of study and another focus of this thesis.  The 
following section will discuss Src’s role in the tumor microenvironment.  
Significance of Src in the tumor-stromal microenvironment 
The role of Src in the tumor microenvironment has been mostly observed in 
bone metastases and in osteoclast and osteoblast functions.  Initial studies demonstrate 
that Src -/- mice undergo osteopetrosis, a bone-remodeling disorder, causing defective 
bone resorption by osteoclasts (150).  This study led to multiple studies dedicated to 
Src’s role in bone based upon the fact that Src inhibition may decrease bone turnover.  
Studies supporting this theory demonstrate that inhibition of Src increases osteoblast 
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differentiation and bone formation while decreasing osteoblast proliferation.  Src also 
regulates the bone remodeling process by negative regulation of osteoblasts and positive 
regulation of osteoclasts (151).  The use of Src inhibitors in in vitro studies, such as 
dasatanib and saracatanib, demonstrated decreases in bone regulatory mechanisms, such 
as osteoclast activity and PCa-cell induced osteoclast activity (152-154).  As projected 
by the initial src -/- mouse study and the ensuing in vitro studies, multiple Phase I and II 
clinical trials have been conducted with SFK inhibitors demonstrating decreases of bone 
remodeling markers, such as N-telopeptie of type 1 collagen (urinary NTX) and C-
telopeptide of type 1 collagen (serum CTX) in healthy men. This led to Phase I/II trials 
with saracatinib and dasatanib which showed promising results, in the dasatanib trial, in 
a small cohort of men with metastatic CRPC.  
Although these studies suggest that Src modulates biological functions of the 
tumor and possibly the bone microenvironment, there are still some patients that will 
not respond to these therapeutic strategies.  As a result, we must investigate other cell 
types in the tumor microenvironment contributing to tumor progression that contain 
Src-mediated signaling cascades. Earlier reports show that increased Src expression in 
bone marrow stromal cultures correlates with increased growth factor and cytokine 
stimulation (155). 
 
Another study demonstrates that Src activity mediates prostate 
epithelial cell migration to prostate stromal cells in the presence of growth factors (156). 
These studies suggest that Src regulates signaling pathways in cells supporting and 
associated with PCa progression, but the mechanism of Src activation and signaling 
pathways associated with Src activation in the stromal microenvironment are unclear.  
However, there is information to suggest that, not only Src activation, but factors 
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produced and secreted by the stromal microenvironment contribute to PCa progression.  
Recent studies suggest that one of those stromal produced factors, IL-8, modulates 
tyrosine kinase activation, but it is unclear if or how tumor and stromal produced IL-8 
modulates the tyrosine kinase activation of  Src to promote the metastatic potential of 
PCa.  As a result, an integral part of my PhD thesis will be to determine how IL-8 
contributes to Src activation in metastatic properties of PCa as well as explore how 
stromal produced IL-8 contributes to Src activation in PCa. The next section will 
introduce and discuss the function and roles of IL-8 in PCa.   
THE ROLE OF INTERLEUKIN-8 IN PROSTATE CANCER 
Of the many cytokines and chemokines discovered, IL-8 represents one that 
modulates a variety of biological processes, not observed, by other cytokines.  Much of 
the work addressing the roles of cytokines in PCa has been focused on IL-8, IL-12 and 
IL-6. IL-6 has been associated with tumor burden and metastatic CRPC, but in vitro 
studies have identified IL-6 more as a facilitator of growth and survival while IL-12 has 
been shown to modulate, primarily, invasion of PCa cells in vitro (158-161).  It is 
evident that these cytokines play important roles in modulating biological functions of 
PCa progression, but it is unclear what role IL-8 signaling plays in PCa progression to 
metastatic disease and the mechanism of IL-8 signaling in biological functions of PCa.  
This thesis will discuss these topics in upcoming sections.  The following section will, 
first, discuss IL-8 structure and regulation.   
Interleukin 8: General Structure and Regulation 
IL-8 (also known as CXCL8, GCP-1 and NAP-1) is an 8 kDa member of the 
CXC chemokine family. The IL-8 protein belongs to a family of CXC chemokines 
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denoted by two cysteines surrounding any amino acid. IL-8 is also classified according 
to the absence or presence of the ELR (Glu-Leu-Arg) motif in the N-terminus.  IL-8 is a 
99-amino acid precursor which is processed as a mature protein by cleavage of the 
leader sequence. Two forms of the mature protein exist, a 72-amino acid protein and a 
77-amino acid protein with the 72-amino acid protein representing the most 
predominate form. (Figure 4a and b) It was first discovered as a pro-inflammatory 
cytokine on chromosome 4 secreted by human blood monocytes and later redefined as a 
“chemokine” for its chemotactic capabilities.  
Since then, IL-8 has been shown to be expressed and secreted by multiple cell types 
including stromal cells and tumor cells (162).  Binding studies indicate that IL-8 binds 
to two G protein coupled receptors, CXCR1 and CXCR2.  CXCR1 exhibits high 
affinity for IL-8 while CXCR2 exhibits affinity for three ligands, IL-8, GROα and 
NAP-2 (163,164).  Although the role of CXCR1 and 2 are important to the function of 
IL-8, there is still controversy over how the receptors contribute to biological functions 
and how they initiate changes in cancer progression which will not be a highlight of this 
thesis.  This thesis will address the importance of IL-8 in cancer progression with an 
emphasis on its significance to PCa progression outlined in the next section. 
Significance of IL-8 in cancer progression 
Clinical evidence demonstrates that increased IL-8 expression and serum levels 
correlates with poor prognosis and recurrent disease in many cancers, including 
melanoma, ovarian, colon, lung, breast, lymphoma, head and neck small cell carcinoma, 
liver and prostate (165-171).  Therapies targeting IL-8 have been investigated, such as 
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Figure 4 
Structure and Regulation of Interleukin 8 
A. Illustration of IL-8 and sites required for activity.  The ELR sequence is 
essential to the binding of the IL-8 receptors and for its activity .  The tyrosine and 
lysine residues and the alpha helical region located near the C-terminus are required for 
binding of the IL-8 receptors as well.   
B. Transcriptional regulation of IL-8. The picture shows transcription factors 
important in IL-8 transcription.  The basal levels of transcription are regulated by 
binding of the NF-kB repressing factor (NFR) to the negative regulatory element 
obstructing NFk-B binding.  Binding of octamer-1 (OCT-1) occupies the C/EBP site 
and deacetylation of histone proteins by histone deacetylase 1 (HDAC-1) modulates 
basal transcription as well.  Upon either induced or constitutive activity, NFk-B 
translocates to the nucleus binding near NRF.  C/EBP occupies the OCT-1 site while 
CREB binding protein (CBP)/p300 initiates chromatin remodeling through histone 
acetylation and activator protein-1 (AP-1) transcription factor becomes phosphorylated 
as well. The culmination of these events results in transcription of IL-8. 
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the administration of the humanized monoclonal antibody ABX-IL-8.  ABX-IL-8 
administration demonstrated decreased metastatic potential of melanoma in xenograft 
models and decreased tumor growth in bladder cancer (172-173).  Although this 
treatment did not provide significant clinical benefit, it provided necessary information 
regarding how IL-8 signaling modulates tumor progression in a subset of cancers.  
Many of these studies prompted the investigation of a potential role for IL-8 in PCa 
progression.   
Significance of IL-8 in PCa progression 
Zabransky et al. demonstrate that lenalidomide treatments decreased IL-8 
serum levels in patients with PCa, but, interestingly, IL-8 levels remained high in 
patients who progressed (169).  A phase I/II trial with Dasatanib demonstrates that a 
cohort of responding patients display a decrease in serum IL-8 while non-responders 
showed either increased or stable IL-8 levels.  Dayanni et al. report a correlation 
between dasatanib levels and decreased serum IL-8.  This preliminary data strongly 
suggests that IL-8 may be an additional marker of response, but a larger study is 
warranted and has been completed with results pending. Further support comes from in 
vitro and in vivo studies demonstrating that IL-8 expression correlates with 
tumorigenecity and metastasis of PCa (172,173).  However, there is controversy and 
unclear evidence concerning IL-8’s particular role in metastatic CRPC.   
In vitro studies have demonstrated that IL-8 overexpression in androgen-
positive cells desensitizes PCa cells to anti-androgens, such as bicalutamide and the 
DNA damage agent, oxaliplatin, while IL-8 also reduces growth inhibition 
(146,174,175).  In contrast, another report demonstrates IL-8 increases the proliferation 
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of PCa cells, but this is not observed in the presence of bicalutamide (176).  Other 
conflicting results from these and other studies are surrounded around how IL-8 
regulates AR and PSA levels (146,147,176).  These controversies have also led to an 
unclear understanding of how IL-8 signaling modulates PCa progression and the 
metastatic properties it involves.  This thesis will identify IL-8 signaling pathways 
involved in regulating metastatic properties of PCa progression to metastatic CRPC.  
The next section will discuss studies prompting more investigation about the signaling 
mechanisms and biological processes surrounding the role of IL-8 in PCa progression.   
Significance of IL-8 in metastatic properties of PCa 
IL-8 induces classical biological functions including, chemotaxis, migration, 
calcium mobilization, protein translation, inflammatory responses and cell proliferation, 
with chemotaxis and migration being the first identified biological effects in normal 
cells, illustrated in Figure 5.  IL-8 was recognized as a regulator of chemotaxis through 
neutrophil-activation in vitro (163).  Later studies demonstrated that IL-8 is involved in 
other biological functions of normal cellular functions and cancer cell functions. One of 
the first studies observing IL-8 in PCa demonstrated that neutralization of IL-8 
decreases angiogenic activity and tumorigenecity of PC-3 cells (249).  Since then, it has 
been well established that IL-8 plays a critical role in angiogenesis of cancer cells 
(177,178).  Kim et al. demonstrated that PCa cell lines express high levels of IL-8 
contributing to increases in microvessel density increasing prostate tumor growth (179).   
In vivo studies by Inoue et al. also report increased VEGF and IL-8 expression 
demonstrating a correlation between neovascularization and IL-8 expression (173).  
More recent studies have been aimed at determining factors that potentially regulate IL-
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8 or that IL-8 regulates modulating angiogenesis (146,147,175,176).  There have been 
many advances made in understanding the role of IL-8 in the process of angiogenesis in 
PCa, but there has been and increasing effort put towards understanding how IL-8 
contributes to other biological processes of PCa, such as migration and invasion and its 
suggested role in the progression to metastatic PCa.
 
 
Although the first studies demonstrate IL-8 as a novel chemoattractant, 
subsequent reports determined that IL-8 also regulates shape change and directional  
migration (180-182). As a result of these studies, IL-8 has been identified as a migratory 
regulator in multiple cancers,  acute myeloid and lymphoid leukemia (AML and ALL) 
and melanoma being the first cancers to describe IL-8 as a relevant chemoattractant and 
migratory factor (183,184).  Bar-Eli et al. demonstrates that IL-8 directly regulates 
matrix metalloproteinase (MMP) gene expression increasing invasion providing some 
of the foundational studies for examining the invasive role of IL-8 in numerous cancers, 
including PCa (185).  Following these studies, Reiland et al. provided one of the first 
PCa studies demonstrating that PCa cells show significant increases in migration and 
invasion in response to exogenous IL-8 (186).  Inoue et al. also demonstrates that 
overexpression of IL-8 in PCa cells significantly increases migration, while antisense 
transfection of IL-8 in high IL-8 expressing PCa cells decreases 
migration (173).  More recent studies have demonstrated that IL-8 increases the 
migration of androgen-independent PCa cells suggesting that IL-8 production regulates 
PCa progression in the absence or in the place of androgen regulation (146,147).  This 
evidence suggests that IL-8-mediated migration and invasion participates in PCa 
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progression to a metastatic phenotype, but there are questions about the signaling 
mechanisms involved.   
Significance of IL-8 signaling in metastatic properties of PCa 
Although information regarding IL-8 signaling cascades modulating biological 
functions of PCa is increasing, the mechanisms are still unclear. A comprehensive 
review by Waugh et al. provides a schematic of suggestive IL-8 signaling pathways that 
contribute to biological functions of cancer progression (175).  There is information 
regarding specific canonical IL-8 signaling pathways regulating biological functions of 
cancer and it is suggested that protein tyrosine kinase activity is involved, where the 
clinical observation of increased IL-8 expression and SFK activity in PCa tissues, these 
reports provide interesting implications for a cooperative role of IL-8 and Src in PCa 
progression.  This phenomenon had not been explored until recently where the results 
are interesting, but inconclusive, and are limited in scope.    
 
In PCa, studies suggest that IL-8 signals through tyrosine kinases, such as Src 
and FAK, during the transition of androgen dependent PCa to androgen independent 
PCa (146,147).  A recent study demonstrates that IL-8 participates in the transition of 
androgen dependent PCa to androgen independent PCa by increasing AR transcriptional 
activity (176).  These reports suggest that, not only, do tyrosine kinases activate 
signaling mechanisms important for metastatic properties in PCa cells, but that this may 
occur through IL-8 cytokine-induced stimulation of tyrosine kinase activity in 
metastatic CRPC (146,147).
 
As a result, this thesis will address if IL-8 and Src 
cooperate to induce changes in biological functions related to PCa progression to 
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Figure 5 
IL-8-Mediated Signaling Pathways in Cancer 
This is a simplified illustration of how IL-8 regulates multiple pathways that lead to 
changes in angiogenesis, proliferation, invasion and survival.  The solid blue lines are 
known pathways that IL-8 regulates, such as the canonical IL-8 activation of PLC and 
PKC.  The dashed blue lines represent less understood pathways of IL-8 regulation, 
such as the IL-8-mediated regulation of RhoGTPase.  Lastly, the orange solid lines 
represent pathways that stimulate transcription factor activity.  This illustration displays 
known and unknown pathways of IL-8 regulation and modulation of multiple biologic 
functions of cancer.  
DJ Waugh Clin Can Res 2008 Nov 1;14(21): 6735-41 
Modified with permission 
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metastatic disease.  In addition to understanding the contributions of factors expressed 
and secreted by the tumor and their role in tumor progression, PCa is also influenced by 
the microenvironment. As a result a major thrust of this thesis will be to address how 
IL-8 signaling in the tumor microenvironment affects PCa progression.  The next 
section will discuss the importance of understanding IL-8 in the tumor 
microenvironment and what role that plays in PCa progression.      
Significance of IL-8 in the tumor-stromal microenvironment 
It is well established that IL-8 is a potent cytokine secreted by cell types 
surrounding and interacting with cancer cells. The intratumoral production of IL-8 is 
associated with increased survival and growth, but IL-8 production also occurs by cells 
supporting the tumor.  Initial studies demonstrate that IL-8 is expressed and secreted in 
abundance by bone marrow stromal cells (190,191).  Other studies demonstrate that IL-
8 is elevated in bone remodeling cells and fibroblastic stromal cells, two cell types 
directly interacting with PCa cells.  Earlier studies supporting this demonstrate that the 
stromal compartment has a direct impact on epithelial cell behavior (192).
 
 However, 
initial studies reported the stromal compartment as a passive structure of support with 
very little aid to the biological function of cells.  Over the past decade, there has been 
increasing evidence demonstrating that the stromal compartment provides a permissive 
and supportive environment of survival for cancer cells.  As a result, it is suggestive that 
cancer progression, including PCa, is also a result of microenvironmental-mediated 
effects.   
These microenvironmental-mediated effects have been studied in other cancers 
and have demonstrated that cancer-produced growth factors and cytokines modulate 
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bone formation (193,194).  Interestingly, evidence also demonstrates that IL-8 can 
induce fibroblast or stromal derived cells to become reactive stroma. (196).  As the 
information grows concerning how factors, such as IL-8, modulate the 
microenvironment, there is less information indicating the sources of IL-8 production, 
albeit tumor-produced and/or stroma-produced.  There is also little evidence discussing 
how this IL-8 production affects PCa progression and what IL-8 signaling pathways are 
involved.  
It is possible that a heterotypic crosstalk mechanism exists whereby IL-8 
production by either the stromal or tumor compartments modulates IL-8-mediated 
signaling pathways in the tumor compartment to increase PCa progression. Since, there 
is evidence supporting a collaborative role of IL-8 and Src in PCa progression, there is a 
possibility that the crosstalk mechanism in the stromal compartment involves these 
factors.  However, this has not been studied and will be addressed in this thesis.    
We know that the tumor microenvironment provides a rich milieu of factors 
contributing to PCa cell survival, proliferation, migration and invasion.  IL-8 production 
by fibroblasts and stromal cells is associated with survival of PCa cells, but we do not 
know if Src is involved in this mechanism and whether this is an IL-8 autocrine and/or 
paracrine mediated event. There have been preclinical mouse model studies addressing 
the role of IL-8 in the metastatic potential of PCa (173,196).  These studies suggest that 
overexpression of IL-8 increases the metastatic potential of PCa in mouse models, but 
the microenvironment-mediated  nature of PCa leads us to hypothesize that the tumor is 
not the only contributing cell type in PCa progression to metastatic disease.   
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Questions that are still unclear are how and why the tumor-stromal interaction 
affects the metastatic potential of PCa, which is integral to this thesis. These questions 
are capitalized by current efforts to assess therapeutic strategies that target factors 
expressed and/or secreted by both tumors and microenvironmental cells.  The next 
section will discuss current therapeutic strategies in PCa and will highlight the efforts 
made in developing strategies that target the tumor and microenvironment.     
CURRENT STRATEGIES IN TREATING PROSTATE CANCER 
Treatment strategies for localized and castration resistant prostate cancer  
Treatment of localized PCa usually involves radiation or surgery which 
eradicates nearly 100% of the cancer, but there are 30-50% of these patients that will 
incur either a local or distant recurrence.  For recurring patients, first-line therapies 
involve androgen deprivation therapies (ADT), such as luteinizing hormone-releasing 
hormone (LHRH) and anti-androgens, but unfortunately in many of these patients, 
CRPC develops.  Many of the earlier treatment options for CRPC, such as 
mitoxantrone-based treatments or bisphosphonates, provided palliative benefits, but did 
not provide overall survival benefits (197,198).  In 2004, the randomized clinical trials, 
TAX 327 and SWOG 9916, reported the first evidence for increased survival benefit 
and reduced PSA in patients with metastatic CRPC using docetaxel-based 
chemotherapies and resulted in FDA approval for use of docetaxel as a treatment for 
metastatic CRPC (199,200).  Docetaxel was the only FDA approved drug used to target 
metastatic CRPC.  Now, multiple drugs have been approved due to the increased 
number of drugs entering into clinical development.  The number of drugs in clinical 
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development has increased, in part, due to the advances in the understanding of the 
cellular and biological mechanisms of PCa progression.   
The principal increase in understanding that has led to new drugs is that 
androgen ablation does not effectively block AR signaling. As a result, there has been 
increased development of anti-hormonal therapies, such as abiraterone acetate and 
MDV3100.  Abiraterone acetate, an inhibitor of the key enzyme for hormonal synthesis 
(cytochrome P17), demonstrated a >50% decline in PSA in CRPC docetaxel-treated 
patients in a phase II trial with 38% of the patients showing partial response and also 
demonstrated an overall survival of ~4 months with abiraterone treatment. In April 
2011, abiraterone became an FDA-approved anti-androgen therapy for use in metastatic 
CRPC (5,201).  MDV3100, an AR antagonist, has also been used in a phase I/II study 
whereby patients treated with chemotherapy showed >50% decrease in PSA and non-
chemotherapy treated patients displayed >60% decrease in PSA levels (202).  
MDV3100 (Enzalutimide) is now an FDA approved therapeutic agent that disrupts 
translocation of AR to the nucleus decreasing AR binding to DNA and preventing 
coactivator recruitment which is a proposed mechanism thought to contribute to tumor 
regression of CRPC (202).  These results suggest that patients with androgen responsive 
metastatic CRPC may gain from therapeutics targeting continued AR signaling. 
However, targeting sustained androgen signaling is only one aspect of current 
therapeutic strategies addressing the cellular events in metastatic CRPC.  Therapies 
targeted against signaling molecules, such as growth factor and tyrosine kinase 
signaling, upregulated in metastatic CRPC are needed as well.   
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The observed aberrant expression of kinase pathways, such as Her2/Neu, 
EGFR, PDGFR, FAK, Raf, VEGFR, PI3K/Akt, MAPK, Axl, MET and Src, in 
metastatic CRPC have prompted the development of many therapeutic agents (203-
206).  Detailed information regarding these pathways will not be discussed further, but 
are mentioned to highlight that targeting aberrantly active kinase pathways is an 
increased area for therapeutic strategy. However, I will discuss recent efforts in the 
development of therapeutic strategies for targeting the aberrant activity of the tyrosine 
kinase, Src, a major subject of this thesis.  These recent efforts are, in part, due to 
studies from our laboratory and others demonstrating aberrant Src activity in the 
progression of PCa to metastatic CRPC and in the microenvironmental compartment as 
well.   
Evidence suggests that the expression of Src in multiple microenvironment cell 
types contributes to the progression of PCa.  Mouse model studies using Src -/- mice 
develop osteopetrosis (bone-building disease) suggesting that Src expression impairs 
osteoclast activity important for the balance of the bone remodeling process (207).  The 
disruption of Src activity also increases bone-building activities by negative regulation 
of osteoblasts (151).  Araujo et al. provides a comprehensive review demonstrating  that 
SFK inhibition has anti-osteoclast activity preventing osteolytic metastases in breast 
cancer and decreased growth of tibially-injected prostate tumors (208).  These studies 
have prompted the development of SFK inhibitors, such as AZD0530 (Saracatinib) and 
Dasatanib, that demonstrate inhibition of tumor growth and osteoclast activity.  
Saracatinib was introduced as a dual SFK/Abl inhibitor and has demonstrated promising 
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in vitro and in vivo results and has entered into phase I/II trials (209,210).  The clinical 
importance of SFK inhibition by Saracatinib is still pending.  
Dasatanib is another SFK inhibitor that is considered to be the most clinically 
studied Src inhibitor (212).  Dasatanib was developed as a potent biochemical inhibitor 
of Src and Bcr/Abl kinase activity in multiple solid tumors, including PCa.  Initial in 
vitro findings demonstrated that dasatanib, now known to be a multi-kinase inhibitor, 
decreases SFK activity in PCa cell lines (107,117). Preclinical studies from our 
laboratory demonstrate that dasatanib decreased lymph node metastases as well as 
migration and invasion of cells in vitro (107).  
 
In 2009, our institution completed a 
Phase 1/2 trial on dasatinib + docetaxel, with results so promising a worldwide Phase 3 
trial has been completed with results pending (211).  Some of the preliminary results 
demonstrate that combination therapy of docetaxel and dasatanib in metastatic CRPC 
(CA180-086) showed dramatic decreases in bone alkaline phosphatase, BAP, and 
urinary N-telopeptide, UNTx and 28% of patients displayed a reduction in size and 
number of lesions due to bone scan (213).  The remaining endpoints of overall survival 
and progression free-survival are being analyzed.  These studies suggest that dasatanib 
may serve therapeutic benefit for patients by targeting, not only, metastatic CRPC, but 
also the tumor microenvironment.  As mentioned, osteoblast and osteoclasts are two cell 
types in the tumor microenvironment affected by Src, but cytokine-producing cell types, 
such as fibroblasts are also located in the tumor microenvironment.  One of the 
cytokines produced by fibroblasts is IL-8 known to be important in PCa progression.  
We are slowly gaining an understanding of the biological pathways and 
mechanisms over-expressed or deregulated in metastatic CRPC. The combination of 
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therapies targeting kinase-mediated signaling pathways in the tumor and the 
microenvironment may serve as one therapeutic strategy to disrupt the growth and 
progression of metastatic CRPC.  As a result, this thesis will focus on understanding 
thecontributions of Src signaling in metastatic disease and will identify signaling 
pathways associated with progression to metastatic disease. 
 
SUMMARY OF PROBLEM AND HYPOTHESIS 
Prostate cancer is a leading cause of cancer mortality in men in western 
civilization.  While localized disease is almost always incurable, <40% of men will 
incur metastatic disease despite local therapies. As a result, therapies targeting factors 
involved in PCa progression will be beneficial in preventing metastatic spread. Two 
contributing factors to the metastatic spread of PCa are IL-8 and Src.  These factors are 
also produced and expressed by microenvironmental cells, such as stromal cells, which 
take part in the bidirectional interactions increasing prostate carcinogenesis.  
The goal of this Ph.D. dissertation is to investigate the role of IL-8-mediated Src 
family kinase activation in tumor-tumor and tumor-stromal interactions in metastasis of 
prostate cancer.  Previous studies suggest that aberrant Src activity regulates functions 
that increase IL-8 secretion by PCa cells.  In addition, IL-8 overexpression, by the 
tumor and stroma, and increased Src activity have, individually, been implicated as 
mediators of PCa progression. However, there is not a clear understanding of the 
relationship between IL-8 signaling and SFK activation.  The questions surrounding IL-
8 and SFK involvement in PCa are: 1) is there a feed forward loop whereby IL-8-
induces Src activation further increasing IL-8 secretion which affects metastatic 
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properties of PCa? 2) is there a paracrine mechanism whereby IL-8 production by the 
stroma affects Src activation and metastatic properties of PCa? and 3) how does IL-8 
production by the stroma affect tumor growth and metastatic potential?   
The hypothesis tested in the work of this dissertation is that IL-8-mediated Src 
activation regulates increased metastatic potential of prostate cancer through tumor-
tumor and tumor-stromal interactions.   To test this hypothesis, I determined if  IL-8 
expression and secretion by PCa cells affects Src activity and migration in vitro.  I  next 
determined the effects of stroma-produced IL-8 on migration and invasion of PCa 
through Src activation in vitro.  Lastly, I determined whether IL-8 production by the 
stroma affects tumor growth and metastatic potential in vivo.   The work in this 
dissertation has led to a better understanding of  how IL-8 signaling in PCa and the 
stroma modulates PCa progression as well as increased our understanding of the role of 
SFK activation in IL-8 signaling in PCa. 
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CHAPTER 2 
MATERIALS AND METHODS 
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Cell Lines 
The approach for this study was to use two well established cell culture models 
that mimic the progression of PCa from low metastatic to high metastatic potential with 
high metastatic potential representing advanced stage disease. The LNCaP human PCa 
progression model and the PC3 model contain isogenic variants of differing metastatic 
potential.  The LNCaP cells are non-metastatic and androgen dependent while C4-2B4 
cells are bone metastatic and androgen independent, as previously described (43).  The 
LNCaP cell lines were provided by Dr. Mike Gray (MDACC). The PC3-MM2 cell line 
was created and kindly provided by the lab of Dr. Isaiah J. Fidler in the Department of 
Cancer Biology, the University of Texas MD Anderson Cancer Center. PC3 cells are 
low metastatic and androgen-dependent while PC3-MM2 cells are lymph node 
metastatic and androgen-independent, as previously described (214,215).  The HS5 cell 
line is an immortalized fibroblastic stromal cell derived from  human bone marrow and 
purchased  from  ATCC.  This cell line was established as previously described (224). 
Briefly, the LNCaP and C4-2B4 cell lines were maintained in RPMI 1640 
medium (Sigma Aldrich) containing L-glutamine supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin (HyClone), MEM Non-Essential Amino 
Acids (NEAA), Sodium Pyruvate and MEM Vitamin Solution.  NEAA, Sodium 
Pyruvate and Vitamin Solution were purchased from Gibco.  The PC3, PC3-MM2 and 
HS5 cell lines were maintained in Dulbecco’s Modified Eagle Media (DMEM)/ Ham’s 
F-12 (Sigma Aldrich) medium supplemented with 10% FBS and 1% 
penicillin/streptomycin.  Cells were also tested for mycoplasma using an enzymatic 
based method, MycoAlert™ Detection Kit, by Lonza and polymerase chain reaction 
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(PCR) method, Lookout® Plasma Elimination Kit by Sigma Aldrich.  All cells were 
tested and found to be mycoplasma free. 
Reagents 
Recombinant IL-8 (72a.a.;rh-IL-8) was purchased from PeproTech. The 
thiazole-based dual Src/Abl kinase inhibitor, 2-acylamino-5-carboxamidothiazole 
(BMS-354825/dasatanib) was a gift from Bristol Myers Squibb.   
Construction of Lentiviral shRNA to IL-8 
For this study, PC3-MM2 and HS5 cells were infected with a GFP-labeled 
lentiviral-based IL-8 short hairpin RNA (shRNA).  The lentiviral system is a well-
established system developed by Didier Trono and the specific lentivirus system for IL-
8 was made and kindly provided to us by Dr. Bar-Eli (215).  Briefly, sense and 
antisense oligonucleotides from the IL-8 siRNA target sequence (5’-GCCAAGGA 
GUGCUAAAGAA-3′) were designed with a hairpin and sticky ends (ClaI and MluI), 
annealed to the green-fluorescent protein (GFP) labeled pLVTHM lentviral gene 
transfer vector, used for DNA isolation and lentiviral production by the described 
method (216).  A nontargeting sequence (5′-UUCUCCGAACGUGUCACGU-3′) was 
used as a control.  
After plating of PC3-MM2 or HS5 cells, 500ul of viral supernatants were 
added to semi-confluent  cells along with 6ug/ml of polybrene infection reagent 
(Millipore) and 500ul of growth media. After 48 hour incubation, GFP cells were 
visualized using fluorescence microscopy. Cells were then expanded to 150cm
2
 tissue 
culture plates and GFP sorted by fluorescence activated cell sorting (FACS) using the 
Flow Cytometry and Cellular Imaging (FCCI) Core Facility at MD Anderson.  qRT-
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PCR and ELISA was performed to determine if endogenous and secretory IL-8 
knockdown using methods in the previous mentioned sections on qRT-PCR and ELISA.  
Construction of IL-8 expression vector  
The work discussed in this section was done in collaboration with Lily Huang 
and Dr. Bar-Eli (Department of Cancer Biology, MDACC).  The protein encoding 
region was amplified from human PC3-MM2 cDNA using the Touchdown PCR 
program.  This method is useful in increasing the annealing specificity of PCR by using 
multiple cycles and multiple annealing temperatures enhancing formation of a more 
specific final PCR product. The sequences for the PCR primers were made with 
restriction enzyme sequences for Xho1 and Sal1 (Promega) - F- 5’ GGCTCGAG 
GCCACCATGACTTCCAAGCTGGCCGT-3’ and R- 5’ GAGTCGACTTATGAA 
TTCTCAGCCCTCT-3’.  The program was as follows: 94°C for 2 min.; 10 cycles of 
94°C for 15 sec., 68°C for 45 sec., -1.5 sec/cycle, 72°C for 2 min 30 sec.; 35 cycles of 
94°C for 15 sec., 50°C for 45 sec., 72°C for 2 min 30 sec, + 3 sec/cycle; 72°C for 20 
min. and holding at 4°C.  PCR samples were purified using QIAquick PCR Purification 
Kit (Qiagen).  Digestions were completed with purified PCR and pSI vector (Promega) 
according to manufacturer’s protocol (Promega).  Digested vector and PCR were run on 
a crystal violet gel.  Bands specific to IL-8 and digested pSI vector were extracted from 
the crystal violet gel using the gel extraction method and purified using the EZ Gel 
Extraction Kit (EZ Bioresearch) and Geneclean Turbo Kit (QBiogene) following the 
manufacturer’s protocol.  The pSI vector and IL-8 purified DNA were ligated and 
transformations were performed using XL-10 Gold competent cells using the 
manufacturer’s protocol (Stratagene).  After selection of 8-10 single colonies and 
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expansion, DNA was purified by performing the QIAPrep Spin Miniprep Kit according 
the manufacturer’s protocol (Qiagen).  Completion of cloning was observed by enzyme 
digestion and pSI/IL-8 DNA samples were confirmed by DNA sequencing using the 
DNA Analysis Core Facility (DAF) at MD Anderson Cancer Center. 
Construction of IL-8 mutagenesis vector 
We constructed a sequence that introduced point mutations in the shRNA 
target region without affecting the peptide sequences.  The QuikChange II XL Site 
Directed Mutagenesis (Stratagene) method allowed us to make point mutations in the 
basic IL-8 expression vector through PCR-based methodology.  Mutagenic primers 
were designed using the QuikChange Primer Design Program  
www.agilent.com/genomics/qcpd.  The primers are as follows: F-5’ 
CTGTGTGAAGGTGCAGTTTTACCTAGAAGCGCAAAGGAGCTTAGATGTCAG
TGCATAAAG-3’andR-5’ CTTTATGCACTGACATCTAAGCTCCTTTGCGCTTCT 
AGGTAAAACTGCACCTTCACACAG-3’.   
Briefly, synonymous mutations were introduced into the pSI/IL-8 DNA by 
performing PCR using PfuUltra Hotstart DNA polymerase. After Dpn1 digestion of 
amplified product, transformation into XL-10 Gold ultracompetent cells (Stratagene) 
was performed according to manufacturer’s protocol. After selection of 8-10 single 
colonies and expansion, DNA was purified by performing the QIAPrep Spin Miniprep 
Kit according the manufacturer’s protocol (Qiagen).  Completion of cloning was 
observed by enzyme digestion and pSI/IL-8 DNA samples were confirmed by DNA 
sequencing using the DNA Analysis Core Facility (DAF) at MD Anderson Cancer 
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Center.  pUC18 transformation and pWhitescript mutagenesis controls provided with 
the kit were used.   
The resulting rescue vector, pSI/IL-8, was transfected into cells using Fugene 6 
(Roche) according to manufacturer’s protocol and Quantikine IL-8 ELISA (R&D 
Systems) was performed to determine IL-8 levels.  
Immunoblot 
Cell lysates were extracted using previously described methods (107).  Protein 
concentration was determined by RC DC BioRad Protein Assay Kit followed by 
spectrophotometric analysis by the Perkin Elmer Envision 2104 Multilabel Reader. 
Equal amounts of protein (50ug) were boiled at 100°C for five minutes, separated on 
8% sodium dodecyl sulfate (SDS)- polyacrylamide gel electrophoresis (PAGE), 
transferred to PVDF membrane at 100 volts at 4°C and blocked with either 5% BSA or 
5% Milk dissolved in Tris-base with .05% Tween 20 (TBST). 
Cell lysates were subjected to immunoblot analysis using the following 
antibodies: anti-pSRC
 Y416
, anti-pAKT
S473
, anti-pAKT
S308
, anti-p38 MAPK, total AKT 
(Cell Signaling Technology, Inc.), CXCR1, CXCR2, pNF-κB/65 (Santa Cruz 
Biotechnology, Inc.), total SRC (Oncogene Science, Inc.), pFAK
Y861
 (Biosource, Inc.),  
total FAK (BD Transduction, Inc.) and vinculin (Sigma, Inc.).  Secondary antibodies 
used were as follows: anti-mouse IgG-HRP and anti-rabbit IgG-HRP (Bio-Rad, Inc.).  
The dilutions for primary antibodies used were 1:1000 with the exception of Vinculin 
1:10,000.  The dilutions for secondary antibodies used were 1:3000.  The primary 
antibodies were applied overnight at 4°C, membranes were washed 5 times for 5 
minutes at room temperature, secondary antibodies were applied to membranes for 1 
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hour at room temperature, membranes were washed again 5 times for 5 minutes at room 
temperature.  After application of the enhanced chemiluminescence reagent ECL 
(Pierce, Inc.), blots were visualized on X-ray films. Experiments were completed at 
least twice. 
Immunoprecipitation 
Immunoprecipitation method was used to determine expression of the IL-8 
receptors, CXCR1 and CXCR2. Cell lysates were extracted using previously described 
methods (107).  To immunoprecipitate CXCR1, 4 ug of CXCR1 or CXCR2 antibody 
(Santa Cruz, Inc.) was added to 1mg of cell lysate and incubated overnight on a rotator 
at 4°C.  Protein A-Agarose beads (Roche Applied Sciences) were used to form a 
complex between the CXCR1 receptor with high affinity for rabbit IgG and Protein G-
Agarose beads (Thermo Scientific Pierce) were used to form a complex between the 
CXCR2 receptor with high affinity for mouse IgG. To prepare agarose beads, 50ul of 
Protein A or G beads were centrifuged at 12,000rpm for 20 seconds to remove 
supernatant.  Beads were resuspended in 50ul RIPA buffer, lysate-antibody samples 
were added to the resuspended beads and samples were incubated for 2 hours on a 
rotator at 4°C.  Samples were then centrifuged at 5,000rpm for 2 min at room 
temperature and supernatant was aspirated.  To wash the lysate-antibody complex 
samples, ICKA wash buffer was added and samples were centrifuged for 5,000rpm for 
2 min at room temperature.  This step was repeated three times and 1X Lamelli sample 
buffer was added to samples and boiled for 5 minutes at 100°C.  The supernatants were 
loaded onto a 6% SDS-PAGE gel and the remaining immunoblot was performed using 
the methods in the immunoblot section.   
  
~ 48 ~ 
 
Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) and Quantitative 
Real Time-PCR (qRT-PCR)  
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen) 
manufacturer’s protocol. Purified RNA was subjected to RT-PCR and qRT-PCR using 
the Peltier Thermal Cycler (MJ Research) and the MX3000P™ Real-Time PCR System 
(Stratagene). The following primers were used: CXCR1F- 5’- GCTGTTGAGGTAC 
CTCCAAG-3’, CXCR1R- 5’ AGTTCTTGGCACGTCATCG-3’; CXCR2F-5’-TCTG 
CTACGGATTCACCCTG-3’,CXCR2R-5’ ACATTCCTGTGCAAG GTGG-3’; IL-8F-
5’ ATGACTTCCAAGCTGGCCGT-3’, IL-8R- 5’CCTCTTCAAAAACTTCTCCA 
CACC-3’.  All PCR reactions were completed using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as a control using the following primers: GAPDHF-
5’GAGGGGGCAGGGGACCTG-3’,GAPDHR- 5’GGGAAG TGGGGGCTGGG 
AAG3’.  For reverse transcriptase, 1ug of RNA was transcribed into cDNA using the 
Thermoscript™ RT-PCR System following the manufacturer’s protocol. PCR was 
completed with initial denaturation at 95°C for 5 minutes,  25 cycles of denaturation 
(95°C for 2 min), annealing (63°C (IL-8), 59°C (CXCR1/2), 62°C (GAPDH) for 45 
seconds), extension (72°C for 2 minutes), and final extension (72°C for 10 minutes) 
after all cycles completed.  PCR samples were analyzed on a 1.5% agarose gel 
containing ethidium bromide using diluted Biorad™ Tris/Acetic 
Acid/Ethylenediaminetetraacetic acid (EDTA) (TAE) buffer.  Bands were visualized by 
Bio-Rad Gel Doc 2000 (BioRad, Inc.).  
qRT-PCR was performed by extracting RNA using the aforementioned 
procedure.  One microgram of  RNA was transcribed into cDNA using TaqMan® 
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Universal PCR Master Mix (Applied Biosystems) according to the manufacturer’s 
protocol. The PCR reaction was made using TaqMan Gene Expression Assays (Applied 
Biosystems) for IL-8 (Hs00174103_m1) and GAPDH (HS02758991_g1) following the 
manufacturer’s protocol.  Quantitative PCR was completed using the following cycling 
program: 60°C for 15 minutes, 95°C for 2 min., 40 cycles of 95°C for 15 seconds and 
60°C for 30 seconds. Gene expression was quantified relative to the GAPDH 
housekeeping gene. Threshold cycle (Ct) was determined for all cell lines and the 
relative level of transcript (2
∆Ct
) was determined by the following formula: 2
(Sample IL-8 Ct- 
GAPDH of Sample Ct)
 and differences between cell lines were obtained using the formula, 
1/2
∆Ct
. Experiments were completed in triplicate and completed at least twice. 
Enzyme-linked immunosorbent assay (ELISA) 
To obtain conditioned media for ELISA, 50,000 viable cells were plated and 
the appropriate serum free medium was added for 24 or 48 hours.  Conditioned media 
were subjected to centrifugation and stored at -20°C or used immediately.  Remaining 
viable cells were detected by trypan blue exclusion and counted using the ViCell™ XR 
Cell Viability Analyzer (Beckman Coulter). For the ELISA, each conditioned medium 
was assayed for IL-8 using Quantikine
® 
ELISA Human CXCL8/IL-8 Immunoassay 
(Research Diagnostics, Inc.: R&D Systems) according to the manufacturer’s protocol, 
and IL-8 levels were determined by comparison of absorbance of IL-8 protein to the 
standard curve. This system utilizes trypan blue exclusion to determine the population 
of viable cells and reports viable cells and total cell populations. These and subsequent 
experiments use viable cell counts for conducting experiments.  The production of IL-8 
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was calculated to relative cell number.  Experiments were completed in triplicate and 
completed at least twice. 
In vitro Cell Proliferation Assay 
To determine the rate of cell proliferation, cells were incubated for 12, 24, 48 
or 72 hours with changes of medium every 48 hours.  At each time point, cells were 
trypsinized and neutralized with growth medium, and viable cells were counted using 
the ViCell™ XR Cell Viability Analyzer.  Cells were counted in triplicate and the 
experiments were repeated at least once. 
To determine the effect of rhIL-8 on rate of cell proliferation, rhIL-8 was 
administered at concentrations of 10, 25, 50 or 100ng/ml in serum-free medium for 24 
hours.  Viable cells were determined by using the colorimetric CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) (Promega).  Cells were counted in 
triplicate and the experiments repeated at least once. 
In Vitro Migration and Invasion Assays 
Migration and invasion assays were performed using boyden chamber inserts 
with 8.0µm-pore sizes.  Invasion assays were performed using similar boyden chamber 
inserts with a BD Matrigel™ basement membrane matrix mimicking a physiological 
basement membrane.  Briefly, 50,000 cells were plated in the top insert of a 24-well 
plate, and serum-free medium, growth medium or serum-free medium with recombinant 
IL-8 (rhIL-8) was added to the bottom chamber.   After 18 hours, inserts were removed 
from the chamber, non-migratory cells were removed and migrated cells on the bottom 
of the insert were fixed and stained with HEMA 3
®
 Stain Set (Fisher Scientific 
Company) according to the manufacturer’s protocol.  After staining, migratory or 
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invasive cells were counted at 10x magnification in five random fields; counts were 
averaged for each insert and represented as cells migrated or invaded.  
To determine the effects of dasatanib on migration and invasion, either 50nM 
or 100nM of dasatanib was added to serum- free medium in the bottom chamber, and 
inserts were placed atop wells for 18 hours.  Migration and invasion were determined 
using the protocol already described.  Experiments were completed in triplicate at least 
once. 
In vitro Co-culture migration and invasion assay of prostate cancer cells to 
immortalized human bone stromal cells 
To produce conditioned medium from stromal cells, 50,000 HS5 cells were 
plated in 24-well plates overnight, and serum-free medium was added to cells for 24 or 
48 hours.  Conditioned medium was used immediately or subjected to centrifugation 
and stored at -80°C.   
To determine if stromal cell-conditioned medium affects migration and 
invasion of PCa cells, PC3 or PC3-MM2shIL-8 cells were plated in 24-well inserts in 
growth medium overnight.  After the growth medium was removed and the cells 
washed, HS5 conditioned medium was placed in the bottom chambers of the plates and 
the inserts with PCa cells were placed on top of the bottom chambers for 12-24 hours. 
To determine the number of migrated or invaded cells, fixing, staining and counting 
were performed as described in the migration and invasion assay section.  This assay 
was also completed with HS5 nontargeting control cells and shIL-8-cell conditioned 
medium. Each experiment was performed in triplicate.  
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In vitro Co-culture of immortalized human bone stromal cell conditioned media 
with prostate cancer cells  
We tested whether co-culture of stromal cell conditioned medium with PCa 
cells affects Src activity.  Briefly, HS5 or HS5shIL-8 cells were plated in 100 cm
2
 
dishes, serum-free medium was added and conditioned medium was collected after 24 
or 48 hours, subjected to centrifugation and stored at -80°C or used immediately. Each 
stromal cell-conditioned medium was placed on PC3 or PC3-MM2shIL-8 cells for 10, 
15 or 60 minutes.    Cell lysates were subjected to immunoblot analysis using the 
procedure already described.   
Orthotopic implantation of tumor cells 
Male athymic nude mice were purchased from the Department of Veterinary 
Medicine and Surgery Rodent Facility at MD Anderson Cancer Center.  Animals were 
housed in pathogen-free conditions in the Research Animal Support Facility (RASF) at 
MDACC and used according to the institutional guidelines.  In order to monitor PC3 
cells in vivo, PC3 cells were plated in 12 well plates and infected with pre-made Renilla 
Luciferase-RFP fusion lentiviral particles (PC3RL) purchased from GenTarget, Inc  
(#LVP369).  Briefly, 50ul of lentiviral particles were added to PC3 cells in fresh growth 
media and allowed to incubate for 48hrs.  The transduction rate was determined by 
fluorescence imaging and sorted using MDACC Flow Cytometry and Cellular Imaging 
Core Facility.  
Prior to orthotopic implantation, confluent PC3RL cells, HS5NT and 
HS5shIL-8 cells were detached and neutralized with growth media.  A total of 5x10
6
 
cells for the PC3RL group, 10x10
6
 cells for the PC3RL:HS5NT group and 10x10
6
 cells 
  
~ 53 ~ 
 
for the PC3RL:HS5shIL-8 group were counted and subjected to centrifugation.  Cells 
were resuspended in serum free DMEM in the following groups: .25x10
6
 of PC3RL 
cells in 25ul, .25x10
6
 of PC3RL cells plus .25x10
6
 of HS5NT cells in 25ul and .25x10
6
 
of PC3RL cells plus .25x10
6
 of HS5shIL-8 cells in 25ul.  
For orthotopic implantations, male athymic nude mice (ages 3-5 wk) were 
anesthetized using Isoflurane.  After which, mice were placed in a supine position and 
an incision was made in the lower abdomen.  After prostate exteriorization, 25ul of 
SFM containing either PC3RL, PC3RL:HS5NT or PC3RL:HS5shIL-8 were injected 
into the lateral lobe of the prostate.  Surgical clips were used to close the wound and 
removed one week post-surgery.  To monitor tumor growth by luciferase activity, mice 
were injected with 100ul of Luciferin (GoldBio,Inc.) at 2.5 mg/ml and analyzed using 
the IVIS Imaging System (Caliper Life Sciences) in the Small Animal Imaging Facility 
at MDACC. 
Tissue Preparation 
After 20 days, mice were anesthetized with Isoflurane and mice were 
sacrificed.  Primary tumors were excised, weighed and immediately portions were fixed 
in 10% formaldehyde in phosphate buffer.  Another portion was embedded in OCT 
compound (Sakura Finetek) and flash frozen.  The remaining portions were sealed in 
microcentrifuge tubes, flash frozen in liquid nitrogen and stored in -80°C.  Iliac and 
renal metastases were determined by the enlarged size and opaque color observed and 
metastases were harvested.  
Phase I/II Dasatanib + Docetaxel Clinical Trial in Patients with Metastatic CRPC 
  
~ 54 ~ 
 
To determine the effects of dasatanib + docetaxel treatments in patients with 
metastatic CRPC, a Phase II clinical trial was performed and the parameters that were 
assessed were the maximum tolerated dose, toxicity profile and pharmacokinetics.  The 
patient and eligibility critieria, study design and pharmacokinetics evaluation are 
outlined in detail in the study submitted by Araujo et al (211).  Briefly, a small cohort of 
46 patients were treated with intravenous administration of docetaxel and oral dasatanib 
administration in escalated dosages for 21 days.  Blood samples were collected at days 
1 (docetaxel alone), 14 (dasatanib alone) and 21 (docetaxel and dasatanib). Tumor 
progression was also measured using response evaluation criteria in solid tumors 
(RECIST) and bone radiographic measurements were taken pre- and post-treatments to 
indicate response.  PSA and IL-8 levels were assessed using a cytokine platform.  
Statistics 
Statistical analyses were performed using GraphPad Prism 5 software 
(GraphPad, Inc.).  Absorbance counts from proliferation assays  and cell numbers from 
migration and invasion assays were compared using the Student t-test.  All statistical 
tests were two-sided.  Statistical values are as follows: nonsignificant (ns)  p > 0.05 , * p 
≤ 0.05,  ** p ≤ 0.01,  *** p ≤ 0.001 ****  p ≤ 0.0001 
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CHAPTER 3 
 
THE EFFECTS OF IL-8-MEDIATED SFK ACTIVITY IN PROSTATE 
CANCER IN VITRO 
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Although recent androgen deprivation therapies have demonstrated promising 
success in decreasing metastatic CRPC, there are still many patients that do not respond 
(5).  Mechanisms involved in the development of tumor resistance to these AR-targeted 
therapies are unclear.  As a result, there has been an increased effort in identifying 
signaling mechanisms in CRPC that may be targeted in addition to AR signaling.   
Of the many signaling mechanisms increased in CRPC, one protein known to 
be increased in signaling mechanisms of CRPC is IL-8.  Studies demonstrate that, upon 
androgen withdrawal, IL-8 production is increased and, upon unresponsiveness to anti-
androgen therapy, circulating IL-8 levels are increased (146,173,218).  Studies also 
demonstrate that increased IL-8 increases angiogenesis, migration and invasion 
(175,220).  These results suggest that IL-8 production enhances metastatic disease, but 
it is unclear what IL-8-associated signaling molecules are involved in CRPC.  Our 
laboratory demonstrates that SFKs regulate IL-8 secretory levels and recent in vitro 
evidence demonstrates that IL-8 stimulation of SFK activity is a partial contributor to 
the survival of IL-8 expressing cells against therapeutic effects (148).  This suggests 
that SFKs regulate IL-8 and, in turn, IL-8 mediates SFK activity creating a feed forward 
loop.  However, this has not been investigated in CRPC.  As a result, this chapter will 
investigate if IL-8 affects Src activity in PCa cell lines and if this signaling axis affects 
biological functions of metastatic disease.  To accomplish this, I used the non-metastatic 
LNCaP cell line and its metastatic variant, C4-2B4, and the metastatic PC3 cell line and 
its highly metastatic variant, PC3-MM2.  Observations from this chapter will: (1) 
determine if IL-8 expression and Src activity are increased in metastatic disease, (2) 
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determine how IL-8 mediates Src activity in PCa and (3) determine if IL-8 mediation of 
SFK activity affects biological functions of metastatic disease. 
IL-8 receptors expressed in PCa cell lines 
IL-8 is known to signal through G- protein coupled receptors, CXCR1 and 
CXCR2. CXCR1 is the high affinity IL-8 receptor (14,159). Binding of IL-8 to CXCR1 
is primarily responsible for mediating proliferative and motility functions of tumor cells 
(220).  Shamaladevi et al. reports that CXCR1 contributes to changes in tumor growth 
and cell proliferation, while other reports demonstrate that CXCR2 does not contribute 
to tumorigenesis of PCa (186,221).  These results suggest that the CXCR1 receptor is 
more relevant in PCa progression.  As a result, I determined  CXCR1 expression in the 
PCa cell lines, by examining  mRNA and protein levels through RT-PCR and 
immunoblot analysis in LNCaP, C4-2B4, PC3 and PC3-MM2 cell lines. First, RT-PCR 
was performed to determine the level of CXCR1 mRNA expression in all PCa cell 
lines.  Figure 6a shows that CXCR1 mRNA is expressed in all cell lines while 
displaying a decrease in mRNA expression in the PC3-MM2 cell line.  Secondly, 
immunoprecipitations were performed using a CXCR1 antibody and immunoblot 
analysis was done to assess CXCR1 protein expression in all PCa cell lines. Figure 6b 
demonstrates that there is CXCR1 protein expression in all cell lines with a decrease in 
protein levels in PC3-MM2 cells.  Studies, by other laboratories, demonstrate that  
CXCR1 undergoes receptor internalization and/or down-regulation upon IL-8 
stimulation in cells with high IL-8 levels (166).  This led me to ask the question of 
whether  IL-8 levels are high or low in the cell models.  As a result, I determined if IL-8 
levels were increased in all PCa cell lines.  
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FIGURE 6  CXCR1 Expression in PCa Cell Lines 
A. LNCaP, C4-2B4, PC3-PC3-MM2 cell lines were grown to sub-confluence, RNA 
was isolated and RT-PCR was performed using primer sequences targeting CXCR1.  B. 
Cells were grown to sub-confluence, immunoprecipitations were performed with the 
anti-CXCR1 antibody and cell lysates were subjected to immunoblot analysis.  
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IL-8 expression and protein production is increased in metastatic variants 
I determined if there were differences in IL-8 mRNA expression and protein 
levels amongst the PCa cell lines and their metastatic variants. To determine the  
mRNA expression levels of IL-8 in PCa cell lines, qRT-PCR was performed. As shown 
in Figure 7a and c, qRT-PCR demonstrated that IL-8 mRNA expression levels were 
increased in the C4-2B4 cells relative to LNCaP cells and increased in the PC3-MM2 
cells relative to PC3 cells (p≤0.001 and p≤0.01, respectively).  To determine if IL-8 
secreted levels correlated with mRNA levels, I performed an ELISA using the 
conditioned media of PCa cells and quantified the results according to cell number.  The 
results demonstrate that IL-8 secretory levels were significantly increased in PC3-MM2 
and C4-2B4 relative to their isogenic variants (p≤0.001 and p≤0.01, respectively). IL-8 
levels were virtually undetectable in LNCaP cells, shown in Figure 7b and d.  These 
results, first, demonstrate that IL-8 mRNA expression correlates with secretory levels.  
Second, the results demonstrate that there is a correlation between IL-8 levels and 
metastatic potential  (LNCaP<C4-2B4<PC3<PC3-MM2).  
Src activity is increased in metastatic variants 
While the previous data show that IL-8 levels are increased in metastatic cell 
lines, our laboratory demonstrated that Src activity is increased in metastatic cells (PC3 
and PC3-MM2) (107).  As a result, I wanted to determine whether there was  
a correlation between IL-8 levels and Src activity in PCa cell lines and their metastatic 
variants.  To accomplish this, immunoblot analysis was performed using 
phosphorylated SFK and total Src antibodies. Immunoblot analysis demonstrated that 
Src activity was significantly increased in C4-2B4 cells relative to LNCaP cells and 
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FIGURE 7  IL-8 mRNA Expression and Production in PCa Cell Lines 
A. LNCaP, C4-2B4, PC3 and PC3-MM2 cells were grown to subconfluence and mRNA 
was isolated for qRT-PCR. IL-8 mRNA expression was assessed by qRT-PCR and 
reported as IL-8 mRNA expression relative to either LNCaP or PC3 IL-8 mRNA 
expression.   B. Cells were seeded, serum starved and conditioned media was collected 
from all cell lines. ELISA was performed to determine secretory levels of IL-8 in all 
cells and reported as pg/ml of IL-8 relative to total cell number.  ** p ≤ 0.01,  *** p ≤ 
0.001 
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significantly increased in PC3-MM2 cells relative to PC3 cells (shown in Figure 8a 
and b).  The results, first, demonstrate that Src activity is increased in the cell lines in 
the following order, LNCaP<C4-2B4<PC3<PC3-MM2.  Second, the results 
demonstrate that although  there is not a direct correlation between absolute IL-8 levels 
and Src activity the highly metastatic cells have the highest Src activity and IL-8 
expression.  
Next, to determine if exogenous IL-8 increases Src activity in low and high 
metastatic cells, I treated cell lines with 50ng/ml of recombinant IL-8 (rhIL-8) for 5, 10 
and 30 minute timepoints. 50ng/ml of rhIL-8 was used as an optimal concentration 
demonstrated to increase downstream signaling in PCa cell lines as determined by 
previously published results (223).  Addition of rhIL-8 significantly increased Src 
activity by 3.5 fold in LNCaP cells, 1.7 fold in C4-2B4 and 3.1 fold in PC3 cells, shown 
in Figures 9 and 10.  However, there were no increases seen in the highly metastatic 
PC3-MM2 cell line.  These results demonstrate that IL-8 increases Src activity in non- 
and low metastatic PCa cells, while demonstrating IL-8 does not increase Src activity in 
highly metastatic PCa cells.  
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FIGURE 8  Src Activity in Low and High Metastatic PCa Cell Lines 
Cell lysates from (A) LNCaP and C4-2B4 cells, (B) PC3 and PC3-MM2 cells were 
subjected to immunoblot analysis. Src activity was determined by using anti-phospho 
Src 
Y419
 and Total Src antibodies.   
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FIGURE 9  Effects of Exogenous IL-8 on Src Activity in the LNCaP Model 
A and B. LNCaP and C4-2B4 cells were grown to subconfluence, serum starved and 
treated with rhIL-8- (50ng/ml). Lysates were analyzed by immunoblot and Src activity 
was determined by using anti-phospho Src 
Y419
 and Total Src antibodies. Vinculin was 
used as a loading control. ** p ≤ 0.01,  *** p ≤ 0.001 
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FIGURE 10  Effects of Exogenous IL-8 on Src Activity in the PC3 Model 
A and B. PC3 and PC3-MM2 cells were grown to subconfluence, serum starved and 
treated with rhIL-8- (50ng/ml). Lysates were analyzed by immunoblot and Src activity 
was determined by using anti-phospho Src 
Y419
 and Total Src antibodies. Vinculin was 
used as a loading control. *** p ≤ 0.001 
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Exogenous IL-8 increases proliferation in low metastatic variants 
Past studies demonstrated that overexpression of IL-8 in LNCaP cells 
increased proliferation (146, 223).  However, I wanted to determine if exogenous IL-8 
increases proliferation between low and high metastatic cells. Cells were plated and 
rhIL-8 was added to cells at 10, 50 and 250ng/ml concentrations for 72 hours and an 
MTS assay was performed.  Figure 11a-c show that the LNCaP, C4-2B4 and PC3 cell 
lines demonstrate increased proliferation at 72hr (p≤0.05) with 250ng/ml of rhIL-8, 
while PC3-MM2 cells do not demonstrate changes in proliferation at any timepoint or 
rhIL-8 concentration, shown in Figure 11d.  These results, first, confirm that IL-8 
induces proliferation in the non-metastatic LNCaP cells and demonstrates that IL-8 
induces proliferation in low metastatic C4-2B4 and metastatic PC3 cells.  Second, these 
results demonstrate that IL-8 does not induce proliferation of the high metastatic cell 
line, PC3-MM2, likely because of high endogenous IL-8 expression and high Src 
activity, shown in Figure 7b and d Figure 8.
 
 
Exogenous IL-8 increases migration in low metastatic variants 
Next, I determined if exogenous IL-8 affects migration in low and high 
metastatic cells. To accomplish this, cells were allowed to migrate for 18 hours in the 
absence or presence of rhIL-8 (50ng/ml).  Media with 10% FBS was used as a control.  
As shown in Figure 12b, migration was significantly increased in LNCaP (p≤0.01), C4-
2B4 (p≤0.05) and PC3 (p≤0.001) cells upon addition of rhIL-8, but this effect was not 
seen in the highly metastatic variant of PC3, PC3-MM2.    These results demonstrate 
that IL-8 increases migration of low metastatic PCa and not the highly metastatic PCa 
cell, PC3-MM2. 
  
~ 66 ~ 
 
 
 
 
 
FIGURE 11  Effects of Exogenous IL-8 on Proliferation of PCa Cells 
A-D. LNCaP, C4-2B4, PC3 and PC3-MM2 cells were treated with 0, 10,50 and 
250ng/ml  of rhIL-8 in serum-free medium (SFM) or 10% FBS growth medium for 72 
hours.  The growth rate of viable cells was determined by MTS assay at 12, 24, 48 and 
72 hour timpoints.* p ≤ 0.05, *** p ≤ 0.001 
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FIGURE 12  Effects of Exogenous IL-8 on Migration of PCa Cells 
A. Migration assay of LNCaP, C4-2B4, PC3 and PC3-MM2 cells migrating toward 
50ng/ml of rhIL-8 in serum free media (SFM) for 18 hours.  Pictures were taken of 
migrated cells after fixation and staining. B. Graph of migrated cells to SFM, rhIL-
8/SFM or growth medium. Numbers represent five random fields of cells counted at 
10x magnification. Significance of differences within cell lines were calculated and 
statistics represent migration relative to SFM control.  * p ≤ 0.05, ** p ≤ 0.01,  *** p ≤ 
0.001 
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SFK inhibition reverses IL-8-mediated increases in migration of low metastatic 
variants 
While IL-8 increases the migration of low metastatic PCa cells, I next 
determined if IL-8 mediated increases in migration were SFK-dependent.  PC3 cells 
were allowed to migrate in three conditions: (1) in the presence of the SFK inhibitor, 
dasatanib (50nM), (2) in the presence of rhIL-8 (50ng/ml) and (3) in the presence of 
dasatanib and rhIL-8 for 18 hours, shown in Figure 13a.  Figure 13b shows that, as 
expected, rhIL-8 significantly increased migration (p≤0.05).  In the presence of 
dasatanib, migration was significantly decreased (p≤0.01).  However, the addition of IL-
8 to dasatanib-treated PC3 cells did not overcome the dasatanib-mediated decreases in 
migration (p≤0.01).  These results demonstrate that IL-8-mediated migration is an SFK-
dependent event.  Previous results from our laboratory demonstrate that SFK inhibition 
decreases IL-8 production. (138).  Altogether, these results show IL-8 is regulated by 
SFKs and, in turn, SFKs regulate IL-8 suggesting that a feed forward mechanism is 
present.  To determine if an IL-8-mediated feed forward loop exists, I knocked down 
IL-8 in highly metastatic PCa cells.   
IL-8 shRNA decreases endogenous IL-8 expression and production 
For these experiments, I chose the PC3-MM2 cells because they exhibit the 
highest IL-8 mRNA expression, secretory levels and Src activity amongst all PCa cells.  
Knockdown of IL-8 in PC3-MM2 cells was performed by using the IL-8 shRNA 
lentiviral vector kindly provided by Dr. Menashe Bar-Eli.  Construction of the lentivirus 
is described in the Materials and Methods section.  Cells were infected with a  
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FIGURE 13  Effects of SFK inhibition on IL-8-Mediated Migration 
A. Migration assay of PC3 cells performed in the absence or presence of the SFK 
inhibitor, dasatanib, (50nM) with or without rhIL-8 (50ng/ml), for 18 hours.  Pictures 
were taken of migrated cells after fixation and staining and cell were counted at 10x 
magnification.  B. Graph illustrates cells that have migrated in the absence or presence 
of dasatanib and in the presence of rhIL-8 and dasatanib. Bars represent the average 
number of cells migrated from triplicate wells. * p ≤ 0.05, ** p ≤ 0.01   
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nontargeting control (GN18) or the shIL-8 vector and subjected to RT-PCR, qRT-PCR 
and ELISA to determine the efficiency of the IL-8 knockdown.  The nomenclature for  
cells was as follows: PC3-MM2 (no vector control), PC3-MM2NT (PC3-MM2 
nontargeting control) and PC3-MM2shIL-8 (PC3-MM2 IL-8 knockdown). 
To determine if IL-8 knockdown was successful, first, I determined the mRNA 
expression level of IL-8 in PC3-MM2shIL-8 compared to PC3-MM2 cells by qRT-
PCR. As shown in Figure 14a and b, IL-8 mRNA levels were significantly reduced in 
PC3-MM2shIL-8 cells relative to the PC3-MM2 cells (65% of PC3-MM2;  p≤0.001). 
To determine if IL-8 secretory levels were inhibited, conditioned media was collected 
from all cell lines for ELISA detection as described in Materials and Methods.  IL-8 
secretory levels were also significantly decreased, by ~55% (p≤0.001), shown in Figure 
14c.  Thus, the IL-8shRNA lentivirus vector could be used to examine the effects of IL-
8 knockdown.  
IL-8 knockdown decreases Src activity and downstream targets in PCa cells 
Next, I determined if IL-8 knockdown decreases SFK activity.  Lysates were 
subjected to immunoblot analysis and a Src
Y419
 specific antibody were used to detect 
activity shown in Figure 15. These results demonstrate that in the PC3-MM2shIL-8 
cells, Src activity was decreased by 56% relative to PC3-MM2NT cells, shown in 
Figure 15a.   This is the first evidence demonstrating that knockdown of IL-8 in PC3-
MM2 cells results in decreased SFK activity.   
 
 
 
 
  
~ 71 ~ 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14  Lentiviral Knockdown IL-8 in PC3-MM2 
PC3-MM2 cells were infected with lentiviral IL-8 nontargeting vector (PC3-MM2 NT) 
and IL-8 shRNA vector (PC3-MM2 shIL-8). A and B. RNA was isolated from PC3-
MM2, PC3-MM2NT and PC3-MM2shIL-8 cells and subjected to qRT-PCR using IL-8 
specific primers. C. Cells were seeded, serum starved and conditioned media was 
collected from cells. Secretory IL-8 levels were assessed by ELISA in  PC3-MM2, 
PC3-MM2NT and PC3-MM2shIL-8 cells. The results were normalized to total cell 
number. *** p ≤ 0.001   
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FIGURE 15  Effects of IL-8 Knockdown on Src Activity and IL-8 Signaling 
PC3-MM2, PC3-MM2NT and PC3-MM2shIL-8 cells were grown to subconfluency, 
lysates were extracted and analyzed by immunoblot. A. Immunoblot analysis using 
antiphospho- and  anti-total SFK antibodies. B. Immunoblot analysis using 
antiphospho- and  anti-total ERK and AKT antibodies. C. Immunoblot analysis using 
pNFk-B/65 antibody and vinculin as a loading control. Densitometry was done by 
quantitating the ratio of anti-phospho bands to anti-total bands or  vinculin bands. 
Numbers represent arbritary units normalized to no vector control. 
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I also examined downstream targets important to Src and IL-8 function, such 
as AKT, ERK and NF-κB as seen in Figure 15b and c.  The results demonstrate that 
IL-8 knockdown significantly decreases pAkt by 52%, pErk by 70%  and NFk-B levels  
by 90%.  These observations indicate that IL-8 mediates SFK activity and downstream 
targets.    
IL-8 knockdown decreases biological functions of PC3-MM2 cells  
To determine if knockdown of IL-8 decreases migration and invasion in PCa 
cells, I performed migration and invasion assays by allowing cells to migrate for 18 
hours. The results in Figure 16a and b demonstrate that knockdown of IL-8 
significantly decreased migration (p ≤ 0.001).  Knockdown of IL-8 also decreased 
invasion (p ≤ 0.001), Figure 16c and d.  These results confirm that IL-8 mediates 
migration and invasion as shown by Figure 12. 
IL-8 rescue vector restores IL-8 expression and Src activity in PC3-MM2shIL-8 
cells 
To determine if results of the IL-8 shRNA knockdown experiments were due 
to specific IL-8 targeting and not due to off-target effects, an IL-8 rescue vector 
(pSI/IL-8) was constructed using a PCR-based mutagenesis approach introducing point 
mutations in the shRNA target region without affecting the peptide sequences.  The 
pSI/IL-8 rescue vector was described in Materials and Methods.   For the rescue  
experiments, PC3-MM2shIL-8 cells were transfected with the pSI/IL-8 vector and an 
ELISA was performed to determine if IL-8 production was restored. Transfection of 
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FIGURE 16  Effects of IL-8 Knockdown on Migration and Invasion 
A. PC3MM2NT and PC3-MM2shIL-8 cells were plated in boyden chambers and 
allowed to migrate for 18 hours.  B. PC3MM2NT and PC3-MM2shIL-8 cells were 
plated in boyden chambers with Matrigel coating and allowed to invade for 18 hours.  
Pictures were taken of migrated (B) or invaded (D) cells after fixation, staining and 
numbers represent five random fields of cells counted at 10x magnification. 
Significance of differences within cell lines were calculated and statistics represent 
migration or invasion relative to nontargeting (NT) control. *** p ≤ 0.001  
 
   . 
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PC3-MM2shIL-8 cells with pSI/IL-8 rescue vector fully restored IL-8 production levels 
relative to PC3-MM2NT cells (Figure 17a).  This result demonstrates the targeting 
vector does not have off-target effects.   
Next, to determine if Src activity were restored, immunoblot analysis was 
performed with PC3-MM2NT, PC3-MM2shIL-8 and PC3-MM2shIL-8 + rescue vector.  
Figure 17b demonstrates restoration of Src activity in the PC3-MM2shIL-8 with the 
pSI/IL-8 rescue vector.  This experiment demonstrates that Src activity is regulated by 
IL-8.  These results demonstrate that there is a feed forward loop whereby IL-8 
regulates Src activity and Src activity further regulates IL-8 production.   
IL-8 rescue vector restores migration and invasion in sh-knockdown 
To determine if rescue of IL-8 in PC3-MM2shIL-8 cells also restores 
migration and invasion, migration and invasion assays were performed with the pSI/IL-
8 rescue vector.  Figure 18 shows that, post-transfection with the IL-8 rescue vector, 
migration was restored relative to nontargeting control ( p ≤ 0.001).  Invasion was also 
restored relative to nontargeting control (p ≤ 0.05), shown in Figure 18.  These results 
suggest that IL-8 is a regulator of the migratory and invasive events in the PC3-MM2 
metastatic cells. 
 
 
 
 
 
 
 
 
 
 
 
 
  
~ 76 ~ 
 
 
 
 
 
 
FIGURE 17  Effects of Rescue of IL-8 in PC3-MM2shIL-8 on IL-8 Production and 
Src Activity  
Mutagenesis experiments were performed introducing mutations that restore the 
expression of IL-8 without affecting the sh-mediated knockdown vector. PC3-
MM2shIL-8 cells were transfected with the pSI/IL-8 rescue vector.  A. ELISA was 
performed to determine the levels of IL-8 production in PC3-MM2shIL-8 and PC3-
MM2shIL-8+IL-8 rescue vector.  B. Lysates were extracted from PC3-MM2NT, PC3-
MM2shIL-8 and PC3-MM2shIL-8 + IL-8 rescue vector cells and were analyzed by 
immunoblot using antiphospho- or anti-total Src antibodies. Densitometry was done by 
quantitating the ratio of pSrc
Y419
 bands to the ratio of Total Src bands and numbers 
represent arbritary units normalized to NT control. 
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FIGURE 18  Effects of Rescue of IL-8 in PC3-MM2shIL-8 on Migration and 
Invasion 
A. PC3-MM2shIL-8 cells were transfected with the pSI/IL-8 rescue vector and cells 
were allowed to migrate or invade for 18 hours in serum free medium. Cells migrating 
or invading are reported as the average migrated or invaded cells.  B. Cells were fixed, 
stained and counted at 10x in five random fields* p≤0.05,  *** p≤0.001 
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CHAPTER 4 
 
THE ROLE OF HS5 STROMAL-PRODUCED IL-8 ON SFK ACTIVITY AND 
PROSTATE CANCER PROGRESSION IN VITRO 
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PCa progresses due to changes not only in the tumor cells, but also in the 
microenvironment. In vitro studies demonstrate that stromal cells play a regulatory role 
in prostate carcinogenesis (77).   The contributions of stromal cells in the progression of 
PCa can exist by physical contact, but also by factors secreted and/or expressed by the 
stromal cells, particularly cytokines.  There are multiple studies, outlined in the 
introduction, demonstrating that stromal factors affect PCa progression, but there is 
unclear evidence regarding the role of stromal IL-8 production in metastatic disease.   
Therefore, I have chosen to use a stromal IL-8 producing cell line as a model 
to investigate how IL-8 production by stromal cells affects biological functions of PCa 
cells in vitro.  In this chapter, I used a stromal cell line, HS5, derived from bone marrow 
fibroblasts, known to produce IL-8 (224).  The HS5 cell line is used in this chapter to 
investigate the role of stromal IL-8 production in the regulation of biological functions 
of PCa cells.  Observations from this chapter will: (1) determine if stromal IL-8 affects 
migration and invasion of PCa cells and (2) determine if stromal IL-8 affects Src 
activity of PCa cells.  Results are discussed in this chapter. 
HS5 stromal cells characterized by IL-8 expression and production and CXCR1 
protein expression 
First, to determine if the high affinity CXCR1 receptor were expressed in the 
HS5 cells, CXCR1 was immunoprecipitated with an anti-CXCR1 specific antibody and 
immunoblot analysis was performed.  Results are shown in Figure 19. Figure 19c 
shows that the CXCR1 receptor is expressed in the HS5 stromal cells.  Along with 
CXCR1 expression, I examined IL-8 mRNA expression and IL-8 protein levels in HS5  
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FIGURE 19  IL-8 mRNA Expression and Production and CXCR1 Protein 
Expression in the HS5 Stromal Cell Line 
A. HS5 cells were grown to subconfluence, serum starved for 24 hours and RNA was 
isolated for RT-PCR to determine IL-8 mRNA expression.  B. After seeding and serum 
starving HS5 cells, conditioned media from was collected and ELISA was performed to 
determine levels of IL-8.  C. Immunoprecipitation with anti-CXCR1 antibody and 
rabbit IgG (control) was completed and immunoblot analysis was performed to 
determine the expression of CXCR1.   
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stromal cells by performing RT-PCR and an ELISA.  Figure 19a shows that the HS5 
cells express IL-8 mRNA and Figure 19b shows that HS5 cells produce high levels of 
IL-8. Thus, these cells were a suitable model for studying stromal IL-8 production and 
its effects on PCa cells.     
Effects of HS5 stromal produced IL-8 on migration and invasion of PCa cells 
Next, I determined if conditioned media from HS5 stromal cells affects 
biological functions of PCa, such as migration and invasion. To accomplish this, I 
collected stromal conditioned media from the HS5 cells and allowed PC3 cells to 
migrate and/or invade for 18 hours. The results in Figure 20a and b demonstrate that 
HS5 stromal conditioned media significantly increased the migration of PC3 cells 
(p≤0.01).  Results also demonstrate in Figure 20c and d that HS5 stromal conditioned 
media significantly increased the invasion of PC3 cells (p≤0.01).    
Knockdown of endogenous IL-8 in HS5 bone stromal cells  
After demonstrating in Figure 20 that HS5 stromal conditioned media 
increases biological functions of PCa cells, I determined whether the HS5 stromal 
production of IL-8 contributes to these changes.   To test this, I, first, knocked down IL-
8 in the HS5 stromal cells using the same lentiviral system utilized for knock down of 
IL-8 in PC3-MM2 cells.  HS5 cells were infected with the shIL-8 lentivirus (HS5shIL-
8) as previously described.  The nomenclature for infection with the nontargeting and 
shIL-8 vectors was HS5NT and HS5shIL-8, respectively. To determine if effective IL-8 
knockdown was achieved, I assessed mRNA expression and secretory levels, by 
performing qRT-PCR and ELISA, respectively.  As shown in Figure 21a, IL-8 mRNA 
expression was knocked down by 60% (p≤0.01).  IL-8 secretory levels were knocked  
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FIGURE 20   Effects of HS5 Stromal Conditioned Media on Migration and 
Invasion of PC3 Cells  
Conditioned media from HS5NT and HS5shIL-8 stromal cells was collected for use as a 
chemoattractant. PC3 cells were seeded in (A and B) migration or (C and D) invasion 
chambers, placed atop the HS5NT or HS5shIL-8 conditioned media and cells were 
allowed to migrate or invade for 18 hours. Cells were fixed, stained, counted at 10x in 
five random fields and reported as the average migrated or invaded cells. ** p≤0.01  
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FIGURE 21  Lentiviral Knockdown IL-8 in HS5 Stromal Cells 
HS5 cells were infected with lentivirus particles containing the IL-8 nontargeting vector 
(HS5 NT) or IL-8 shRNA vector (HS5 shIL-8).   A. RNA was isolated from HS5, 
HS5NT and HS5shIL-8 cells and qRT-PCR analysis was performed.  B.  Cells were 
seeded, serum starved and conditioned media was collected from cells. IL-8 production 
was measured by ELISA. The results were normalized to total cell number.  ** p ≤ 0.01 
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down to 55% in HS5shIL-8 cells (p≤0.01), shown in Figure 21b.  These results 
demonstrate successful knock down of IL-8 in stromal cells.   
Knockdown of IL-8 in HS5 stromal cells decreases SFK activity and downstream 
targets 
I next determined if IL-8 knockdown decreases SFK activity in HS5 stromal 
cells. To do this, I compared SFK activity in NT and IL-8 knockdown cells by 
immunoblot analysis using antibodies specific to Src 
Y419
 activity and total Src.    
Figure 22a shows that IL-8 knockdown decreased Src activity by 60% relative to HS5 
cells.  These results demonstrate for the first time that IL-8 regulates SFK activity in 
stromal cells.  
I also determined if knockdown of IL-8 decreases downstream targets 
important to Src and IL-8 function, such as Akt, Erk and NFk-B.  Figure 22b and c 
demonstrate that IL-8 knockdown significantly decreases pAkt by 75%, pErk by 70% 
and NFk-B levels by 80%.  These results demonstrate that IL-8 mediates targets 
downstream of IL-8 and Src.   
SFK regulates IL-8 expression and Src activity in HS5 stromal cells 
Next, I determined if SFKs regulate IL-8 expression and secretory levels in 
HS5 stromal cells.  To accomplish this, HS5 cells were treated with 10, 50, 100, 200 
and 500nM of the SFK inhibitor, dasatanib.  Cell lysates were subjected to immunoblot 
analysis and anti-phospho and total Src antibodies were used. I observed a 75% 
significant decrease in Src activity after treatment with 50nM dasatanib, while 
subsequent increasing concentrations abolished Src activity (Figure 23).  These results 
demonstrate that SFK inhibition decreases Src activity in a dose-dependent manner in  
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FIGURE 22  Effects of IL-8 knockdown in HS5 cells on Src activity and IL-8 
Signaling 
HS5, HS5NT and HS5shIL-8 cells were grown to subconfluency, lysates were extracted 
and analyzed by immunoblot. A. Immunoblot analysis using antiphospho- and  anti-
total SFK antibodies. B. Immunoblot analysis using antiphospho- and  anti-total ERK 
and AKT antibodies. C. Immunoblot analysis using  pNFk-B/65 antibody and vinculin 
as a loading control. Densitometry was done by quantitating the ratio of anti-phospho 
bands to anti-total bands or vinculin bands. Numbers represent arbritary units 
normalized to no vector control. 
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FIGURE 23   Effects of SFK Inhibition on Src Activity in HS5 Stromal Cells   
SFK inhibition was performed by treating HS5 cells with dasatanib  (10, 50, 100, 200 
and 500nM) for 4 hours.  Cell lysates were extracted and immunoblot analysis was 
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin 
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc 
Y419
 bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units 
normalized to DMSO control. 
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HS5 stromal cells.  It also demonstrates that maximal SFK inhibition occurs with 50nM 
dasatanib. 
Next, to determine if Src regulates IL-8 mRNA expression in HS5 stromal 
cells, HS5 cells were treated with 10, 50 and 100nM of dasatanib and cells were 
collected for RNA isolation and RT-PCR was performed.  Conditioned media was also 
collected to determine IL-8 secretory levels by ELISA.  The results demonstrate that 
dose-dependent treatment of HS5 cells with dasatanib decreased IL-8 mRNA 
expression and secretory levels.   IL-8 protein levels were significantly decreased by > 
60% with 50nM and 100nM dasatanib (Figure 24b), whereas IL-8 mRNA levels were 
significantly decreased by >50% at all dasatanib concentrations (Figure 24a).  These 
results demonstrate that SFKs regulate IL-8 expression and secretory levels in HS5 
stromal cells, similarly to how regulation occurred in tumor cells.  This allowed me to 
test effects of stromal produced IL-8 on tumor cells. 
HS5 stromal production of IL-8 increases Src activity in PCa cells 
Next, I determined if stromal produced IL-8 regulates Src activity of PCa cells.  
To accomplish this, conditioned media from stromal cells (HS5NT and HS5shIL-8) was 
added to PCa cells with (PC3, PC3-MM2shIL-8 and PC3-MM2NT) for 10, 15 and 60 
minutes.  Cells were, then, subjected to immunoblot analysis and phosphorylated Src 
and total Src activity was assessed.  First, I determined if HS5 stromal conditioned 
media increased SFK activity in low metastatic PC3 cells by adding HS5NT 
conditioned media. The results, shown in Figure 25, demonstrate that HS5 stromal 
conditioned media increased SFK activity in PC3 cells.  I, next, determined if increased 
Src activity was a result of HS5 stromal produced IL-8 by adding HS5shIL-8- 
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FIGURE 24   Effects of SFK inhibition on IL-8 Expression in HS5 Stromal Cells   
SFK inhibition was performed by ttreating HS5 cells with dasatanib.  A. For IL-8 
mRNA expression, dasatanib (10, 50 and 100nM) was added to HS5 cells for 4 hours 
and RT-PCR was performed with primers targeting the IL-8 sequence. B. For ELISA, 
cells were seeded, treated with dasatanib concentrations and conditioned media was 
collected from cells. The results were normalized to total cell number.  ** p ≤ 0.01 
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FIGURE 25   Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3 Cells   
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested.  PC3 cells 
were grown until subconfluent and serum starved for 24hours. Conditioned media from 
either HS5NT and HS5shIL-8 stromal cells was added to cells for 10, 15 and 60 
minutes, cell lysates were extracted and immunoblot analysis was performed by using 
antiphospho- or anti-total Src antibodies and by using a vinculin antibody as a loading 
control. Densitometry was done by quantitating the ratio of pSrc bands to the ratio of 
Total Src/Vinculin bands and numbers represent arbritary units normalized to no 
treatment (0’). 
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conditioned medium to PC3 cells. These results demonstrate that Src activity is 
decreased with addition of HS5shIL-8. These results demonstrate that IL-8 is one factor 
produced by HS5 stromal cells contributing to increases in Src activity. These results 
were also observed with PC3-MM2shIL-8 cells shown in Figure 26.  As a control 
experiment, I determined if HS5NT or HS5shIL-8 conditioned medium affects SFK 
activity in cells with high IL-8 expression and Src activity. I added the conditioned 
medium to PC3-MM2NT cells using the same conditions as above. Results from this 
experiment demonstrate no change in Src activity with the addition of either HS5NT or 
HS5-shIL-8 conditioned medium (Figure 27). These results confirm results in Figure 9 
demonstrating that exogenous IL-8 has no further effect on increasing Src activity on 
highly metastatic PC3-MM2 cells. Overall, these results demonstrate that stromal 
production of IL-8 increases SFK activity in PCa cells and IL-8 produced from stromal 
cells.  
Knockdown of IL-8 production in HS5 stromal cells decreases migration and 
invasion of PCa cells  
Next, I determined if stromal production of IL-8 affects migration and 
invasion. Conditioned medium from HS5NT and HS5shIL-8 cells was used as a 
chemoattractant and migration and invasion assays were performed.   To determine if 
HS5 stromal conditioned medium increases migration of PC3 cells, HS5NT conditioned 
medium was used a chemoattractant.  As shown in Figure 28a and b, HS5NT 
conditioned medium significantly increased migration of low-metastatic, PC3 cells 
(p≤0.01).   Next, I determined if HS5 stromal cells producing less IL-8 decreases 
migration of PC3 cells by using HS5shIL-8 cell-conditioned medium as a  
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FIGURE 26   Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3-
MM2shIL-8 Cells   
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested.  PC3-
MM2shIL-8 cells were grown until subconfluency and serum starved for 24hours. 
Conditioned media from either HS5NT and HS5shIL-8 stromal cells was added to cells 
for 10, 15 and 60 minutes, cell lysates were extracted and immunoblot analysis was 
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin 
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc 
bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units 
normalized to no treatment (0’). 
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FIGURE 27   Effects of HS5 Stromal Produced IL-8 on Src Activity in PC3-MM2 
Nontargeting Cells   
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3-
MM2NT cells were grown until subconfluency and serum starved for 24hours. 
Conditioned media from either HS5NT and HS5shIL-8 stromal cells was added to cells 
for 10, 15 and 60 minutes, cell lysates were extracted and immunoblot analysis was 
performed by using antiphospho- or anti-total Src antibodies and by using a vinculin 
antibody as a loading control. Densitometry was done by quantitating the ratio of pSrc 
bands to the ratio of Total Src/Vinculin bands and numbers represent arbritary units 
normalized to no treatment (0’). 
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FIGURE 28   Effects of HS5 Stromal Conditioned Media on Migration and 
Invasion of PC3 Cells  
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3 cells 
were seeded in (A and B) migration or (C and D) invasion chambers, chambers were 
placed atop the conditioned media (HS5NT or HS5shIL-8) and allowed to migrate or 
invade for 18 hours. Cells were fixed, stained, counted at 10x magnification in five 
random fields and reported as the average migrated or invaded cells. * p≤0.05,  ** 
p≤0.01  
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chemoattractant.  The results demonstrate that HS5 stromal cells producing less IL-8 
significantly decreased migration relative to co-culture of PC3 cells with HS5NT cell-
conditioned medium (p≤0.05).    An invasion assay performed under the same 
conditions showed similar results, as seen in the right panel of Figure 28c and d.  
Figure 29a-d demonstrates that migration and invasion were also significantly 
decreased when PC3-MM2shIL-8 cells were co-cultured with HS5shIL-8 cell 
conditioned medium relative to HS5NT cell conditioned medium (p≤0.01). These 
results demonstrate that HS5 stromal production of IL-8 affects migration and invasion 
of PCa cells. 
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FIGURE 29   Effects of HS5 Stromal Conditioned Media on Migration and 
Invasion of PC3-MM2shIL-8 Cells  
Conditioned media from HS5NT and HS5shIL-8 stromal cells was harvested. PC3-
MM2shIL-8 cells were seeded in (A and B) migration or (C and D) invasion chambers, 
chambers were placed atop the conditioned media (HS5NT or HS5shIL-8) and allowed 
to migrate or invade for 18 hours. Cells were fixed, stained, counted at 10x in five 
random fields and reported as the average migrated or invaded cells. * p≤0.05,  ** 
p≤0.01  
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CHAPTER 5 
 
THE ROLE OF HS5 STROMAL-PRODUCED IL-8 IN TUMOR GROWTH AND 
METASTATIC POTENTIAL OF PROSTATE CANCER IN VIVO 
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PCa progression to metastatic disease is a result of multiple factors produced 
by the tumor and by the stromal microenvironment.  There is in vivo evidence 
supporting the role of IL-8 tumor production in PCa progression whereby 
overexpression of IL-8 in LNCaP cells increases tumor growth and microvessel density 
(146).  However, we know that stromal production of IL-8 contributes to PCa 
progression, as evidenced by chapter 4, where I demonstrate that stromal production of 
IL-8 is one factor increasing the migration and invasion of PCa cells in vitro.  To date, 
there are no current in vivo models addressing if stromal production of IL-8 contributes 
to the metastatic potential of PCa.  As a result, this chapter will assess if stromal IL-8 
production affects PCa growth and metastatic incidence by performing co-inoculations 
with stromal cells and PCa cells.  Observations from this chapter: (1) determines if the 
tumor-stromal interaction contributes to metastatic potential in vivo (2) determines if 
stromal IL-8 contributes to metastatic potential of PCa in vivo.  
Orthotopic co-inoculation of HS5 stromal cells and PCa cells  
This study was designed to determine if co-inoculation of stromal cells and 
PCa cells affects tumor growth and metastatic incidence. For co-inoculations, low 
metastatic PC3 cells and HS5 stromal cells (NT or shIL-8) were injected into the 
prostate of athymic nude mice in the following ratios:  .25x10
6
 of PC3 cells for Group 
1, .25x10
6
 of PC3 cells: .25x10
6
 of HS5NT cells for Group 2 and .25x10
6
 of PC3 cells: 
.25x10
6
 of HS5shIL-8 cells for Group 3 with an n=10 for each group.  Tumors in mice 
were monitored by luciferase activity detected by bioluminescence imaging.   
First, I determined the viability of the co-inoculation post-injection by 
culturing the stromal-prostate cancer cell combination in vitro and monitoring the 
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growth and viability for one week.  Figure 30 shows a graph and representative pictures 
of the PC3:HS5 combination group from day 3 and 6 demonstrating that cells are 
viable.   
Effects of orthotopic co-inoculation of HS5 stromal cells and PCa cells on tumor 
growth and weight     
To assess tumor growth, mice were monitored every three days according to in 
vivo bioluminescence imaging using IVIS™-100 (Xenogen Co.) for changes in tumor 
growth and luciferase activity was used as a parameter of tumor growth.  Figure 31 
displays representative images of tumors in each mouse. After injection of luciferin, 
mice were anesthesized, placed in the bioluminescence imager and luciferase activity 
was measured.  The red circles, in Figure 31a-c, represent the region of interest (ROI) 
encompassing the entire region of luciferase activity and the numbers represent 
luciferase activity within that region.   
First, I determined if stromal cells increase tumor growth of PCa cells. As 
shown in Figure 32, there was a consistent increase in luciferase activity in all groups 
showing consistent tumor growth. The results also demonstrate that there were no 
significant differences in luciferase activity amongst different groups from day 0 until 
day 14.  This result demonstrates that tumors grew similarly among all groups from day 
0 to 14.  At day 14, there was a significant increase in luciferase activity in the 
PC3:HS5NT group relative to PC3 alone group (p≤0.05), while there was no significant 
difference between PC3:HS5shIL-8 group relative to PC3 alone group.  This 
demonstrates that stromal cells increase tumor growth of PCa cells as measured by 
luciferase activity.   
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FIGURE 30  Post-injection effects of Cell Viability and Growth with Stromal Cell 
and PCa Cells  
Directly after co-inoculations of HS5 stromal cells and PC3/RFP luciferase labeled 
cells, cells were seeded together, counted and monitored for 6 days in culture. A. Cells 
were counted on days 3 and 6 and viable PC3 and HS5 cells were plotted in the graph. 
B. Pictures shown are representative of day 6 before sorting and counting cells. Pictures 
were taken at 4x magnification. 
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FIGURE 31  Determination of Luciferase Activity in Mice by in vivo 
Bioluminescence Imaging    
Tumor growth was monitored by bioluminescence imaging mice every three days.  
Mice were injected with luciferin (20mg/ml) and placed  under anesthesia.  Mice were 
placed in the IVIS-100 Xenogen imager and luciferase activity was measured. Pictures 
were taken indicating luminescence value according to scale on right and region of 
interest (ROI) was indicated encompassing the entire region of luciferase activity. The 
luciferase values were calculated and used as a measurement of growth for each mice in 
each group.                 
The representative mice are as follows: (A)  mouse in PC3 group, (B) mouse in 
PC3:HS5NT group and (C) mouse in PC3:HS5shIL-8.  
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FIGURE 32 Effects of HS5 Stromal Produced IL-8 on Tumor Growth   
After intraprostatic injections of PCa cells and stromal cells in mice, tumor growth was 
monitored by imaging mice every two-three days, observing luciferase counts in each 
mouse by measuring the region of interest (ROI) of the tumor for each mouse.                
, * p≤0.05,** p≤0.01 
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Next, I assessed whether stromal cells producing IL-8 affects tumor growth.  
The results demonstrate that, at day 14, there was a significant increase in luciferase 
activity in the PC3:HS5NT group relative to PC3:HS5shIL-8 group (p≤0.05).   There 
was a larger increase seen at day 18 demonstrating that HS5 stromal produced IL-8 
increases tumor growth.  
Co-inoculation of HS5 stromal cells and tumor cells increases tumor weight 
After termination of the experiment, tumor weights were measured. The 
average tumor weights were as follows: 126mg for PC3 group, 193mg for PC3:HS5NT 
group and 169 for PC3:HS5shIL-8 group. First, I determined if co-inoculation of PC3 
cells and HS5 stromal cells increases tumor weight.  The results demonstrate that there 
was a significant increase in tumor weight between the PC3:HS5NT group and PC3 
alone (p≤0.0019).  This result demonstrates that the tumor-stromal interaction 
contributes to tumor growth and suggests that HS5 stromal production of IL-8 
contributes to increased tumor growth.  
To determine if IL-8 production in stromal cells increases tumor weight, I 
compared the changes in tumor weights between the PC3:HS5NT and PC3:HS5shIL-8 
groups. There was a significant decrease in the PC3:HS5shIL-8 tumor weights relative 
to PC3:HS5NT tumor weights (p≥0.05) demonstrating that stromal production of IL-8 
contributes to tumor weight in vivo.   Results also demonstrate that PC3:HS5shIL-8 
tumor weights are significantly higher than PC3 alone (p≤0.0363), shown in Table 1.  
This result demonstrates that stromal cells producing less IL-8 increase tumor weights 
compared tumor cells alone suggesting that, expectantly, other factors contribute to  
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TABLE 1  Effects of Stromal Production of IL-8 on Primary Tumor Weight of 
PC3 cells in an Orthotopic Mouse Model 
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tumor weight.  Overall, these results demonstrate that stromal production of IL-8 is one 
factor contributing to tumor weight.   
Orthotopic co-inoculation of HS5 stromal cells and PCa cells increases metastatic 
incidence 
To assess if metastatic incidence is affected by IL-8 producing stroma, the 
same groups were assessed for the presence of metastases.  Mice were opened and 
thoroughly examined for iliac and renal lymph node metastases. Renal and iliac lymph 
nodes were observed and confirmed by H&E (107).  All three mice groups had at least 
one metastasis either in the renal or iliac lymph nodes shown in Table 2.  Mice injected 
with PC3 cells displayed on average 1.4 metastases.  Mice injected with PC3:HS5NT 
cells displayed on average 3.5 metastases per mouse, while mice injected with 
PC3:HS5shIL-8 cells displayed on average 2.4 metastases per mouse.  To determine if 
HS5 stromal cells increases metastatic incidence of PC3 cells, I compared metastases 
from PC3:HS5NT group and PC3 alone group.  The results in Table 2 demonstrate that 
co-inoculation with PC3:HS5NT significantly increased metastatic incidence relative to 
PC3 alone (p=.018).  These results demonstrate that co-inoculation of stromal cells with 
PCa cells increases metastatic incidence.   
I, next, determined whether the increases seen in metastatic incidence were due to HS5 
production of IL-8.  The results demonstrate that PC3:HS5shIL-8 co-inoculations 
produced significantly less metastases in comparison to PC3: HS5NT (p=.018).  These 
results demonstrate that stromal IL-8 production contributes to metastatic incidence.  
There was also a significant increase in metastatic incidence with co-inoculations of 
PC3:HS5shIL-8 relative to PC3 alone (p=.0019).  This result demonstrates that stromal  
  
~ 105 ~ 
 
 
 
 
 
 
 
 
 
 
TABLE 2  Effects of Stromal Production of IL-8 on Metastatic Incidence of PC3 
Cells in an Orthotopic Mouse Model 
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cells producing less IL-8 increase metastatic incidence compared to tumor cells alone 
suggesting that, expectantly, other factors contribute to metastatic incidence.  Overall, 
results from this experiment demonstrates that stromal cells producing IL-8 increase 
metastatic incidence making IL-8 one factor involved in metastatic potential. 
In addition, the co-inoculation groups (PC3:HS5NT and PC3:HS5shIL-8) were 
observed to have iliac and renal lymph node metastases, while inoculation with PC3 
cells alone had only iliac lymph node metastases.  This finding indicates that stromal 
IL-8 production alters the spectrum of lymph node metastases. Overall, this in vivo 
model demonstrates, for the first time, that stromal cells producing IL-8 increase the 
metastatic potential of PCa. 
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CHAPTER 6 
 
CLINICAL SIGNIFICANCE OF IL-8 SECRETION AND SFK ACTIVITY IN 
METASTATIC CRPC 
 
 
 
 
 
 
 
 
 
  
~ 108 ~ 
 
In clinical practice, PSA serves as the ‘gold’ standard for the detection of PCa.  
Although a frequent upward trend of PSA levels is evident in patients with advanced 
disease, there seems to be no definite, linear relationship between serum PSA levels and 
PCa stage or metastasis (212).  This has led to controversies over its role as a biomarker 
for metastatic disease and suggests that it may instead better serve as a marker of 
predisposition to abnormalities of the prostate. 
 
As a result, the investigation of other 
markers, such as IL-8, are of great interest to this thesis.   Several reports demonstrate 
detection of increased IL-8 in serum and tissue of patients with metastatic disease in 
comparison to disease-free patients or patients exhibiting benign prostatic hyperplasia 
(165,171).
 
 SFK activity is also increased in patients with metastatic PCa (129,225). 
Supporting in vitro and in vivo data, from our laboratory and others, demonstrates that 
IL-8 increases survival of PCa in the presence of docetaxel, while SFK inhibition by 
dasatanib, in preclinical models, demonstrates decreased tumor growth and metastasis 
and decreased growth of PCa in the bone (226,211).  These results suggest that: (1) 
increased IL-8 levels contributes to disease progression and (2) SFK inhibition may 
decrease tumor progression and bone metastatic disease. 
Results from my in vitro studies in Chapter 3 demonstrate that exogenous IL-8 
increases PCa cell progression in an SFK-dependent mechanism.  I also demonstrate in 
Chapter 4 and 5 that stromal IL-8 increases PCa progression in vitro and increases the 
metastatic potential of PCa in vivo. As a result, I investigated, clinically, if serum IL-8 
levels in patients with metastatic CRPC are affected by dasatanib treatments.    I was 
able to investigate this due to a Phase II trial with dasatanib+docetaxel in metastatic 
CRPC, conducted at MDACC by Dr. John Araujo. This clinical trial aimed to determine 
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if dasatanib alone or dasatanib+docetaxel treatments decreases metastatic CRPC.  
Additional studies from this trial were to determine if PSA, bone turnover markers and 
IL-8 serum levels were changed.  Observations from this study: (1) determined if 
patients with metastatic CRPC responding to SFK inhibition have decreased serum IL-8 
levels and (2) determined if the changes in IL-8 levels correlates with PSA levels.   
Clinical administration of dasatanib decreases IL-8 levels in patients with 
metastatic CRPC 
This Phase I/II trial was designed to determine if dasatanib decreased 
metastatic CRPC by using bone radiographic measurements and PSA levels as a 
measure of response.  I was interested in determining whether IL-8 levels were a better 
predictor of response in comparison to PSA levels.  First, to determine if dasatanib 
decreases IL-8 levels in patients with metastatic CRPC, serum samples were collected 
at the following timepoints: before any treatments as a control and at day 21 
constituting cycle 2/dasatanib+docetaxel.  Samples were split into two groups- patients 
that responded to treatment and those that did not respond (responders vs. non-
responders). ELISA was performed with all samples to determine the levels of serum 
IL-8 and PSA.  I, first, determined if PSA levels predicted response. The results, in 
Figure 33b, demonstrate that PSA levels in responders were decreased and PSA levels 
in non-responding patients were also decreased.  These results demonstrate that PSA 
levels of responding patients mimicked the PSA levels of those patients who did not 
respond.  Next, I wanted to determine if IL-8 levels predicted response.  Figure 33a 
demonstrates that IL-8 levels in responders were decreased, whereas IL-8 levels in non-
responders remained elevated. These results demonstrate that IL-8 may be a better  
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FIGURE 33  Effects of Phase I/II l Dasatanib + Docetaxel  ClinicaTrial on IL-8 
and PSA Production in Bone Metastatic Prostate CRPC     
Serum samples collected from patients with bone metastatic PCa undergoing dasatanib 
+ docetaxel treatments were assessed by radiographic measurements and ELISA was 
performed for PSA and IL-8 production.  PSA and bone radiographic measurements 
were used as parameters of response.  (A) IL-8 and (B) PSA serum levels in responders 
and non-responding patients after treatments.   The waterfall plot illustrates responders 
(patients which do not progress on treatment) and non-responders (patients which 
progress on treatment). Blue bars represent responders and orange bars represent non-
responders. 
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predictor of response for patients with metastatic CRPC.  Although a wider study has 
been conducted and is pending, these results suggest that patients with metastatic 
disease exhibiting high IL-8 levels could be selected for dasatinib+docetaxel 
combination therapy.  
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CHAPTER 7 
 
DISCUSSION 
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Protein tyrosine kinases signal through multiple pathways leading to 
subsequent changes in biological functions of PCa.  One well-studied kinase family 
mediating these signaling pathways are SFKs, outlined in chapter 1.  Through extensive 
studies, from our laboratory and others, we have demonstrated that increased SFK 
activation results in deregulation of migration, invasion, apoptosis, angiogenesis, 
proliferation and survival.  Work by Park et al. demonstrates that SFKs play differential 
roles in PCa progression which has contributed to investigations providing a better 
understanding of the biological roles of SFK members and how they contribute to tumor 
progression.   
As outlined in the Introduction, SFKs constitute nine family members of which 
three are ubiquitously expressed (Src, Yes and Fyn) and the remaining members are 
expressed in a tissue-specific manner.    Src has been one of the most widely studied 
SFK members and has been shown to be increased in multiple cancers. In vitro 
evidence demonstrates that Src contributes to survival, migration and invasion in the 
progression of cancer.  In vivo studies demonstrate that Src activation is a mediator of 
tumor progression in multiple cancers, but it was unclear whether Src activation was a 
contributor to progression of PCa to metastatic disease (127,131). 
 
To better understand how Src activation contributes to metastatic disease, there 
has been an increased effort in the investigation of signaling factors regulating Src 
activity. We have learned that Src activity is not a result of direct activation by 
extracellular signals, but by activated PTKs, GFRs, GPCRs and integrins, outlined in 
the Introduction.  However, there is less evidence describing a role for GPCRs and 
GPCR ligands in Src activation in PCa.  This is important because there are studies 
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demonstrating that some GPCR ligands, which can also be classified as cytokines, 
contribute to PCa progression.   
Of the many cytokines contributing to PCa progression, IL-8 is one factor that 
has been implicated in, not only, PCa progression, but in metastatic disease, due to its 
overexpression. In addition, similar to Src, we know that IL-8 mediates biological 
functions, such as angiogenesis, migration and invasion in PCa and, likewise, there is 
less information regarding signaling mechanisms regulating these biological functions.  
As a result, the investigation of pathways regulating IL-8 expression and Src activation 
are, currently, being studied as two separate signaling mediators of PCa progression.  
However, our laboratory provides evidence that Src regulates IL-8 production in PCa 
cells and, more recent studies, suggest that IL-8 activates PTKs, Src and FAK, to induce 
migration of PCa cells (138,147).  These results suggest that the signaling mechanisms 
of Src and IL-8 are, not entirely exclusive, and that regulation of Src activation may be 
associated with IL-8 signaling in PCa.  This becomes important because, although, we 
know that IL-8 signaling is increased in PCa, IL-8 signaling by cells in the 
microenvironment, such as stromal cells contributes to tumor progression.   
So, it is possible that IL-8 signaling may also contribute to signaling 
mechanisms, such as SFK activity, and this mechanism may contribute to increases in 
PCa progression to metastatic disease.  Delineation of whether IL-8 mediates SFK 
activity in PCa, either tumor-mediated or stromal-mediated, could also provide another 
mechanism of increased SFK activity in PCa progression.     
The effects of IL-8-mediated SFK activity in metastatic prostate cancer in vitro 
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Previous studies demonstrate that IL-8 and Src, individually, increase 
metastatic properties of PCa as well as Src (107,146). Studies from our laboratory 
demonstrate that Src regulates IL-8 secretion (138).  However, there was no clear 
understanding of whether Src regulation of IL-8 secretion results in Src activation and 
whether this contributes to migration and invasion.   Studies in Chapter 3 determined 
that a feed-forward loop in PCa exists whereby IL-8 increased SFK activity increases 
IL-8 production and expression, which in turn increases IL-8 activity.  I also determined 
that this feed forward loop contributes to migration and invasion of non-metastatic and 
low metastatic PCa cells.   
To determine how IL-8 affected SFK activity, I first determined that the high 
affinity IL-8 receptor, CXCR1, was present in all cell lines (Figure 6). Expression of 
CXCR1 was decreased in the highly metastatic PC3-MM2 cells.  This result may be 
explained by studies showing that higher IL-8 levels correlates with rapid 
internalization of the CXCR1 receptor resulting in decreased CXCR1 expression (221). 
So, it is likely that the decrease observed in PC3-MM2 is due to the presence of high 
IL-8 expression and secretory levels in comparison to the other PCa cell lines (Figure 
7).  
In addition to PC3-MM2 cells having the highest IL-8 levels, they also 
expressed the highest SFK activity in comparison to the other PCa cell lines (Figure 8).  
While the levels of IL-8 do not directly correlate with levels of SFK activity, the trend 
of increased secretion and expression of IL-8 and increased Src activity in PC3-MM2 
cells is striking.   However, one explanation for there not being a direct correlation may 
be because IL-8 receptor does not directly associate with SFKs.  There is no 
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information suggesting that IL-8 binding to the CXCR1 receptor elicits direct activation 
of SFKs. There are numerous reports demonstrating that RTKs activate SFKs, outlined 
in the introduction.   It is likely that there is crosstalk between CXCR1 and RTKs  
resulting in SFK activation.  This is supported by evidence demonstrating that IL-8 
binding of CXCR1 promotes the transactivation of RTKs, such as EGFR in ovarian 
cancer and VEGFR in endothelial cells (175).  While EGFR plays less of a role in PCa, 
VEGFR, PDGFR, MET, IGF-1R and AXL activation, to name a few, have been shown 
to induce SFK activation in PCa.  It would be interesting to investigate whether IL-
8/CXCR1 signaling promotes transactivation of these RTKs and whether there are other 
unknown upstream signaling factors involved in IL-8-mediated SFK activity.  
While increased IL-8 expression and Src activity are, individually, known to 
increase progression, I showed that IL-8 and Src function in the same signaling pathway 
to increase metastatic properties of PCa.  Specifically, I demonstrated that IL-8 
stimulation increases SFK activity and migration and proliferation of non-, low and 
moderately metastatic PCa cells (Figures 9-12), but not that of the highly metastatic 
PC3-MM2 cells.  IL-8 has also been shown to increase PCa cell SFK activity, 
proliferation and migration in non- to low metastatic PCa cells, while the results from 
highly metastatic PC3-MM2 cells have never been reported (146,223).
 
 One explanation 
for the unresponsiveness of PC3-MM2 cells to further IL-8 stimulation may be due to 
their intrinsic high production of IL-8 (Figure 6).  In terms of migration, this 
explanation is supported by Schraufstatter et al. demonstrating that IL-8 stimulation 
with 30nM or 100nM has the same effect on migration of high IL-8 producing cells 
suggesting that IL-8 does not have any further effect on migration beyond these 
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concentrations of IL-8 (227).  In addition, Park et al. demonstrated that two SFK 
members, Src and Lyn, contribute to PCa progression through differential biological 
roles. Their work shows that Src primarily contributes to migration and invasion, while 
Lyn contributes to proliferation in PCa cells (107).  It is possible that IL-8-mediated 
changes in Src activity contribute to migration and invasion of PCa, while IL-8 
mediated changes in Lyn activity contribute to the proliferation of PCa cells would 
require further studies.  Another explanation for the changes in proliferation stems from 
studies demonstrating that IL-8-mediated expression of cyclin D1, proliferative marker, 
is a contributor to the proliferation of PCa cells (146).  Further studies will need to be 
done to determine whether the significant but minor changes in proliferation are due to 
IL-8-mediated Lyn activation in PCa as well as cyclin D1.  While studies demonstrate 
that IL-8 does not play a role in the proliferation of other cancers, such as melanoma 
and lung cancer, my studies along with others demonstrate that IL-8 is a contributing 
factor to the proliferation of low metastatic PCa (147,185,223).
 
 However, I note that 
IL-8’s role in increasing proliferation, while significant are small whereas there were 
major increases in migration and invasion.   
Thus far, I demonstrated that IL-8 production and Src activity are increased in 
the highly metastatic PC3-MM2 cells and additional IL-8 does not increase Src activity 
and biological functions in these cells.  This work demonstrates that one mechanism 
contributing to the increases in metastatic properties of PCa is through IL-8 increasing 
SFK activity in vitro.  Likewise, depletion of IL-8 should result in decreased SFK 
activity, migration and invasion. To test this possibility, I used a lentiviral system to 
knockdown IL-8 in PC3-MM2 cells (Figure 14).  I demonstrate that lentiviral 
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knockdown of IL-8 decreases Src activity (Figure 15a).  In addition, I demonstrate that 
targets, integral to IL-8 signaling, such as Akt and Erk, are also decreased, while the 
well-known IL-8 transcription factor, NFk-B, is decreased as well (Figure 15b-c).  
Many studies provide evidence demonstrating that IL-8 signaling increases Akt and Erk 
activation in multiple cancer cells supporting my current results (229). While there are 
other mechanisms of decreasing IL-8 production, such as the use of IL-8 neutralizing 
antibodies, this study aimed to deplete endogenous levels of IL-8 in a stable context 
rather than deplete the production of IL-8 (250,251).  The use of neutralizing antibodies 
are beneficial and would be useful in future experiments.   
Surprisingly, there was also a 90% decrease in the phosphorylation of NFk-B 
at p65 after knock down of IL-8 in PC3-MM2 cells.  These results are supported by 
studies from Singh et al. demonstrating that depletion of IL-8 decreases NFk-B activity, 
and Wilson et al. showing that, upon IL-8 overexpresssion, IL-8 increases NFk-B 
activity (174,229). While these studies demonstrate that NFk-B activity is regulated by 
an IL-8-mediated signaling mechanism, it is possible that IL-8-mediated SFK activation 
contributes to NFk-B activation. An earlier study demonstrates that SFK-deficient B 
cells (either Blk -/-, Fyn -/- or Lyn-/-) lack proper IkB phosphorylation and display 
decreased NF-kB DNA binding activity demonstrating that NFkB activation is, in part, 
SFK-dependent (230).  Future studies would need to be performed to determine if SFK 
activation mediates NFk-B activity as opposed to expression  in PCa cells. It would also 
be important to determine NFk-B activity in my system by performing an activity assay 
or assessing whether phosphorylation of proteins involved in NFk-B sequestration, such 
as IkB members, are associated with NFk-B.  The observed reductions in NFk-B may, 
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partly, explain the feed forward loop because if Src activation is decreased upon IL-8 
depletion and contributes to decreased NFk-B function than less IL-8 secretion would 
be expected.   
While NFk-B is an essential transcriptional regulator of IL-8 in PCa, evidence 
suggests that other transcriptional regulator, STATs, may also regulate IL-8 expression 
(138,231).  This result is supported by a previous study from our laboratory 
demonstrating that Src activation leads to STAT3 activation, binding to the IL-8 
promoter and increased IL-8 secretion (138).  More recently, Okutani et al. 
demonstrates that STAT5 activation induces IL-8 secretion, STAT5 is also directly 
phosphorylated and activated as a transcription factor by Src (232).  
 
Gu et al. shows 
that STAT5 activity is decreased by Src inhibition and in turn decreases metastatic 
behaviors of PCa (233). It would be interesting to determine if SFK activity leads to 
STAT3 or STAT5 transcriptional regulation and whether this promotes IL-8 production 
and expression demonstrating another mechanism for IL-8-mediated SFK activity in 
PCa cells.   
Overall, this chapter provides, for the first time, a mechanism of IL-8 mediated 
SFK activation whereby IL-8 stimulates SFK activation that further stimulates IL-8 
production increasing migratory and invasive capabilities of metastatic PCa in vitro.  
The work in this chapter suggests that further investigation into the following areas 
would be beneficial in understanding PCa progression: 1) investigation of biological 
functions associated with IL-8 mediated Lyn activity and 2) examining whether 
STAT3- or STAT5-binding to IL-8 promoter affects transcription dependently or 
independently of NFk-B transcriptional regulation. 
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The role of HS5 stromal-produced IL-8 on SFK activity prostate cancer 
progression in vitro 
Studies in chapter 4 demonstrated a feed forward loop whereby production of 
IL-8 in HS5 stromal cells increases SFK activity which in turn activates IL-8 in these 
cells.  I also demonstrated that, upon silencing IL-8 production in HS5 stromal cells, 
SFK activation was decreased to baseline levels in PCa as were migration and invasion.  
This demonstrates a paracrine mechanism whereby IL-8 produced in stromal cells can 
also affect metastatic properties of PCa.   
Prior to work in this dissertation, there has been an  increased effort in the 
investigation of mechanisms that contribute to bidirectional activities in the progression 
of PCa to metastatic disease (234,235).  Studies demonstrate that interactions, such as 
those between bone marrow stromal cells (BMSCs) and PCa cells, alter gene expression 
in PCa cells, but there is limited information regarding how stromal cells alter gene and 
protein expression or whether this affects  PCa progression (236,237).
   
In PCa, we 
know that IL-8 secretory levels and gene expression are elevated as PCa progresses, but 
previous studies did not address whether paracrine-mediated contributions of stromal 
produced IL-8 affects PCa progression or whether SFK activation is involved.  
To investigate the effects of stromal produced IL-8, I utilized the well-
established and commercially available fibroblast HS5 bone marrow-derived cell line as 
representative of the stromal compartment.  Torok and Storob et al. report that the 
immortalized, non-tumorigenic forming HS5 cells produce high levels of IL-8 and, thus, 
are an attractive model to explore the effects of stromal production of IL-8 on PCa 
progression (224).  
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I first demonstrated that conditioned media from HS5 stromal cells increases 
migration and invasion of PCa cells (Figure 20) and through successful knockdown of 
IL-8 in HS5 stromal cells (HS5shIL-8), I then demonstrated that HS5 stromal IL-8 is 
one factor contributing to increases in migration and invasion of low metastatic PCa 
cells (Figure 28-29). It is likely that stromal IL-8 production contributes to the 
production of migratory and invasive factors through other cell types.  There is evidence 
suggesting that IL-8 increases endothelial cell production of MMP-2 and MMP-9, 
known invasion markers, and this production correlates with tumor invasiveness (173).   
Endothelial cells are involved in the process of trans-endothelial migration of cancer 
cells which is correlated with increased metastatic spread of cancer cells (77).
 
Thus, 
production of stromal IL-8 could stimulate MMP production in endothelial cells which 
increases the migratory and invasive properties of PCa cells.  Further studies addressing 
whether stromal IL-8-mediated MMP production through SFK activation in PCa cells 
affects migration and invasion are needed.   
There are also other cell types secreting IL-8 that likely contribute to changes 
in PCa progression because PCa is also known to induce an inflammatory 
microenvironment whereby IL-8 is also regulated by inflammatory responses (238).
 
 
While my current study did not address cancer-induced inflammation, I note that 
increased IL-8 secretion in PCa may be due, in part, to the recruitment of inflammatory 
cells that also produce IL-8, such as macrophages.   Studies show that tumor-infiltrating 
macrophages were located near non-small cell lung cancer cells expressing high levels 
of IL-8 (239).  An interesting question that may be addressed in future studies is what 
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role does IL-8 play in prostate cancer-induced inflammation and if it increases 
progression of PCa.   
In the next set of experiments, I demonstrated that HS5 conditioned media 
increases SFK activity in PCa cells, while SFK activity was decreased in the presence 
of HS5shIL-8 conditioned media in PCa cells (Figure 25 and 26).  I also show that a 
feed forward loop exists whereby stromal knockdown of IL-8 decreases Src activity 
while SFK inhibition decreases IL-8 activity (Figure 23 and 24).  Prior to studies from 
this dissertation, investigations studying whether there was an IL-8-mediated SFK 
signaling mechanism in stromal cells that contributes to SFK activity in PCa cells had 
not been reported.  Work from this dissertation demonstrates that IL-8 production by 
HS5 stromal cells contributes to increased SFK activity in PCa cells by stromal 
production of IL-8 which in turn increases IL-8 production.   
Although my results provide a mechanism for stromal IL-8-mediation of SFK 
activation in PCa, I do not propose that all of the changes in SFK activity in PCa cells 
are mediated by stromal IL-8 because it is likely that other stromal produced factors are 
involved in SFK activation. In particular, SFK activation is associated with CXCL-12, 
previously referred to as stromal-derived factor 1α and the production of CXCL-12  in 
turn affects migration and proliferation (240-242).  Further studies are required to 
determine if CXCL-12 is relevant in paracrine-mediated events in PCa in an IL-8 
independent mechanism.  In addition, conditioned media from stromal cells also 
produces cytokine factors, such as IL-2 and 3 also increases migration.
 
 It would be 
interesting to study if these increases were SFK-dependent or independent.   
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This study provides a better understanding of how IL-8-mediated SFK 
activation contributes to the crosstalk between stromal and PCa cells in PCa 
progression.  It also suggests that further investigation into the following areas would be 
beneficial in understanding PCa progression: 1) investigation of other stromal derived 
factors that contribute to PCa progression and 2) exploring how other IL-8 producing 
cell models contribute to PCa progression. 
The role of HS5 stromal-produced IL-8 in metastatic potential of prostate cancer 
In Chapter 5 of this dissertation, I determined that increases in tumor growth 
and metastatic potential are, in part, due to HS5 stromal production of IL-8. There were 
significant increases in tumor growth, at days 14 and 18, between the PC3:HS5NT cell 
combination and the PC3 alone group demonstrating that the tumor-stromal interaction 
contributes to tumor growth (Figure 32).  I then demonstrate that mice injected with the 
combination of PC3 and HS5shIL-8 cells led to tumors that were larger than control but 
smaller than the combination of PC3 and HS5NT cells, showing that HS5 stromal IL-8 
producing cells contributes to tumor growth.  This was further confirmed by the 
significant increases seen in the tumor weights of PC3:HS5NT group when compared to 
the PC3:HS5shIL-8 group (Table 1). Prior to this investigation, studies investigating 
the effects of stromal IL-8 on PCa progression in vivo were limited in scope.  It is likely 
that the increases in growth observed with PC3:HS5NT group were due to the secretion 
and expression of multiple stromal factors, discussed in the previous discussion section.   
The next part of this study was to determine if HS5 stromal cells increase the 
metastatic potential of PCa cells and whether stromal produced IL-8 is a contributing 
factor.  I demonstrated that there was a significant increase in metastatic incidence with 
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PC3:H5NT stromal cells when compared to PC3 cells (Table 2).  There were 4.5 
average metastases in the PC3:HS5NT group when compared to 1.5 average metastases 
in the PC3 group.  The results demonstrate increases in metastatic incidence were due, 
in part, to stromal production of IL-8 whereby the PC3:HS5NT group displayed 
significantly more metastases than PC3:HS5shIL-8.  I demonstrated that stromal 
contributions favor increased metastatic potential of PCa, but that, specifically, IL-8 
production is one contributing factor.    
An interesting finding was the presence of both iliac and renal lymph nodes in 
the PC3:HS5NT and PC3:HS5shIL-8 groups whereas the PC3 group only exhibited 
iliac lymph node metastases.  While it is clear that the tumor-stromal interaction 
increased metastases, this variability in metastatic site had not been observed prior to 
this study.  While the PC3:HS5NT group demonstrated significantly more metastases 
relative to PC3:HS5shIL-8 or PC3 groups, there was no significant difference between 
renal lymph node metastases in PC3:HS5NT and PC3:HS5shIL-8 groups suggesting 
that IL-8 is not responsible for the variability in lymph node metastases.  Other factors 
that increase metastatic potential need to be investigated.  However, this study is 
supported by Giannoni et al. demonstrating that the co-injection of PCa cells and 
cancer-associated fibroblasts resulted in ‘spontanteous micrometastases’ in the lungs of 
mice, not seen in their control groups (235).  They suggest that the cancer-associated 
fibroblasts increase the aggressiveness of PCa cells creating an opportunity for 
metastasis to other less common sites.   
To address metastatic potential, my current study uses an orthotopic in vivo 
model.  While PCa orthotopic mouse models are known to primarily produce lymph 
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node metastases, but they do not produce bone metastases (107,244).
 
 This is discussed 
because PCa preferentially metastasizes to the bone and it would be interesting to 
investigate the effects of stromal produced IL-8 in PCa metastasis to the bone.  This 
could be investigated using one model known to produce bone metastases, the 
intracardiac model, whereby intracardiac injection of stromal cells and PCa cells would 
be performed.  This model could be used to address the specific question of whether 
stromal production of IL-8 increases PCa metastasis to the bone.  
Overall, this study provides novel in vivo evidence whereby HS5 stromal cells 
producing IL-8 increase tumor growth and metastatic potential.  It also suggests that 
further investigation into the following areas would be beneficial in understanding PCa 
progression: 1) examining the roles of other IL-8 producing cells in growth, 2) 
investigating stromal IL-8 mediated markers associated with migration and invasion in 
metastatic tissue and 3) exploring other mouse models that assess IL-8’s role in 
metastasis. 
Clinical significance of IL-8 and Src in CRPC 
Preclinical studies from our laboratory demonstrated that tumor size and lymph 
node metastases were reduced upon dasatanib treatment (107).  It was also 
demonstrated that after dasatanib treatments in mice with intratibial injections of 
prostate tumor cells, PSA levels were decreased significantly as well as bone mineral 
density.  This result was attenuated with the addition of docetaxel (226).  As a result, a 
Phase I/II clinical trial with dasatanib+docetaxel trial was completed during my studies 
(211).  The goal of this study was to determine the efficacy of targeting the epithelial 
and bone compartments of PCa with combination docetaxel + dasatanib therapy.  
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Response to therapy was determined by PSA levels, but more objectively by the 
presence of decreased lesions in radiographic bone scans.  Numerous cytokines were 
examined, including IL-8. Figure 33 demonstrates that all patients showed response 
according to PSA levels, but this response was irrespective of whether there was a 
decrease in radiographic response.  Nearly all patients showed response according to 
IL-8 levels, but, interestingly, this response was increased in patients who did not 
respond to treatments.  Although this was a very small cohort of samples, studies from 
chapter 6 suggest that changes in IL-8 from dasatanib + docetaxel treatment may be 
more predictive of response than changes in PSA.     
Several reports demonstrate higher levels of IL-8 in serum and tissue of 
patients with metastatic disease than in patients without prostate disease or with benign 
prostatic hyperplasia (165,244).
 
 While my current studies demonstrate that IL-8-
mediates SFK activity in PCa which contributes to tumor growth and metastatic 
potential, the Phase II clinical trial results suggest clinical significance for investigating 
IL-8 and Src activity in PCa.  It also suggests that by inhibiting SFK activation IL-8 
activity is also targeted.  In support of this study, Zabransky et al. provides another 
study demonstrating that lenalidomide, a thalidomide analog, treatments increased 
numerous cytokine levels in men with biochemically recurrent PCa, except for one 
cytokine IL-8.  Similar to studies with dasatanib, but through a different therapeutic 
strategy, this study demonstrates that IL-8 levels were decreased in patients who 
responded while IL-8 levels were increased in those who had progressive disease (169). 
These results suggest that there is therapeutic benefit in targeting SFK/IL-8 signaling 
and that there may be an advantage to using IL-8 as a biomarker of metastatic disease.  
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Currently, there is a Phase I clinical trial assessing the safety and efficacy of  
lenalidomide + docetaxel treatments in men with metastatic CRPC.  A Phase III study 
assessing the effects of dasatanib in metastatic CRPC has been completed with results 
pending.  As a result, the assessment of IL-8 levels in responding and non-responding 
patients may be crucial in understanding how the inhibition of SFK/IL-8 signaling 
affects metastatic CRPC.   
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Figure 34 Schematic Representation of IL-8-mediated SFK Activity in Tumor and 
Stromal Cells 
The proposed mechanism shows that IL-8 increases Src activity in low metastatic 
prostate cancer cells and in turn IL-8 is produced further stimulating Src activation 
demonstrating a feed forward loop that increases metastatic properties of PCa cells. 
However, the IL-8/SFK signaling axis in the prostate cancer cells is not completely 
sufficient in increasing their metastatic potential, but, rather, stromal IL-8 production is 
contributes to metastatic potential and growth of PCa cells through a paracrine 
mechanism.  Targeting SFK acitivity by dasatanib will likely decrease SFK activity in 
the stromal and prostate cancer cells decreasing production of IL-8 and inhibit 
metastatic spread of PCa. 
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Summary/Current Perspectives 
Collectively, this dissertation demonstrates that: 1) IL-8 mediates SFK activity 
in the tumor through a feed forward mechanism, 2) a stromal IL-8-mediated paracrine 
mechanism increases SFK activity and metastatic properties of PCa an 3)  IL-8 is one 
factor in the tumor-stromal interaction contributing to tumor growth and metastatic 
potential (Figure 34).  Thus, I hypothesized that IL-8 is one factor mediating increases 
in tumor growth and metastatic potential of PCa through SFK activation.    
This study demonstrates that IL-8 increases Src activity in PCa cells, but there 
is increasing evidence suggesting the role of other SFK members in PCa progression.  
Of the SFK members, there is evidence demonstrating a role for Lyn in PCa 
progression, but there is increasing evidence suggesting Fyn plays a putative role in PCa 
progression (245).  This is important because as we begin to understand how Fyn 
contributes to PCa we can explore signaling pathways associated with its expression. 
Park et al. suggests that SFK members have differential roles in PCa, so it likely that 
Fyn’s contributions to biological activities of PCa are not exactly the same as other SFK 
members. As such, the role Fyn plays in the metastatic process should be explored.  In 
addition, it would be interesting to investigate whether Fyn increases the metastatic 
potential of PCa through an IL-8-mediated mechanism.  While studies investigating this 
would be useful in better understanding how activation of SFKs contribute to the 
metastatic process, it would also be beneficial in delineating why SFK inhibitors, such 
as dasatanib, are effective in decreasing tumor growth and metastatic potential.   
There are multiple studies that have investigated therapies that target signaling 
pathways involved with metastatic PCa, outlined in Introduction. While preclinical 
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models of melanoma and other cancers demonstrated successful inhibition of metastasis 
by blocking IL-8 using ABX-IL8 the fully human neutralizing antibody against IL-8, 
this therapy was ineffective in clinical trials as a single therapy.  Studies  supporting this 
demonstrate that therapies, such as dacarbazine, elicit cytotoxic effects which attenuated 
IL-8 and VEGF levels. Further studies suggested that a combination therapy, including 
dacarbazine and ABX-IL8, may be beneficial by abolishing IL-8 production increasing 
the effectiveness of dacarbazine (246).  This implies that the use of IL-8 neutralizing 
antibodies would diminish the drug-induced IL-8 response increasing the effectiveness 
of drug therapies.   
As it relates to prostate cancer, Wilson et al. demonstrates that oxaliplatin 
induces IL-8 production in PCa cells which stabilizes the IL-8-induced changes to PCa 
progression.  In addition, this report demonstrates that the combination of oxaliplatin 
and the depletion of the secondary IL-8 receptor, CXCR2, increases anti-proliferative 
signaling mechanisms (247). This suggests that the receptors are also important targets.  
As a result, the development of small molecule inhibitors targeting CXCR1 and CXCR2 
are being investigated, but in vivo studies are also needed to identify their role as a 
therapeutic strategy (247,248). Future studies would be needed to determine if the  
combination of IL-8 neutralizing antibody therapies and current drug therapies increases 
the effectiveness of drug therapies by diminishing IL-8-induced changes to PCa 
progression.   
In addition, these studies also beg the question of the usefulness of IL-8  as a 
target or as a biomarker for response.  Chapter 6 of this thesis demonstrates, in a small 
cohort of patients, that IL-8 levels are decreased in patients who respond to 
  
~ 131 ~ 
 
docetaxel+dasatanib, while in non-responding patients IL-8 levels are still increased.  
The IL-8-mediated SFK axis is perturbed through SFK inhibition in responding 
metastatic CRPC patients.  It is likely that by targeting SFK activation  IL-8 will be 
inhibited providing a targetable signaling pathway  that exists not only in the tumor but 
in the microenvironment as well as decreasing metastatic disease.  In addition, the 
sustained high IL-8 levels in patients who did not respond to treatments, such as those 
in the Phase I/II dasatanib trial of chapter 6, provides reasoning for the use of IL-8 as a 
marker of response to treatment modalities inhibiting SFKs.  While this provides strong 
implications for IL-8 as a marker of response for bone metastatic disease  in the Phase 
III clinical trials, it is possible that in a larger sample of patients there may not be 
comparable results.  In this context, IL-8 may be useful in assessing disease that has 
metastasized to a primary metastatic site, such as lymph node.  Evidence from  my in 
vivo experiments demonstrates that IL-8 is also involved in PCa metastases to the 
lymph nodes.  The use of therapies inhibiting SFKs can provide benefit for a subset of 
patients that have lymph node metastases by potentially decreasing spread to the bone. 
These studies suggest: 1) that investigating the role of IL-8 and Fyn in PCa 
progression may be useful in understanding SFK activities in the metastatic process, 2) 
that therapies targeting PCa through SFK inhibition, such as dasatanib, subsequently 
decreasing IL-8 levels are needed, 3) studies addressing the significance of the IL-8 
receptors in metastatic disease and as a therapeutic strategy will be beneficial  and 3) 
that IL-8 may serve as a predictor of disease progression.      
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Conclusions 
Aberrant activation of SFK activity and overexpression and production of IL-8 
have been frequently associated with PCa progression.  The regulation of IL-8 by SFK 
activity has been implicated as a mechanism involved in PCa progression.  In addition, 
the production of IL-8 by tumor-associated cells, such as stromal cells, contributes to 
tumor progression.    This dissertation demonstrates that a feed forward loop exists 
whereby IL-8 increases SFK activity which in turn increases SFK in PCa cells and this 
contributes to migration and invasion of  PCa.  In addition, a paracrine loop exists 
whereby stromal production of IL-8 increases SFK activity and inhibition of stromal IL-
8 decreases SFK activity  to baseline levels which was also seen in migration and 
invasion of PCa cells.  The tumor-stromal interaction increased tumor growth and 
metastases while these increases were decreased upon inhibition of stromal IL-8 
demonstrating that stromal IL-8 is one major contributing factor in tumor growth and 
metastatic potential.  My study establishes an IL-8-mediated mechanism in the 
activation of SFKs in PCa.  I also establish that stromal IL-8 contributes to metastatic 
properties in PCa which are involved in increasing tumor growth and metastatic 
potential in PCa.  This study provides evidence that a feed forward loop whereby IL-8 
increases SFK activity exists providing unique evidence that IL-8 mediation of SFK 
activity involves Src.  The paracrine role of stromal IL-8 in vitro and in tumor growth 
and metastatic potential also provides new insights into how IL-8 production by tumor-
associated stromal cells contributes to the metastatic process.  
 
  
~ 133 ~ 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
  
~ 134 ~ 
 
1. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA 
Cancer J Clin 62:10-29. 
2. Mazhar, D., and J. Waxman. 2008. Early chemotherapy in prostate cancer. 
Nat Clin Pract Urol 5:486-493. 
3. Yin, M., S. Bastacky, U. Chandran, M. J. Becich, and R. Dhir. 2008. 
Prevalence of incidental prostate cancer in the general population: a study 
of healthy organ donors. J Urol 179:892-895; discussion 895. 
4. Antonarakis, E. S., M. A. Carducci, and M. A. Eisenberger. 2010. Novel 
targeted therapeutics for metastatic castration-resistant prostate cancer. 
Cancer Lett 291:1-13. 
5. Attard, G., A. H. Reid, R. A'Hern, C. Parker, N. B. Oommen, E. Folkerd, C. 
Messiou, L. R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. 
Lee, M. Dowsett, S. B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J. S. 
de Bono. 2009. Selective inhibition of CYP17 with abiraterone acetate is 
highly active in the treatment of castration-resistant prostate cancer. J Clin 
Oncol 27:3742-3748. 
6. Logothetis, C. J., and S. H. Lin. 2005. Osteoblasts in prostate cancer 
metastasis to bone. Nat Rev Cancer 5:21-28. 
7. Dayyani, F., G. E. Gallick, C. J. Logothetis, and P. G. Corn. 2011. Novel 
therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 
103:1665-1675. 
8. McNeal, J. E., E. A. Redwine, F. S. Freiha, and T. A. Stamey. 1988. Zonal 
distribution of prostatic adenocarcinoma. Correlation with histologic pattern 
  
~ 135 ~ 
 
and direction of spread. Am J Surg Pathol 12:897-906. 
9. Tu, S. M., and S. H. Lin. 2012. Prostate cancer stem cells. Clin Genitourin 
Cancer 10:69-76. 
10. Knudsen, B. S., and V. Vasioukhin. 2010. Mechanisms of prostate cancer 
initiation and progression. Adv Cancer Res 109:1-50. 
11. Chmelar, R., G. Buchanan, E. F. Need, W. Tilley, and N. M. Greenberg. 
2007. Androgen receptor coregulators and their involvement in the 
development and progression of prostate cancer. Int J Cancer 120:719-733. 
12. Balk, S. P., Y. J. Ko, and G. J. Bubley. 2003. Biology of prostate-specific 
antigen. J Clin Oncol 21:383-391. 
13. Knudsen, K. E., and H. I. Scher. 2009. Starving the addiction: new 
opportunities for durable suppression of AR signaling in prostate cancer. 
Clin Cancer Res 15:4792-4798. 
14. Lilja, H., D. Ulmert, and A. J. Vickers. 2008. Prostate-specific antigen and 
prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 
8:268-278. 
15. Bostwick, D. G., and L. Cheng. 2012. Precursors of prostate cancer. 
Histopathology 60:4-27. 
16. Chang, R. T., R. Kirby, and B. J. Challacombe. 2012. Is there a link 
between BPH and prostate cancer? Practitioner 256:13-16, 12. 
17. Lee, S. O., Z. Ma, C. R. Yeh, J. Luo, T. H. Lin, K. P. Lai, S. Yamashita, L. 
Liang, J. Tian, L. Li, Q. Jiang, C. K. Huang, Y. Niu, S. Yeh, and C. Chang. 
2013. New therapy targeting differential androgen receptor signaling in 
  
~ 136 ~ 
 
prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell 
Biol 5:14-26. 
18. Li, H., and D. G. Tang. 2011. Prostate cancer stem cells and their potential 
roles in metastasis. J Surg Oncol 103:558-562. 
19. Lawson, D. A., L. Xin, R. Lukacs, Q. Xu, D. Cheng, and O. N. Witte. 2005. 
Prostate stem cells and prostate cancer. Cold Spring Harb Symp Quant Biol 
70:187-196. 
20. Schalken, J. A., and G. van Leenders. 2003. Cellular and molecular biology 
of the prostate: stem cell biology. Urology 62:11-20. 
21. Maitland, N. J., F. M. Frame, E. S. Polson, J. L. Lewis, and A. T. Collins. 
2011. Prostate cancer stem cells: do they have a basal or luminal 
phenotype? Horm Cancer 2:47-61. 
22. Mimeault, M., and S. K. Batra. 2006. Recent advances on multiple 
tumorigenic cascades involved in prostatic cancer progression and targeting 
therapies. Carcinogenesis 27:1-22. 
23. Leong, K. G., B. E. Wang, L. Johnson, and W. Q. Gao. 2008. Generation of 
a prostate from a single adult stem cell. Nature 456:804-808. 
24. Liao, C. P., H. Adisetiyo, M. Liang, and P. Roy-Burman. 2010. Cancer 
stem cells and microenvironment in prostate cancer progression. Horm 
Cancer 1:297-305. 
25. Goldstein, A. S., J. Huang, C. Guo, I. P. Garraway, and O. N. Witte. 2010. 
Identification of a cell of origin for human prostate cancer. Science 
329:568-571. 
  
~ 137 ~ 
 
26. Taylor, R. A., R. Toivanen, M. Frydenberg, J. Pedersen, L. Harewood, 
Australian Prostate Cancer Bioresource, A. T. Collins, N. J. Maitland, and 
G. P. Risbridger. 2012. Human epithelial basal cells are cells of origin of 
prostate cancer, independent of CD133 status. Stem Cells 30:1087-1096. 
27. Wang, X., M. Kruithof-de Julio, K. D. Economides, D. Walker, H. Yu, M. 
V. Halili, Y. P. Hu, S. M. Price, C. Abate-Shen, and M. M. Shen. 2009. A 
luminal epithelial stem cell that is a cell of origin for prostate cancer. 
Nature 461:495-500. 
28. Grizzle, W. E., S. Srivastava, and U. Manne. 2010. The biology of 
incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark 9:21-
39. 
29. Bostwick, D. G., A. Pacelli, and A. Lopez-Beltran. 1996. Molecular biology 
of prostatic intraepithelial neoplasia. Prostate 29:117-134. 
30. Foster, C. S., D. G. Bostwick, H. Bonkhoff, J. E. Damber, T. van der 
Kwast, R. Montironi, and W. A. Sakr. 2000. Cellular and molecular 
pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl:19-43. 
31. Bostwick, D. G., and L. Cheng. 2012. Precursors of prostate cancer. 
Histopathology 60:4-27. 
32. Bostwick, D. G., L. Liu, M. K. Brawer, and J. Qian. 2004. High-grade 
prostatic intraepithelial neoplasia. Rev Urol 6:171-179. 
33. Montironi, R., R. Mazzucchelli, A. Lopez-Beltran, M. Scarpelli, and L. 
Cheng. 2011. Prostatic intraepithelial neoplasia: its morphological and 
molecular diagnosis and clinical significance. BJU Int 108:1394-1401. 
  
~ 138 ~ 
 
34. Nakashiro, K., Y. Hayashi, and R. Oyasu. 2003. Immunohistochemical 
expression of hepatocyte growth factor and c-Met/HGF receptor in benign 
and malignant human prostate tissue. Oncol Rep 10:1149-1153. 
35. Henrique, R., C. Jerónimo, M. R. Teixeira, M. O. Hoque, A. L. Carvalho, I. 
Pais, F. R. Ribeiro, J. Oliveira, C. Lopes, and D. Sidransky. 2006. 
Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: 
clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4:1-
8. 
36. Dickinson, S. I. 2010. Premalignant and malignant prostate lesions: 
pathologic review. Cancer Control 17:214-222. 
37. Cai, H., D. A. Smith, S. Memarzadeh, C. A. Lowell, J. A. Cooper, and O. 
N. Witte. 2011. Differential transformation capacity of Src family kinases 
during the initiation of prostate cancer. Proc Natl Acad Sci U S A 
108:6579-6584. 
38. van der Sluis, T. M., E. J. Meuleman, R. J. van Moorselaar, H. N. Bui, M. 
A. Blankenstein, A. C. Heijboer, and A. N. Vis. 2012. Intraprostatic 
testosterone and dihydrotestosterone. Part II: concentrations after androgen 
hormonal manipulation in men with benign prostatic hyperplasia and 
prostate cancer. BJU Int 109:183-188. 
39. Huggins, C., and C. V. Hodges. 2002. Studies on prostatic cancer: I. The 
effect of castration, of estrogen and of androgen injection on serum 
phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9-
12. 
  
~ 139 ~ 
 
40. Akaza, H. 2011. Combined androgen blockade for prostate cancer: review 
of efficacy, safety and cost-effectiveness. Cancer Sci 102:51-56. 
41. Knudsen, K. E., and H. I. Scher. 2009. Starving the addiction: new 
opportunities for durable suppression of AR signaling in prostate cancer. 
Clin Cancer Res 15:4792-4798. 
42. Marech, I., A. Vacca, G. Ranieri, A. Gnoni, and F. Dammacco. 2012. Novel 
strategies in the treatment of castration-resistant prostate cancer (Review). 
Int J Oncol 40:1313-1320. 
43. Thalmann, G. N., R. A. Sikes, T. T. Wu, A. Degeorges, S. M. Chang, M. 
Ozen, S. Pathak, and L. W. Chung. 2000. LNCaP progression model of 
human prostate cancer: androgen-independence and osseous metastasis. 
Prostate 44:91-103 Jul 101;144(102). 
44. Han, G., G. Buchanan, M. Ittmann, J. M. Harris, X. Yu, F. J. Demayo, W. 
Tilley, and N. M. Greenberg. 2005. Mutation of the androgen receptor 
causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 
102:1151-1156. 
45. Dutt, S. S., and A. C. Gao. 2009. Molecular mechanisms of castration-
resistant prostate cancer progression. Future Oncol 5:1403-1413. 
46. Zhang, L., S. Wu, L. R. Guo, and X. J. Zhao. 2009. Diagnostic strategies 
and the incidence of prostate cancer: reasons for the low reported incidence 
of prostate cancer in China. Asian J Androl 11:9-13. 
47. Mimeault, M., and S. K. Batra. 2011. Animal models relevant to human 
prostate carcinogenesis underlining the critical implication of prostatic 
  
~ 140 ~ 
 
stem/progenitor cells. Biochim Biophys Acta 1816:25-37. 
48. Urbanucci, A., B. Sahu, J. Seppälä, A. Larjo, L. M. Latonen, K. K. 
Waltering, T. L. Tammela, R. L. Vessella, H. Lähdesmäki, O. A. Jänne, and 
T. Visakorpi. 2012. Overexpression of androgen receptor enhances the 
binding of the receptor to the chromatin in prostate cancer. Oncogene 
31:2153-2163. 
49. Hu, R., W. B. Isaacs, and J. Luo. 2011. A snapshot of the expression 
signature of androgen receptor splicing variants and their distinctive 
transcriptional activities. Prostate 71:1656-1667. 
50. Locke, J. A., E. S. Guns, A. A. Lubik, H. H. Adomat, S. C. Hendy, C. A. 
Wood, S. L. Ettinger, M. E. Gleave, and C. C. Nelson. 2008. Androgen 
levels increase by intratumoral de novo steroidogenesis during progression 
of castration-resistant prostate cancer. Cancer Res 68:6407-6415. 
51. Montgomery, R. B., E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. 
Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson. 2008. Maintenance of 
intratumoral androgens in metastatic prostate cancer: a mechanism for 
castration-resistant tumor growth. Cancer Res 68:4447-4454. 
52. Bonkhoff, H., and R. Berges. 2010. From pathogenesis to prevention of 
castration resistant prostate cancer. Prostate 70:100-112. 
53. Kung, H. J., and C. P. Evans. 2009. Oncogenic activation of androgen 
receptor. Urol Oncol 27:48-52. 
54. Knudsen, K. E., and T. M. Penning. 2010. Partners in crime: deregulation 
of AR activity and androgen synthesis in prostate cancer. Trends 
  
~ 141 ~ 
 
Endocrinol Metab 21:315-324. 
55. Brooke, G. N., and C. L. Bevan. 2009. The role of androgen receptor 
mutations in prostate cancer progression. Curr Genomics 10:18-25. 
56. Zhu, M. L., and N. Kyprianou. 2008. Androgen receptor and growth factor 
signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15:841-
849. 
57. Mellado, B., J. Codony, M. J. Ribal, L. Visa, and P. Gascón. 2009. 
Molecular biology of androgen-independent prostate cancer: the role of the 
androgen receptor pathway. Clin Transl Oncol 11:5-10. 
58. Migliaccio, A., L. Varricchio, A. De Falco, G. Castoria, C. Arra, H. 
Yamaguchi, A. Ciociola, M. Lombardi, R. Di Stasio, A. Barbieri, A. Baldi, 
M. V. Barone, E. Appella, and F. Auricchio. 2007. Inhibition of the SH3 
domain-mediated binding of Src to the androgen receptor and its effect on 
tumor growth. Oncogene 26:6619-6629. 
59. Efstathiou, E., and C. J. Logothetis. 2010. A new therapy paradigm for 
prostate cancer founded on clinical observations. Clin Cancer Res 16:1100-
1107. 
60. Bubendorf, L., A. Schöpfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T. C. 
Gasser, and M. J. Mihatsch. 2000. Metastatic patterns of prostate cancer: an 
autopsy study of 1,589 patients. Hum Pathol 31:578-583. 
61. Fidler, I. J. 2003. Understanding bone metastases: the key to the effective 
treatment of prostate cancer. Clin Adv Hematol Oncol 1:278-279. 
62. Morgan, T. M., P. H. Lange, M. P. Porter, D. W. Lin, W. J. Ellis, I. S. 
  
~ 142 ~ 
 
Gallaher, and R. L. Vessella. 2009. Disseminated tumor cells in prostate 
cancer patients after radical prostatectomy and without evidence of disease 
predicts biochemical recurrence. Clin Cancer Res 15:677-683. 
63. Kaplan, R. N., B. Psaila, and D. Lyden. 2006. Bone marrow cells in the 
'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 
25:521-529. 
64. Chirgwin, J. M. 2012. The stem cell niche as a pharmaceutical target for 
prevention of skeletal metastases. Anticancer Agents Med Chem 12:187-
193. 
65. Iwasaki, H., and T. Suda. 2009. Cancer stem cells and their niche. Cancer 
Sci 100:1166-1172. 
66. Shiozawa, Y., E. A. Pedersen, A. M. Havens, Y. Jung, A. Mishra, J. Joseph, 
J. K. Kim, L. R. Patel, C. Ying, A. M. Ziegler, M. J. Pienta, J. Song, J. 
Wang, R. D. Loberg, P. H. Krebsbach, K. J. Pienta, and R. S. Taichman. 
2011. Human prostate cancer metastases target the hematopoietic stem cell 
niche to establish footholds in mouse bone marrow. J Clin Invest 121:1298-
1312. 
67. Kitagawa, Y., J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. 
Keller. 2005. Vascular endothelial growth factor contributes to prostate 
cancer-mediated osteoblastic activity. Cancer Res 65:10921-10929. 
68. Lee, S. O., W. Lou, K. M. Qureshi, F. Mehraein-Ghomi, D. L. Trump, and 
A. C. Gao. 2004. RNA interference targeting Stat3 inhibits growth and 
induces apoptosis of human prostate cancer cells. Prostate 60:303-309. 
  
~ 143 ~ 
 
69. Franks, L. M., P. N. Riddle, A. W. Carbonell, and G. O. Gey. 1970. A 
comparative study of the ultrastructure and lack of growth capacity of adult 
human prostate epithelium mechanically separated from its stroma. J Pathol 
100:113-119. 
70. Chung, L. W., S. M. Chang, C. Bell, H. E. Zhau, J. Y. Ro, and A. C. von 
Eschenbach. 1989. Co-inoculation of tumorigenic rat prostate mesenchymal 
cells with non-tumorigenic epithelial cells results in the development of 
carcinosarcoma in syngeneic and athymic animals. Int J Cancer 43:1179-
1187. 
71. Bronisz, A., J. Godlewski, J. A. Wallace, A. S. Merchant, M. O. Nowicki, 
H. Mathsyaraja, R. Srinivasan, A. J. Trimboli, C. K. Martin, F. Li, L. Yu, S. 
A. Fernandez, T. Pécot, T. J. Rosol, S. Cory, M. Hallett, M. Park, M. G. 
Piper, C. B. Marsh, L. D. Yee, R. E. Jimenez, G. Nuovo, S. E. Lawler, E. A. 
Chiocca, G. Leone, and M. C. Ostrowski. 2012. Reprogramming of the 
tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell 
Biol 14:159-167. 
72. Joyce, J. A., and J. W. Pollard. 2009. Microenvironmental regulation of 
metastasis. Nat Rev Cancer 9:239-252. 
73. Suva, L. J., R. J. Griffin, and I. Makhoul. 2009. Mechanisms of bone 
metastases of breast cancer. Endocr Relat Cancer 16:703-713. 
74. Chinni, S. R., S. Sivalogan, Z. Dong, J. C. Filho, X. Deng, R. D. Bonfil, 
and M. L. Cher. 2006. CXCL12/CXCR4 signaling activates Akt-1 and 
MMP-9 expression in prostate cancer cells: the role of bone 
  
~ 144 ~ 
 
microenvironment-associated CXCL12. Prostate 66:32-48. 
75. Bussard, K. M., C. V. Gay, and A. M. Mastro. 2008. The bone 
microenvironment in metastasis; what is special about bone? Cancer 
Metastasis Rev 27:41-55. 
76. Sung, S. Y., C. L. Hsieh, A. Law, H. E. Zhau, S. Pathak, A. S. Multani, S. 
Lim, I. M. Coleman, L. C. Wu, W. D. Figg, W. L. Dahut, P. Nelson, J. K. 
Lee, M. B. Amin, R. Lyles, P. A. Johnstone, F. F. Marshall, and L. W. 
Chung. 2008. Coevolution of prostate cancer and bone stroma in three-
dimensional coculture: implications for cancer growth and metastasis. 
Cancer Res 68:9996-10003. 
77. Josson, S., Y. Matsuoka, L. W. Chung, H. E. Zhau, and R. Wang. 2010. 
Tumor-stroma co-evolution in prostate cancer progression and metastasis. 
Semin Cell Dev Biol 21:26-32. 
78. Nannuru, K. C., and R. K. Singh. 2010. Tumor-stromal interactions in bone 
metastasis. Curr Osteoporos Rep 8:105-113. 
79. Taylor, B. S., N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. 
Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. 
Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. 
E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, 
C. Sander, C. L. Sawyers, and W. L. Gerald. 2010. Integrative genomic 
profiling of human prostate cancer. Cancer Cell 18:11-22. 
80. Song, H., B. Zhang, M. A. Watson, P. A. Humphrey, H. Lim, and J. 
Milbrandt. 2009. Loss of Nkx3.1 leads to the activation of discrete 
  
~ 145 ~ 
 
downstream target genes during prostate tumorigenesis. Oncogene 28:3307-
3319. 
81. Bowen, C., and E. P. Gelmann. 2010. NKX3.1 activates cellular response to 
DNA damage. Cancer Res 70:3089-3097. 
82. Gurel, B., T. Z. Ali, E. A. Montgomery, S. Begum, J. Hicks, M. Goggins, 
C. G. Eberhart, D. P. Clark, C. J. Bieberich, J. I. Epstein, and A. M. De 
Marzo. 2010. NKX3.1 as a marker of prostatic origin in metastatic tumors. 
Am J Surg Pathol 34:1097-1105. 
83. Wang, H., S. Y. Quah, J. M. Dong, E. Manser, J. P. Tang, and Q. Zeng. 
2007. PRL-3 down-regulates PTEN expression and signals through PI3K to 
promote epithelial-mesenchymal transition. Cancer Res 67:2922-2926. 
84. Wang, S., J. Gao, Q. Lei, N. Rozengurt, C. Pritchard, J. Jiao, G. V. Thomas, 
G. Li, P. Roy-Burman, P. S. Nelson, X. Liu, and H. Wu. 2003. Prostate-
specific deletion of the murine Pten tumor suppressor gene leads to 
metastatic prostate cancer. Cancer Cell 4:209-221. 
85. Sircar, K., M. Yoshimoto, F. A. Monzon, I. H. Koumakpayi, R. L. Katz, A. 
Khanna, K. Alvarez, G. Chen, A. D. Darnel, A. G. Aprikian, F. Saad, T. A. 
Bismar, and J. A. Squire. 2009. PTEN genomic deletion is associated with 
p-Akt and AR signalling in poorer outcome, hormone refractory prostate 
cancer. J Pathol 218:505-513. 
86. Kim, M. J., R. D. Cardiff, N. Desai, W. A. Banach-Petrosky, R. Parsons, M. 
M. Shen, and C. Abate-Shen. 2002. Cooperativity of Nkx3.1 and Pten loss 
of function in a mouse model of prostate carcinogenesis. Proc Natl Acad 
  
~ 146 ~ 
 
Sci U S A 99:2884-2889. 
87. Carver, B. S., J. Tran, A. Gopalan, Z. Chen, S. Shaikh, A. Carracedo, A. 
Alimonti, C. Nardella, S. Varmeh, P. T. Scardino, C. Cordon-Cardo, W. 
Gerald, and P. P. Pandolfi. 2009. Aberrant ERG expression cooperates with 
loss of PTEN to promote cancer progression in the prostate. Nat Genet 
41:619-624. 
88. King, J. C., J. Xu, J. Wongvipat, H. Hieronymus, B. S. Carver, D. H. 
Leung, B. S. Taylor, C. Sander, R. D. Cardiff, S. S. Couto, W. L. Gerald, 
and C. L. Sawyers. 2009. Cooperativity of TMPRSS2-ERG with PI3-kinase 
pathway activation in prostate oncogenesis. Nat Genet 41:524-526. 
89. Kaltz-Wittmer, C., U. Klenk, A. Glaessgen, D. E. Aust, J. Diebold, U. 
Löhrs, and G. B. Baretton. 2000. FISH analysis of gene aberrations (MYC, 
CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before 
and after androgen deprivation therapy. Lab Invest 80:1455-1464. 
90. Koh, C. M., C. J. Bieberich, C. V. Dang, W. G. Nelson, S. 
Yegnasubramanian, and A. M. De Marzo. 2010. MYC and Prostate Cancer. 
Genes Cancer 1:617-628. 
91. Ellwood-Yen, K., T. G. Graeber, J. Wongvipat, M. L. Iruela-Arispe, J. 
Zhang, R. Matusik, G. V. Thomas, and C. L. Sawyers. 2003. Myc-driven 
murine prostate cancer shares molecular features with human prostate 
tumors. Cancer Cell 4:223-238. 
92. Gurel, B., T. Iwata, C. M. Koh, R. B. Jenkins, F. Lan, C. Van Dang, J. L. 
Hicks, J. Morgan, T. C. Cornish, S. Sutcliffe, W. B. Isaacs, J. Luo, and A. 
  
~ 147 ~ 
 
M. De Marzo. 2008. Nuclear MYC protein overexpression is an early 
alteration in human prostate carcinogenesis. Mod Pathol 21:1156-1167. 
93. Kim, J., I. E. Eltoum, M. Roh, J. Wang, and S. A. Abdulkadir. 2009. 
Interactions between cells with distinct mutations in c-MYC and Pten in 
prostate cancer. PLoS Genet 5:e1000542. 
94. Rouzier, C., J. Haudebourg, X. Carpentier, L. Valério, J. Amiel, J. F. 
Michiels, and F. Pedeutour. 2008. Detection of the TMPRSS2-ETS fusion 
gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and 
paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 
183:21-27. 
95. Saramäki, O. R., A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. 
Tammela, and T. Visakorpi. 2008. TMPRSS2:ERG fusion identifies a 
subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 
14:3395-3400. 
96. Tomlins, S. A., D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. 
W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, 
R. B. Shah, K. J. Pienta, M. A. Rubin, and A. M. Chinnaiyan. 2005. 
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in 
prostate cancer. Science 310:644-648. 
97. Tomlins, S. A., B. Laxman, S. Varambally, X. Cao, J. Yu, B. E. Helgeson, 
Q. Cao, J. R. Prensner, M. A. Rubin, R. B. Shah, R. Mehra, and A. M. 
Chinnaiyan. 2008. Role of the TMPRSS2-ERG gene fusion in prostate 
cancer. Neoplasia 10:177-188. 
  
~ 148 ~ 
 
98. Klezovitch, O., M. Risk, I. Coleman, J. M. Lucas, M. Null, L. D. True, P. S. 
Nelson, and V. Vasioukhin. 2008. A causal role for ERG in neoplastic 
transformation of prostate epithelium. Proc Natl Acad Sci U S A 105:2105-
2110. 
99. Mehra, R., S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, 
K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan. 2008. Characterization of 
TMPRSS2-ETS gene aberrations in androgen-independent metastatic 
prostate cancer. Cancer Res 68:3584-3590. 
100. Carver, B. S., J. Tran, Z. Chen, A. Carracedo-Perez, A. Alimonti, C. 
Nardella, A. Gopalan, P. T. Scardino, C. Cordon-Cardo, W. Gerald, and P. 
P. Pandolfi. 2009. ETS rearrangements and prostate cancer initiation. 
Nature 457:E1; discussion E2-3. 
101. Nishio, Y., Y. Yamada, H. Kokubo, K. Nakamura, S. Aoki, T. Taki, N. 
Honda, A. Nakagawa, S. Saga, and K. Hara. 2006. Prognostic significance 
of immunohistochemical expression of the HER-2/neu oncoprotein in bone 
metastatic prostate cancer. Urology 68:110-115. 
102. Angelucci, A., G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. 
Muzi, A. Teti, C. Vicentini, and M. Bologna. 2006. Suppression of EGF-R 
signaling reduces the incidence of prostate cancer metastasis in nude mice. 
Endocr Relat Cancer 13:197-210. 
103. Chang, Y. M., H. J. Kung, and C. P. Evans. 2007. Nonreceptor tyrosine 
kinases in prostate cancer. Neoplasia 9:90-100. 
104. Verras, M., J. Lee, H. Xue, T. H. Li, Y. Wang, and Z. Sun. 2007. The 
  
~ 149 ~ 
 
androgen receptor negatively regulates the expression of c-Met: 
implications for a novel mechanism of prostate cancer progression. Cancer 
Res 67:967-975. 
105. You, W. K., B. Sennino, C. W. Williamson, B. Falcón, H. Hashizume, L. C. 
Yao, D. T. Aftab, and D. M. McDonald. 2011. VEGF and c-Met blockade 
amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 
71:4758-4768. 
106. Bologna, M., C. Vicentini, P. Muzi, G. Pace, and A. Angelucci. 2011. 
Cancer multitarget pharmacology in prostate tumors: tyrosine kinase 
inhibitors and beyond. Curr Med Chem 18:2827-2835. 
107. Park, S. I., J. Zhang, K. A. Phillips, J. C. Araujo, A. M. Najjar, A. Y. 
Volgin, J. G. Gelovani, S. J. Kim, Z. Wang, and G. E. Gallick. 2008. 
Targeting SRC family kinases inhibits growth and lymph node metastases 
of prostate cancer in an orthotopic nude mouse model. Cancer Res 68:3323-
3333. 
108. Rous, P. 1911. A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN 
AGENT SEPARABLE FROM THE TUMOR CELLS. J Exp Med 13:397-
411. 
109. Stehelin, D., H. E. Varmus, J. M. Bishop, and P. K. Vogt. 1976. DNA 
related to the transforming gene(s) of avian sarcoma viruses is present in 
normal avian DNA. Nature 260:170-173. 
110. Levinson, A. D., H. Oppermann, L. Levintow, H. E. Varmus, and J. M. 
Bishop. 1978. Evidence that the transforming gene of avian sarcoma virus 
  
~ 150 ~ 
 
encodes a protein kinase associated with a phosphoprotein. Cell 15:561-
572. 
111. Thomas, S. M., and J. S. Brugge. 1997. Cellular functions regulated by Src 
family kinases. Annu Rev Cell Dev Biol 13:513-609. 
112. Summy, J. M., and G. E. Gallick. 2003. Src family kinases in tumor 
progression and metastasis. Cancer Metastasis Rev 22:337-358. 
113. Roskoski, R. 2005. Src kinase regulation by phosphorylation and 
dephosphorylation. Biochem Biophys Res Commun 331:1-14. 
114. Brown, M. T., and J. A. Cooper. 1996. Regulation, substrates and functions 
of src. Biochim Biophys Acta 1287:121-149. 
115. Johnson, F. M., and G. E. Gallick. 2007. SRC family nonreceptor tyrosine 
kinases as molecular targets for cancer therapy. Anticancer Agents Med 
Chem 7:651-659. 
116. Paronetto, M. P., D. Farini, I. Sammarco, G. Maturo, G. Vespasiani, R. 
Geremia, P. Rossi, and C. Sette. 2004. Expression of a truncated form of the 
c-Kit tyrosine kinase receptor and activation of Src kinase in human 
prostatic cancer. Am J Pathol 164:1243-1251. 
117. Tatarov, O., T. J. Mitchell, M. Seywright, H. Y. Leung, V. G. Brunton, and 
J. Edwards. 2009. SRC family kinase activity is up-regulated in hormone-
refractory prostate cancer. Clin Cancer Res 15:3540-3549. 
118. Yu, E. Y., G. Wilding, E. Posadas, M. Gross, S. Culine, C. Massard, M. J. 
Morris, G. Hudes, F. Calabrò, S. Cheng, G. C. Trudel, P. Paliwal, and C. N. 
Sternberg. 2009. Phase II study of dasatinib in patients with metastatic 
  
~ 151 ~ 
 
castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428. 
119. Lesslie, D. P., J. M. Summy, N. U. Parikh, F. Fan, J. G. Trevino, T. K. 
Sawyer, C. A. Metcalf, W. C. Shakespeare, D. J. Hicklin, L. M. Ellis, and 
G. E. Gallick. 2006. Vascular endothelial growth factor receptor-1 mediates 
migration of human colorectal carcinoma cells by activation of Src family 
kinases. Br J Cancer 94:1710-1717. 
120. Nam, S., A. Williams, A. Vultur, A. List, K. Bhalla, D. Smith, F. Y. Lee, 
and R. Jove. 2007. Dasatinib (BMS-354825) inhibits Stat5 signaling 
associated with apoptosis in chronic myelogenous leukemia cells. Mol 
Cancer Ther 6:1400-1405. 
121. Guan, H., Z. Zhou, G. E. Gallick, S. F. Jia, J. Morales, A. K. Sood, S. J. 
Corey, and E. S. Kleinerman. 2008. Targeting Lyn inhibits tumor growth 
and metastasis in Ewing's sarcoma. Mol Cancer Ther 7:1807-1816. 
122. Buettner, R., T. Mesa, A. Vultur, F. Lee, and R. Jove. 2008. Inhibition of 
Src family kinases with dasatinib blocks migration and invasion of human 
melanoma cells. Mol Cancer Res 6:1766-1774. 
123. Yadav, V., and M. F. Denning. 2011. Fyn is induced by Ras/PI3K/Akt 
signaling and is required for enhanced invasion/migration. Mol Carcinog 
50:346-352. 
124. Daud, A., Krishnamurthi, S.S., Saleh, M.N., Gitlitz, B.J., Borad, M.J., Gold, 
P.J., Chiorean, E.G., Springett, G.M., Abbas, R., Agarwal, S., Bardy-
Bouxin, N., Hsyu, P.H., Leip, E., Turnbull, K., Zacharchuk, C., 
Messermith, W.A.  2012. Phase I study of bosutinib, a src/abl tyrosine 
  
~ 152 ~ 
 
kinase inhibitor, administered to patients with advanced solid tumors. 
18:1092-100. 
125. Scher, H. I., and S. Fossa. 1995. Prostate cancer in the era of prostate-
specific antigen. Curr Opin Oncol 7:281-291. 
126. Gioeli, D. 2005. Signal transduction in prostate cancer progression. Clin Sci 
(Lond) 108:293-308. 
127. Fizazi, K. 2007. The role of Src in prostate cancer. Ann Oncol 18:1765-
1773. 
128. Wheeler, D. L., M. Iida, and E. F. Dunn. 2009. The role of Src in solid 
tumors. Oncologist 14:667-678. 
129. Saad, F., and A. Lipton. 2010. SRC kinase inhibition: targeting bone 
metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 
36:177-184. 
130. Parsons, S. J., and J. T. Parsons. 2004. Src family kinases, key regulators of 
signal transduction. Oncogene 23:7906-7909. 
131. Summy, J. M., and G. E. Gallick. 2006. Treatment for advanced tumors: 
SRC reclaims center stage. Clin Cancer Res 12:1398-1401. 
132. Kim, L. C., L. Song, and E. B. Haura. 2009. Src kinases as therapeutic 
targets for cancer. Nat Rev Clin Oncol 6:587-595. 
133. Amorino, G. P., P. D. Deeble, and S. J. Parsons. 2007. Neurotensin 
stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b 
pathway. Oncogene 26:745-756. 
134. Dunn, E. F., M. Iida, R. A. Myers, D. A. Campbell, K. A. Hintz, E. A. 
  
~ 153 ~ 
 
Armstrong, C. Li, and D. L. Wheeler. 2011. Dasatinib sensitizes KRAS 
mutant colorectal tumors to cetuximab. Oncogene 30:561-574. 
135. Koppikar, P., S. H. Choi, A. M. Egloff, Q. Cai, S. Suzuki, M. Freilino, H. 
Nozawa, S. M. Thomas, W. E. Gooding, J. M. Siegfried, and J. R. Grandis. 
2008. Combined inhibition of c-Src and epidermal growth factor receptor 
abrogates growth and invasion of head and neck squamous cell carcinoma. 
Clin Cancer Res 14:4284-4291. 
136. Levitt, J. M., H. Yamashita, W. Jian, S. P. Lerner, and G. Sonpavde. 2010. 
Dasatinib is preclinically active against Src-overexpressing human 
transitional cell carcinoma of the urothelium with activated Src signaling. 
Mol Cancer Ther 9:1128-1135. 
137. Kim, S. J., M. Johnson, K. Koterba, M. H. Herynk, H. Uehara, and G. E. 
Gallick. 2003. Reduced c-Met expression by an adenovirus expressing a c-
Met ribozyme inhibits tumorigenic growth and lymph node metastases of 
PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin 
Cancer Res 9:5161-5170. 
138. Trevino, J. G., J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. 
Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick. 2006. 
Inhibition of SRC expression and activity inhibits tumor progression and 
metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude 
mouse model. Am J Pathol 168:962-972. 
139. Kue, P. F., and Y. Daaka. 2000. Essential role for G proteins in prostate 
cancer cell growth and signaling. J Urol 164:2162-2167. 
  
~ 154 ~ 
 
140. Kirui, J. K., Y. Xie, D. W. Wolff, H. Jiang, P. W. Abel, and Y. Tu. 2010. 
Gbetagamma signaling promotes breast cancer cell migration and invasion. J 
Pharmacol Exp Ther 333:393-403. 
141. Lan, T., Y. Chen, J. Sang, Y. Wu, Y. Wang, L. Jiang, and Y. Tao. 2012. 
Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK 
signal transduction in breast cancer cells. Oncol Rep 27:2039-2044. 
142. Dorsam, R. T., and J. S. Gutkind. 2007. G-protein-coupled receptors and 
cancer. Nat Rev Cancer 7:79-94. 
143. Gutkind, J. S. 2000. Regulation of mitogen-activated protein kinase 
signaling networks by G protein-coupled receptors. Sci STKE 2000:re1. 
144. Raj, G. V., L. Barki-Harrington, P. F. Kue, and Y. Daaka. 2002. Guanosine 
phosphate binding protein coupled receptors in prostate cancer: a review. J 
Urol 167:1458-1463. 
145. Cotton, M., and A. Claing. 2009. G protein-coupled receptors stimulation 
and the control of cell migration. Cell Signal 21:1045-1053. 
146. Araki, S., Y. Omori, D. Lyn, R. K. Singh, D. M. Meinbach, Y. Sandman, V. 
B. Lokeshwar, and B. L. Lokeshwar. 2007. Interleukin-8 is a molecular 
determinant of androgen independence and progression in prostate cancer. 
Cancer Res 67:6854-6862. 
147. Lee, L. F., M. C. Louie, S. J. Desai, J. Yang, H. W. Chen, C. P. Evans, and 
H. J. Kung. 2004. Interleukin-8 confers androgen-independent growth and 
migration of LNCaP: differential effects of tyrosine kinases Src and FAK. 
Oncogene 23:2197-2205. 
  
~ 155 ~ 
 
148. Trevino, J.G., Summy, J.M., Gray, M.J., Nilsson, M.B., Lesslie, D.P., Baker, 
C.H., Gallick, G.E.  2005 Expression and activity of SRC regulate 
interleukin-8 expression in pancreatic adenocarcinoma cells: implications for 
angiogenesis.  Cancer Res 65: 7214-22. 
149. Sabbah, M., S. Emami, G. Redeuilh, S. Julien, G. Prévost, A. Zimber, R. 
Ouelaa, M. Bracke, O. De Wever, and C. Gespach. 2008. Molecular 
signature and therapeutic perspective of the epithelial-to-mesenchymal 
transitions in epithelial cancers. Drug Resist Updat 11:123-151. 
150. Lowe, C., T. Yoneda, B. F. Boyce, H. Chen, G. R. Mundy, and P. Soriano. 
1993. Osteopetrosis in Src-deficient mice is due to an autonomous defect of 
osteoclasts. Proc Natl Acad Sci U S A 90:4485-4489. 
151. Marzia, M., N. A. Sims, S. Voit, S. Migliaccio, A. Taranta, S. Bernardini, T. 
Faraggiana, T. Yoneda, G. R. Mundy, B. F. Boyce, R. Baron, and A. Teti. 
2000. Decreased c-Src expression enhances osteoblast differentiation and 
bone formation. J Cell Biol 151:311-320. 
152. Araujo, J. C., A. Poblenz, P. Corn, N. U. Parikh, M. W. Starbuck, J. T. 
Thompson, F. Lee, C. J. Logothetis, and B. G. Darnay. 2009. Dasatinib 
inhibits both osteoclast activation and prostate cancer PC-3-cell-induced 
osteoclast formation. Cancer Biol Ther 8:2153-2159. 
153. Brownlow, N., C. Mol, C. Hayford, S. Ghaem-Maghami, and N. J. Dibb. 
2009. Dasatinib is a potent inhibitor of tumour-associated macrophages, 
osteoclasts and the FMS receptor. Leukemia 23:590-594. 
154. Vandyke, K., A. L. Dewar, P. Diamond, S. Fitter, C. G. Schultz, N. A. Sims, 
  
~ 156 ~ 
 
and A. C. Zannettino. 2010. The tyrosine kinase inhibitor dasatinib 
dysregulates bone remodeling through inhibition of osteoclasts in vivo. J 
Bone Miner Res 25:1759-1770. 
155. Mladenovic, J., and S. M. Anderson. 1992. Over-expression of c-src or v-src 
in bone marrow stromal cells stimulates hematopoiesis in long-term bone 
marrow culture. Blood 80:3079-3089. 
156. You, X., H. M. Yu, L. Cohen-Gould, B. Cao, M. Symons, G. F. Vande 
Woude, and B. S. Knudsen. 2003. Regulation of migration of primary 
prostate epithelial cells by secreted factors from prostate stromal cells. Exp 
Cell Res 288:246-256. 
157. Drachenberg, D. E., A. A. Elgamal, R. Rowbotham, M. Peterson, and G. P. 
Murphy. 1999. Circulating levels of interleukin-6 in patients with hormone 
refractory prostate cancer. Prostate 41:127-133. 
158. Hobisch, A., H. Rogatsch, A. Hittmair, D. Fuchs, G. Bartsch, H. Klocker, 
and Z. Culig. 2000. Immunohistochemical localization of interleukin-6 and 
its receptor in benign, premalignant and malignant prostate tissue. J Pathol 
191:239-244. 
159. Okamoto, M., C. Lee, and R. Oyasu. 1997. Interleukin-6 as a paracrine and 
autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer 
Res 57:141-146. 
160. Lou, W., Z. Ni, K. Dyer, D. J. Tweardy, and A. C. Gao. 2000. Interleukin-6 
induces prostate cancer cell growth accompanied by activation of stat3 
signaling pathway. Prostate 42:239-242. 
  
~ 157 ~ 
 
161. Chen, T., L. H. Wang, and W. L. Farrar. 2000. Interleukin 6 activates 
androgen receptor-mediated gene expression through a signal transducer and 
activator of transcription 3-dependent pathway in LNCaP prostate cancer 
cells. Cancer Res 60:2132-2135. 
162. Thelen, M., P. Peveri, P. Kernen, V. von Tscharner, A. Walz, and M. 
Baggiolini. 1988. Mechanism of neutrophil activation by NAF, a novel 
monocyte-derived peptide agonist. FASEB J 2:2702-2706. 
163. Moser, B., C. Schumacher, V. von Tscharner, I. Clark-Lewis, and M. 
Baggiolini. 1991. Neutrophil-activating peptide 2 and gro/melanoma 
growth-stimulatory activity interact with neutrophil-activating peptide 
1/interleukin 8 receptors on human neutrophils. J Biol Chem 266:10666-
10671. 
164. Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. Neutrophil-activating 
peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin 
Invest 84:1045-1049. 
165. Veltri, R. W., M. C. Miller, G. Zhao, A. Ng, G. M. Marley, G. L. Wright, R. 
L. Vessella, and D. Ralph. 1999. Interleukin-8 serum levels in patients with 
benign prostatic hyperplasia and prostate cancer. Urology 53:139-147. 
166. Kassim, S. K., E. M. El-Salahy, S. T. Fayed, S. A. Helal, T. Helal, E. l.-D. 
Azzam, and A. Khalifa. 2004. Vascular endothelial growth factor and 
interleukin-8 are associated with poor prognosis in epithelial ovarian cancer 
patients. Clin Biochem 37:363-369. 
167. Kargi, A., A. D. Yalcin, N. Erin, B. Savas, H. H. Polat, and R. M. 
  
~ 158 ~ 
 
Gorczynski. 2012. IL8 and serum soluble TRAIL levels following anti-
VEGF monoclonal antibody treatment in patients with metastatic colon 
cancer. Clin Lab 58:501-505. 
168. Zuccari, D. A., C. Leonel, R. Castro, G. B. Gelaleti, B. V. Jardim, M. G. 
Moscheta, V. R. Regiani, L. C. Ferreira, J. R. Lopes, D. e. S. Neto, and J. L. 
Esteves. 2012. An immunohistochemical study of interleukin-8 (IL-8) in 
breast cancer. Acta Histochem 114:571-576. 
169. Zabransky, D. J., H. A. Smith, C. J. Thoburn, M. Zahurak, D. Keizman, M. 
Carducci, M. A. Eisenberger, D. G. McNeel, C. G. Drake, and E. S. 
Antonarakis. 2012. Lenalidomide modulates IL-8 and anti-prostate antibody 
levels in men with biochemically recurrent prostate cancer. Prostate 72:487-
498. 
170. Patel, S. P., K. B. Kim, N. E. Papadopoulos, W. J. Hwu, P. Hwu, V. G. 
Prieto, M. Bar-Eli, M. Zigler, A. Dobroff, Y. Bronstein, R. L. Bassett, A. G. 
Vardeleon, and A. Y. Bedikian. 2011. A phase II study of gefitinib in 
patients with metastatic melanoma. Melanoma Res 21:357-363. 
171. Lehrer, S., E. J. Diamond, B. Mamkine, N. N. Stone, and R. G. Stock. 2004. 
Serum interleukin-8 is elevated in men with prostate cancer and bone 
metastases. Technol Cancer Res Treat 3:411. 
172. Huang, S., L. Mills, B. Mian, C. Tellez, M. McCarty, X. D. Yang, J. M. 
Gudas, and M. Bar-Eli. 2002. Fully humanized neutralizing antibodies to 
interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis 
of human melanoma. Am J Pathol 161:125-134. 
  
~ 159 ~ 
 
173. Inoue, K., J. W. Slaton, S. J. Kim, P. Perrotte, B. Y. Eve, M. Bar-Eli, R. 
Radinsky, and C. P. Dinney. 2000. Interleukin 8 expression regulates 
tumorigenicity and metastasis in human bladder cancer. Cancer Res 
60:2290-2299. 
174. Wilson, C., T. Wilson, P. G. Johnston, D. B. Longley, and D. J. Waugh. 
2008. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced 
apoptosis through transcriptional regulation of c-FLIP in prostate cancer 
cells. Mol Cancer Ther 7:2649-2661. 
175. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. 
Clin Cancer Res 14:6735-6741. 
176. Seaton, A., P. Scullin, P. J. Maxwell, C. Wilson, J. Pettigrew, R. Gallagher, 
J. M. O'Sullivan, P. G. Johnston, and D. J. Waugh. 2008. Interleukin-8 
signaling promotes androgen-independent proliferation of prostate cancer 
cells via induction of androgen receptor expression and activation. 
Carcinogenesis 29:1148-1156. 
177. Kitadai, Y., K. Haruma, N. Mukaida, Y. Ohmoto, N. Matsutani, W. Yasui, 
S. Yamamoto, K. Sumii, G. Kajiyama, I. J. Fidler, and E. Tahara. 2000. 
Regulation of disease-progression genes in human gastric carcinoma cells by 
interleukin 8. Clin Cancer Res 6:2735-2740. 
178. Kitadai, Y., K. Haruma, K. Sumii, S. Yamamoto, T. Ue, H. Yokozaki, W. 
Yasui, Y. Ohmoto, G. Kajiyama, I. J. Fidler, and E. Tahara. 1998. 
Expression of interleukin-8 correlates with vascularity in human gastric 
carcinomas. Am J Pathol 152:93-100. 
  
~ 160 ~ 
 
179. Kim, S.J., Uehara, H., Karashima, T., Mccarty, M., Shih, N., Fidler, I.J. 
2001. Expression of interleukin-8 correlates with angiogenesis, 
tumorigenecity, and metastasis of human prostate cancer cells implanted 
orthotopically in nude mice.  Neoplasia 3:33-42. 
180. Siddiqui, R. A., L. P. Akard, J. G. Garcia, Y. Cui, and D. English. 1999. 
Chemotactic migration triggers IL-8 generation in neutrophilic leukocytes. J 
Immunol 162:1077-1083. 
181. Robson, R. L., R. M. McLoughlin, J. Witowski, P. Loetscher, T. S. 
Wilkinson, S. A. Jones, and N. Topley. 2001. Differential regulation of 
chemokine production in human peritoneal mesothelial cells: IFN-gamma 
controls neutrophil migration across the mesothelium in vitro and in vivo. J 
Immunol 167:1028-1038. 
182. Cohen-Hillel, E., R. Mintz, T. Meshel, B. Z. Garty, and A. Ben-Baruch. 
2009. Cell migration to the chemokine CXCL8: paxillin is activated and 
regulates adhesion and cell motility. Cell Mol Life Sci 66:884-899. 
183. Vinante, F., A. Rigo, C. Vincenzi, M. M. Ricetti, R. Marrocchella, M. 
Chilosi, M. A. Cassatella, L. Bonazzi, and G. Pizzolo. 1993. IL-8 mRNA 
expression and IL-8 production by acute myeloid leukemia cells. Leukemia 
7:1552-1556. 
184. Wang, J. M., G. Taraboletti, K. Matsushima, J. Van Damme, and A. 
Mantovani. 1990. Induction of haptotactic migration of melanoma cells by 
neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 
169:165-170. 
  
~ 161 ~ 
 
185. Bar-Eli, M. 1999. Role of interleukin-8 in tumor growth and metastasis of 
human melanoma. Pathobiology 67:12-18. 
186. Reiland, J., L. T. Furcht, and J. B. McCarthy. 1999. CXC-chemokines 
stimulate invasion and chemotaxis in prostate carcinoma cells through the 
CXCR2 receptor. Prostate 41:78-88. 
187. Barlic, J., J. D. Andrews, A. A. Kelvin, S. E. Bosinger, M. E. DeVries, L. 
Xu, T. Dobransky, R. D. Feldman, S. S. Ferguson, and D. J. Kelvin. 2000. 
Regulation of tyrosine kinase activation and granule release through beta-
arrestin by CXCRI. Nat Immunol 1:227-233. 
188. Barlic, J., J. D. Andrews, A. A. Kelvin, S. E. Bosinger, M. E. DeVries, L. 
Xu, T. Dobransky, R. D. Feldman, S. S. Ferguson, and D. J. Kelvin. 2000. 
Regulation of tyrosine kinase activation and granule release through beta-
arrestin by CXCRI. Nat Immunol 1:227-233. 
189. Han, L. Y., C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, 
T. J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, W. C. 
Shakespeare, Y. Wang, R. Sundaramoorth, C. A. Metcalf, D. C. Dalgarno, 
T. K. Sawyer, G. E. Gallick, and A. K. Sood. 2006. Antiangiogenic and 
antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 
66:8633-8639. 
190. Chaudhary, L. R., and L. V. Avioli. 1996. Regulation of interleukin-8 gene 
expression by interleukin-1beta, osteotropic hormones, and protein kinase 
inhibitors in normal human bone marrow stromal cells. J Biol Chem 
271:16591-16596. 
  
~ 162 ~ 
 
191. Thalmeier, K., P. Meissner, G. Reisbach, L. Hültner, B. T. Mortensen, A. 
Brechtel, R. A. Oostendorp, and P. Dörmer. 1996. Constitutive and 
modulated cytokine expression in two permanent human bone marrow 
stromal cell lines. Exp Hematol 24:1-10. 
192. Arnold, R., B. Humbert, H. Werchau, H. Gallati, and W. König. 1994. 
Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type 
I release from a human pulmonary epithelial cell line (A549) exposed to 
respiratory syncytial virus. Immunology 82:126-133. 
193. Massagué, J. 2008. TGFbeta in Cancer. Cell 134:215-230. 
194. Futakuchi, M., K. C. Nannuru, M. L. Varney, A. Sadanandam, K. Nakao, K. 
Asai, T. Shirai, S. Y. Sato, and R. K. Singh. 2009. Transforming growth 
factor-beta signaling at the tumor-bone interface promotes mammary tumor 
growth and osteoclast activation. Cancer Sci 100:71-81. 
195. Schauer, I. G., S. J. Ressler, J. A. Tuxhorn, T. D. Dang, and D. R. Rowley. 
2008. Elevated epithelial expression of interleukin-8 correlates with 
myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 
72:205-213. 
196. Rabbani, S. A., M. L. Valentino, A. Arakelian, S. Ali, and F. Boschelli. 
2010. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and 
metastasis in vitro and in vivo through regulation of genes involved in 
cancer growth and skeletal metastasis. Mol Cancer Ther 9:1147-1157. 
197. Tannock, I. F., D. Osoba, M. R. Stockler, D. S. Ernst, A. J. Neville, M. J. 
Moore, G. R. Armitage, J. J. Wilson, P. M. Venner, C. M. Coppin, and K. C. 
  
~ 163 ~ 
 
Murphy. 1996. Chemotherapy with mitoxantrone plus prednisone or 
prednisone alone for symptomatic hormone-resistant prostate cancer: a 
Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-
1764. 
198. Oosterhof, G. O., J. T. Roberts, T. M. de Reijke, S. A. Engelholm, S. 
Horenblas, H. von der Maase, N. Neymark, M. Debois, and L. Collette. 
2003. Strontium(89) chloride versus palliative local field radiotherapy in 
patients with hormonal escaped prostate cancer: a phase III study of the 
European Organisation for Research and Treatment of Cancer, 
Genitourinary Group. Eur Urol 44:519-526. 
199. Petrylak, D. P., C. M. Tangen, M. H. Hussain, P. N. Lara, J. A. Jones, M. E. 
Taplin, P. A. Burch, D. Berry, C. Moinpour, M. Kohli, M. C. Benson, E. J. 
Small, D. Raghavan, and E. D. Crawford. 2004. Docetaxel and estramustine 
compared with mitoxantrone and prednisone for advanced refractory 
prostate cancer. N Engl J Med 351:1513-1520. 
200. Berthold, D. R., G. R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I. F. 
Tannock. 2008. Docetaxel plus prednisone or mitoxantrone plus prednisone 
for advanced prostate cancer: updated survival in the TAX 327 study. J Clin 
Oncol 26:242-245. 
201. Tu, S. M., S. H. Lin, D. A. Podoloff, and C. J. Logothetis. 2010. 
Multimodality therapy: bone-targeted radioisotope therapy of prostate 
cancer. Clin Adv Hematol Oncol 8:341-351. 
202. Tran, C., S. Ouk, N. J. Clegg, Y. Chen, P. A. Watson, V. Arora, J. 
  
~ 164 ~ 
 
Wongvipat, P. M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. 
Welsbie, C. D. Chen, C. S. Higano, T. M. Beer, D. T. Hung, H. I. Scher, M. 
E. Jung, and C. L. Sawyers. 2009. Development of a second-generation 
antiandrogen for treatment of advanced prostate cancer. Science 324:787-
790. 
203. Homsi, J., and A. I. Daud. 2007. Spectrum of activity and mechanism of 
action of VEGF/PDGF inhibitors. Cancer Control 14:285-294. 
204. Bellon, S. F., P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. 
W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, Y. Gu, A. Coxon, T. 
S. Kim, A. Tasker, T. L. Burgess, and I. Dussault. 2008. c-Met inhibitors 
with novel binding mode show activity against several hereditary papillary 
renal cell carcinoma-related mutations. J Biol Chem 283:2675-2683. 
205. Varkaris, A., P. G. Corn, S. Gaur, F. Dayyani, C. J. Logothetis, and G. E. 
Gallick. 2011. The role of HGF/c-Met signaling in prostate cancer 
progression and c-Met inhibitors in clinical trials. Expert Opin Investig 
Drugs 20:1677-1684. 
206. Xue, M., X. Cao, Y. Zhong, D. Kuang, X. Liu, Z. Zhao, and H. Li. 2012. 
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer 
therapy: advances and perspectives. Curr Pharm Des 18:2901-2913. 
207. Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Targeted 
disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 
64:693-702. 
208. Araujo, J. C., A. Poblenz, P. Corn, N. U. Parikh, M. W. Starbuck, J. T. 
  
~ 165 ~ 
 
Thompson, F. Lee, C. J. Logothetis, and B. G. Darnay. 2009. Dasatinib 
inhibits both osteoclast activation and prostate cancer PC-3-cell-induced 
osteoclast formation. Cancer Biol Ther 8:2153-2159. 
209. Lara, P. N., J. Longmate, C. P. Evans, D. I. Quinn, P. Twardowski, G. 
Chatta, E. Posadas, W. Stadler, and D. R. Gandara. 2009. A phase II trial of 
the Src-kinase inhibitor AZD0530 in patients with advanced castration-
resistant prostate cancer: a California Cancer Consortium study. Anticancer 
Drugs 20:179-184. 
210. Yang, J. C., L. Bai, S. Yap, A. C. Gao, H. J. Kung, and C. P. Evans. 2010. 
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic 
lesions using the PC-3 bone model. Mol Cancer Ther 9:1629-1637. 
211. Araujo, J. C., P. Mathew, A. J. Armstrong, E. L. Braud, E. Posadas, M. 
Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, and C. J. 
Logothetis. 2012. Dasatinib combined with docetaxel for castration-resistant 
prostate cancer: results from a phase 1-2 study. Cancer 118:63-71. 
212. Crawford, E. D., and P. A. Abrahamsson. 2008. PSA-based screening for 
prostate cancer: how does it compare with other cancer screening tests? Eur 
Urol 54:262-273. 
213. Pettaway, C. A., S. Pathak, G. Greene, E. Ramirez, M. R. Wilson, J. J. 
Killion, and I. J. Fidler. 1996. Selection of highly metastatic variants of 
different human prostatic carcinomas using orthotopic implantation in nude 
mice. Clin Cancer Res 2:1627-1636. 
214. Sobel, R. E., and M. D. Sadar. 2005. Cell lines used in prostate cancer 
  
~ 166 ~ 
 
research: a compendium of old and new lines--part 1. J Urol 173:342-359. 
215. Wiznerowicz, M., and D. Trono. 2003. Conditional suppression of cellular 
genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 
77:8957-8961. 
216. Merritt, W. M., Y. G. Lin, W. A. Spannuth, M. S. Fletcher, A. A. Kamat, L. 
Y. Han, C. N. Landen, N. Jennings, K. De Geest, R. R. Langley, G. Villares, 
A. Sanguino, S. K. Lutgendorf, G. Lopez-Berestein, M. M. Bar-Eli, and A. 
K. Sood. 2008. Effect of interleukin-8 gene silencing with liposome-
encapsulated small interfering RNA on ovarian cancer cell growth. J Natl 
Cancer Inst 100:359-372. 
217. Lassi, K., and N. A. Dawson. 2009. Emerging therapies in castrate-resistant 
prostate cancer. Curr Opin Oncol 21:260-265. 
218. Aalinkeel, R., M. P. Nair, G. Sufrin, S. D. Mahajan, K. C. Chadha, R. P. 
Chawda, and S. A. Schwartz. 2004. Gene expression of angiogenic factors 
correlates with metastatic potential of prostate cancer cells. Cancer Res 
64:5311-5321. 
219. Murphy, C., M. McGurk, J. Pettigrew, A. Santinelli, R. Mazzucchelli, P. G. 
Johnston, R. Montironi, and D. J. Waugh. 2005. Nonapical and cytoplasmic 
expression of interleukin-8, CXCR1, and CXCR2 correlates with cell 
proliferation and microvessel density in prostate cancer. Clin Cancer Res 
11:4117-4127. 
220. Ahuja, S. K., J. C. Lee, and P. M. Murphy. 1996. CXC chemokines bind to 
unique sets of selectivity determinants that can function independently and 
  
~ 167 ~ 
 
are broadly distributed on multiple domains of human interleukin-8 receptor 
B. Determinants of high affinity binding and receptor activation are distinct. 
J Biol Chem 271:225-232. 
221. Shamaladevi, N., D. A. Lyn, D. O. Escudero, and B. L. Lokeshwar. 2009. 
CXC receptor-1 silencing inhibits androgen-independent prostate cancer. 
Cancer Res 69:8265-8274. 
222. Nasser, M. W., S. K. Raghuwanshi, D. J. Grant, V. R. Jala, K. Rajarathnam, 
and R. M. Richardson. 2009. Differential activation and regulation of 
CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol 183:3425-
3432. 
223. Tsai, C. Y., T. S. Lee, Y. R. Kou, and Y. L. Wu. 2009. Glucosamine inhibits 
IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK 
attenuation. J Cell Biochem 108:489-498. 
224. Roecklein, B. A., and B. Torok-Storb. 1995. Functionally distinct human 
marrow stromal cell lines immortalized by transduction with the human 
papilloma virus E6/E7 genes. Blood 85:997-1005. 
225. Jin, J. K., F. Dayyani, and G. E. Gallick. 2011. Steps in prostate cancer 
progression that lead to bone metastasis. Int J Cancer 128:2545-2561. 
226. Koreckij, T., H. Nguyen, L. G. Brown, E. Y. Yu, R. L. Vessella, and E. 
Corey. 2009. Dasatinib inhibits the growth of prostate cancer in bone and 
provides additional protection from osteolysis. Br J Cancer 101:263-268. 
227. Schraufstatter, I.U., Chung, J., Burger, M. 2001.  IL-8 activates endothelial 
cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.  
  
~ 168 ~ 
 
280:L1094-103. 
228. Luppi, F., A. M. Longo, W. I. de Boer, K. F. Rabe, and P. S. Hiemstra. 2007. 
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer 
through epidermal growth factor receptor transactivation. Lung Cancer 
56:25-33. 
229. Singh, R. K., and B. L. Lokeshwar. 2009. Depletion of intrinsic expression 
of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous 
apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 
8:57. 
230. Saijo, K., C. Schmedt, I. H. Su, H. Karasuyama, C. A. Lowell, M. Reth, T. 
Adachi, A. Patke, A. Santana, and A. Tarakhovsky. 2003. Essential role of 
Src-family protein tyrosine kinases in NF-kappaB activation during B cell 
development. Nat Immunol 4:274-279. 
231. Nagaraj, N. S., M. K. Washington, and N. B. Merchant. 2011. Combined 
blockade of Src kinase and epidermal growth factor receptor with 
gemcitabine overcomes STAT3-mediated resistance of inhibition of 
pancreatic tumor growth. Clin Cancer Res 17:483-493. 
232. Okutani, Y., A. Kitanaka, T. Tanaka, H. Kamano, H. Ohnishi, Y. Kubota, T. 
Ishida, and J. Takahara. 2001. Src directly tyrosine-phosphorylates STAT5 
on its activation site and is involved in erythropoietin-induced signaling 
pathway. Oncogene 20:6643-6650. 
233. Gu, L., Vogiatz, P., Puhr, M., Dagvadorj, A., Lutz, J., Ryder, A., Addya, S., 
Fortina, P., Cooper, C., Leiby, B., Dasgupta, A., Hyslop, T., Bubendorf, L., 
  
~ 169 ~ 
 
Alanen, K., Mirtti, T., and Nevalainen, M.T. 2010. Stat5 promotes metastatic 
behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat 
Cancer 17:481-93. 
234. Kaminski, A., J. C. Hahne, e.-M. Haddouti, A. Florin, A. Wellmann, and N. 
Wernert. 2006. Tumour-stroma interactions between metastatic prostate 
cancer cells and fibroblasts. Int J Mol Med 18:941-950. 
235. Giannoni, E., F. Bianchini, L. Masieri, S. Serni, E. Torre, L. Calorini, and P. 
Chiarugi. 2010. Reciprocal activation of prostate cancer cells and cancer-
associated fibroblasts stimulates epithelial-mesenchymal transition and 
cancer stemness. Cancer Res 70:6945-6956. 
236. Chung, L. W., A. Baseman, V. Assikis, and H. E. Zhau. 2005. Molecular 
insights into prostate cancer progression: the missing link of tumor 
microenvironment. J Urol 173:10-20. 
237. Zhang, S., J. Wang, M. A. Bilen, S. H. Lin, S. I. Stupp, and R. L. Satcher. 
2009. Modulation of prostate cancer cell gene expression by cell-to-cell 
contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis 
26:993-1004. 
238. Walczak, H. 2011. TNF and ubiquitin at the crossroads of gene activation, 
cell death, inflammation, and cancer. Immunol Rev 244:9-28. 
239. Yuan, A., J. J. Chen, P. L. Yao, and P. C. Yang. 2005. The role of 
interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 
10:853-865. 
240. Chin, Y. R., and A. Toker. 2009. Function of Akt/PKB signaling to cell    
  
~ 170 ~ 
 
motility, invasion and the tumor stroma in cancer. Cell Signal 21:470-476. 
241. Nakata, Y., B. Tomkowicz, A. M. Gewirtz, and A. Ptasznik. 2006. Integrin 
inhibition through Lyn-dependent cross talk from CXCR4 chemokine 
receptors in normal human CD34+ marrow cells. Blood 107:4234-4239. 
242. Tabe, Y., L. Jin, K. Iwabuchi, R. Y. Wang, N. Ichikawa, T. Miida, J. Cortes, 
M. Andreeff, and M. Konopleva. 2012. Role of stromal microenvironment in 
nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 
interactions in lipid rafts. Leukemia 26:883-892. 
243. Datta, J., T. Z. Toro, V. L. Keedy, and N. B. Merchant. 2010. Synchronous 
bone marrow metastasis from primary splenic angiosarcoma. Am Surg 
76:E160-162. 
244. McCarron, S. L., S. Edwards, P. R. Evans, R. Gibbs, D. P. Dearnaley, A. 
Dowe, C. Southgate, D. F. Easton, R. A. Eeles, and W. M. Howell. 2002. 
Influence of cytokine gene polymorphisms on the development of prostate 
cancer. Cancer Res 62:3369-3372. 
245. Saito, Y.D., A.R. Jensen, R. Salgia, E.M. Posadas. 2010.  Fyn: a novel 
molecular target in cancer.  Cancer 116:1629-37. 
246. Zigler, M., G. J. Villares, D. C. Lev, V. O. Melnikova, and M. Bar-Eli. 2008. 
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms 
of resistance and escape. Am J Clin Dermatol 9:307-311. 
247. Wilson, C., C. Purcell, A. Seaton, O. Oladipo, P. J. Maxwell, J. M. 
O'Sullivan, R. H. Wilson, P. G. Johnston, and D. J. Waugh. 2008. 
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor 
  
~ 171 ~ 
 
signaling in metastatic prostate cancer cells confers resistance to oxaliplatin 
through potentiation of nuclear factor-kappaB transcription and evasion of 
apoptosis. J Pharmacol Exp Ther 327:746-759. 
248. Gonsiorek, W., X. Fan, D. Hesk, J. Fossetta, H. Qiu, J. Jakway, M. Billah, 
M.  Dwyer, J. Chao, G. Deno, A. Taveras, D. J. Lundell, and R. W. Hipkin. 
2007. Pharmacological characterization of Sch527123, a potent allosteric 
CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 322:477-485. 
249. Moore, B. B., D. A. Arenberg, K. Stoy, T. Morgan, C. L. Addison, S. B. 
Morris, M. Glass, C. Wilke, Y. Y. Xue, S. Sitterding, S. L. Kunkel, M. D. 
Burdick, and R. M. Strieter. 1999. Distinct CXC chemokines mediate 
tumorigenicity of prostate cancer cells. Am J Pathol 154:1503-1512. 
250. Sunaga, N., H. Imai, K. Shimizu, D. S. Shames, S. Kakegawa, L. Girard, M. 
Sato, K. Kaira, T. Ishizuka, A. F. Gazdar, J. D. Minna, and M. Mori. 2012. 
Oncogenic KRAS-induced interleukin-8 overexpression promotes cell 
growth and migration and contributes to aggressive phenotypes of non-
small cell lung cancer. Int J Cancer 130:1733-1744. 
251. Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, J. D. Coudert, M. Desbois, 
F. Ghiringhelli, S. Viaud, B. Ryffel, H. Yagita, L. Chen, S. Mécheri, G. 
Kaplanski, A. Prévost-Blondel, M. Kato, J. L. Schultze, E. Tartour, G. 
Kroemer, M. Degli-Esposti, N. Chaput, and L. Zitvogel. 2012. Cancer-
induced immunosuppression: IL-18-elicited immunoablative NK cells. 
Cancer Res 72:2757-2767. 
 
  
~ 172 ~ 
 
VITA 
Lynnelle Thorpe was born in Plainfield, NJ on June 27, 1980 to  Willie H. Thorpe and 
Sheila L. Thorpe.  After finishing at Plainfield High School in Plainfield, NJ in 1998, 
she entered Delaware State University in Dover, DE.  She received her degree of 
Bachelor of Science degree in biology from Delaware State University in May 2002.  
While applying to graduate schools, she worked for two years in a non-science related 
job and was accepted to the University of Delaware  in 2004.  She enrolled in the Cell 
Biology and Physiology program and completed her Master of Science degree in 2007. 
In August 2006, she entered The University of Texas Health Science Center at Houston 
Graduate School of Biomedical Sciences.  
 
PERMANENT ADDRESS: 
4 Courtney Lane 
Somerset, New Jersey 08873 
 
 
